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ABSTRACT
The AF9 gene is one of the most common chromosomal translocation partners of
the MLL (Mixed Lineage Leukemia) gene in MLL leukemia. Wild-type AF9 is a member
of the pTEFb transcription elongation complex, and interacts with gene regulatory
proteins such as AF4/AF5q31, H3K79 histone methyltransferase DOT1L, Polycomb
repressive protein Pc3/CBX8 and BCL-family co-repressor protein BCoR. These
interactions are retained in the oncogenic MLL-AF9 fusion protein, and may be required
for leukemic transformation.
Using bone marrow progenitor cells isolated from conditional Af9 knockout mice,
we examined in vitro differentiation of hematopoietic progenitor cells to the erythroid,
myeloid and megakaryocytic lineages in the presence or absence of Af9. Based on
previously published studies, we hypothesized that loss of Af9 would result in a loss of
erythroid colony formation. However, our results indicate no significant difference in
erythroid, myeloid or megakaryocytic colony formation ability in cells expressing or null
for Af9. Expression of transcription factor genes associated with erythroid or myeloid
lineage commitment were also unaltered in cells null for Af9 compared to control. There
was, however, a statistically significant decrease in cell surface expression of early
erythroid cell surface marker Ter119 in Af9-null cells compared to control mice,
indicating a potential role for Af9 in early erythroid lineage commitment.

xv

To examine the role of AF9-mediated protein interactions in MLL-AF9-mediated
leukemic transformation, we engineered point mutants in the C-terminus of AF9 in the
context of MLL-AF9 fusion protein predicted to disrupt specific protein-protein
interactions. Amino acid substitutions were selected in collaboration with the laboratories
of Dr. Hemenway and Dr. Bushweller based on structural studies and previously
published results.
Hematopoietic progenitor cells were isolated from the bone marrow of wild type
mice and retrovirally transduced with constructs encoding wild type or mutant MLL-AF9
fusion proteins, or empty vector control. In vitro colony assay experiments indicate that
mutants MLL-AF9(D544R) and MLL-AF9(D546R) dramatically

reduced colony

formation ability and expression of MLL target genes Hoxa9 and Meis compared to
MLL-AF9(WT). Coimmunoprecipitation studies show that the D546R mutation in the
context of amino acids 376-568 of AF9 significantly reduces binding to Dot1l while
maintaining interaction with Af4, complementing biophysical studies performed in the
Bushweller lab at the University of Virginia. Previous work by Dr. Bhavna Malik
indicate that the D544R mutation in the context of AF9 amino acids 376-568 disrupts
binding to Af4 but maintains binding to Dot1l.
These results indicate that disruption of AF9 interaction with AF4 and DOT1L
decreases colony formation and target gene expression in in vitro leukemia assays. These
interactions are attractive targets for designing small molecule inhibitors for the treatment
of MLL leukemia.

xvi

CHAPTER ONE
INTRODUCTION
Blood is composed of four components: plasma, platelets, red blood cells, and
white blood cells. Together, these cells are responsible for delivering oxygen to tissues
and forming the immune system that protects against invading pathogens. All blood cells
arise from a hematopoietic stem cell (HSC) that has the ability to differentiate to any
mature hematopoietic cell.
Leukemia is a cancer of the blood or bone marrow, resulting from the
accumulation of abnormal hematopoietic cells. DNA damaging mutations that occur in
early hematopoietic stem or progenitor cells cause these abnormal cells to proliferate
without properly differentiating to the necessary effector cells of the hematopoietic
system. In 2013, over 48,000 people in the United States were diagnosed with leukemia,
and over 23,000 people died from the disease1. Leukemia is also the most common
cancer in children and adolescents, accounting for one-third of all cancer-related deaths
in individuals 15 years old or younger.
Patients with leukemia involving the MLL (Mixed Lineage Leukemia) gene
develop leukemia that is particularly aggressive and correlated with a poor prognosis2.
MLL leukemias result from the chromosomal translocation of the MLL gene with one of
over 79 fusion proteins3. This results in the expression of an oncogenic fusion protein that
drives leukemic development of either acute myeloid (AML) or lymphoid (ALL)
1

2

phenotype. Understanding the mechanisms of leukemogenesis is necessary in order to
develop targeted therapeutics to treat this heterogeneous disease.
AF9 is one of the most common fusion partners in MLL leukemia4. The wild-type
AF9 protein is a member of the P-TEFb elongation complex that aids RNA Polymerase II
during gene transcription5-7. The C-terminus of AF9 directly interacts with at least four
proteins: AF48 and DOT1L9, which are considered activators of gene expression, and
CBX810 and BCoR11, associated with repression of gene targets. The overall goal of this
project was to first, understand the role of Af9 in normal hematopoiesis, and second, to
examine which protein interactions mediated by Af9 are required for leukemic
development.
In the first aim of this study, we utilized a conditional Af9 knockout mouse to
elucidate the role of Af9 in normal hematopoietic lineage commitment. Based on
previously published data, we hypothesized that Af9 is required for erythroid and
megakaryocytic differentiation, and that loss of Af9 in this system would result in a loss
of these cells. To test this hypothesis, we isolated hematopoietic progenitor cells from the
conditional Af9 knockout mouse and induced deletion of the Af9 gene in vitro. These
cells were then cultured in vitro under conditions which promoted erythroid, myeloid or
megakaryocytic lineage differentiation. Examining colony formation, expression of
lineage-specific transcription factors, and cell surface marker analysis, we concluded that
contrary to our hypothesis, Af9 expression is not required for normal hematopoiesis in
vivo.

3

The second aim of this study examined the role of AF9 interactions with Dot1l
and Af4 in leukemic development. In collaboration with structural biologists in the
laboratory of Dr. John Bushweller at the University of Virginia, we engineered point
mutations in the C-terminus of AF9 predicted to specifically disrupt binding to one
protein while maintaining interaction with the other. These mutants were expressed in the
oncogenic MLL-AF9 fusion protein that has been shown to transform bone marrow and
cause rapid leukemia development when introduced into mice.
Results from this study indicate that AF9 interactions with Af4 and Dot1l are
critical for in vitro transformation ability of an MLL fusion. Amino acid substitutions
disrupting either Af4 or Dot1l binding to AF9 result in a loss of leukemic potential as
measured by colony formation and MLL target gene expression. These structurallyinformed point mutations identified critical residues mediating interactions between AF9
and AF4 or DOT1L that can be used to develop targeted therapeutics in the treatment of
MLL leukemia.

CHAPTER TWO
LITERATURE REVIEW
Hematopoiesis
Hematopoiesis is the process of generating the blood and immune cells found
within an organism from a common pluripotent hematopoietic stem cell (HSC). The
hematopoietic system consists of three main groups of cells: red blood cells
(erythrocytes), white blood cells, and platelets. Red blood cells compose the majority of
blood, with 2-3 million new cells being produced in the bone marrow per second

12

.

White blood cells are sub-divided into three types: lymphocytes, monocytes, and
granulocytes. Lymphocytes include T and B cells that together coordinate the immune
response to foreign pathogens. Monocytes, which mature into macrophages once they
escape the blood and enter into a specific tissue, are responsible for phagocytosing
invading pathogens as a first line of innate immune defense. Granulocytes include
neutrophils, basophils and eosinophils. These cells have enzyme-containing granules
that, when released, aid in digesting pathogens. Platelets are cell fragments shed from
megakaryocytes that are responsible for forming blood clots. Maintaining the balance of
hematopoietic cells circulating in the body is essential for delivering oxygen to tissues,
protecting the organism from invading pathogens, and in maintaining hematopoiesis

.
4

5

The Hematopoietic Hierarchy of Differentiation
All hematopoietic cells originate from HSCs in the bone marrow. The “true” HSC
is the long-term hematopoietic stem cell, or LT-HSC. These cells are found at a very low
frequency in the bone marrow, and exhibit lifelong self-renewal capability and
differentiation potential to all hematopoietic lineages. The short-term hematopoietic stem
cell (ST-HSC) still exhibits multilineage differentiation potential, but has a decreased
capacity for self renewal.
Differentiation from an HSC to a progenitor cell requires a loss of self-renewal
ability concurrent with an activation of genes that enforce differentiation. According to
the classical model of hematopoiesis described by the Weissman group (Figure 1)13, the
earliest progenitor cell capable of differentiating to all hematopoietic lineages is the
Multipotent Progenitor, or MPP13. The Common Lymphoid Progenitor (CLP) and
Common Myeloid Progenitor (CMP) arise from the MPP. As their names suggest, the
CLP can form all cells of the lymphoid lineage but lose all myeloid potential, whereas the
CMP can give rise to all cells from the myeloid lineage but lack lymphoid differentiation
potential13.
B and T cells terminally differentiate from the CLP, while the CMP gives rise to
two additional progenitor cells. The Megakaryocyte/Erythroid Progenitor (MEP) gives
rise to megakaryocytes and erythrocytes, or red blood cells (Figure 1). The
Granulocyte/Monocyte Progenitor (GMP) gives rises to the granulocytes and
monocytes13, although a second study has supported the existence of a shared
macrophage and dendritic cell precursor, the Macrophage/Dendritic Progenitor (MDP)14.
5

6

Figure 1. Weissman Model of the Hematopoietic Hierarchy

Canonical model of hematopoietic differentiation from the LT-HSC to terminally
differentiated hematopoietic cell13. Key transcription factors required for lineage
specification are indicated.

7

While this is considered the classical model of hematopoiesis, a second model
proposed by Adolfsson and colleagues is gaining supporting evidence15. On the basis of
Flt3 expression levels, a surface marker associated with early hematopoietic progenitor
cells, these authors propose that the MEP arises directly from the ST-HSC without transit
through the CMP (Figure 2)15. In this case, the ST-HSC can give rise to either a
Lymphoid Primed Multipotent Progenitor (LMPP) or the MEP directly. The LMPP
terminally differentiates to cells of the lymphoid and myeloid lineage but lacks all
erythroid potential, whereas the MEP gives rise to only megakaryocytes and red blood
cells.
This hypothesis is supported by studies of a SpiI knockout mouse. SpiI encodes
for the Pu.1 transcription factor necessary for myeloid lineage differentiation. Mice
deficient for Pu.1 exhibit a loss of the CLP and CMP, but have a normal MEP
compartment and normal numbers of erythroid cells16. This supports the hypothesis that
the erythroid lineage does not arise from a shared progenitor with the myeloid lineage,
but diverts directly from an earlier progenitor or stem cell.
Transcriptional Control of Hematopoietic Differentiation
While the precise hematopoietic hierarchy is still under investigation, the
mechanisms by which cells are signaled to differentiate is well understood, especially in
the murine system. Genome-wide expression analyses as well as knock-out mouse
models have identified several master regulators of hematopoietic differentiation.

8

Figure 2. Adolfsson Model of the Hematopoietic Hierarchy

Revised model of hematopoietic differentiation as described by Adolfsson et al.
Contrasting to the Weissman model, the ST-HSC gives rise to a lymphoid-myeloid
primer progenitor cell or a megakaryocytic/erythroid progenitor cell, diverting all
megakaryocytic/erythroid development from a shared myeloid progenitor.

9

As mentioned previously, Pu.1 is required for myeloid lineage differentiation. The
Pu.1 protein is a member of the ETS family of transcription factors. This protein binds to
purine-rich DNA sequences termed the PU-box in the promoter of genes involved in
myeloid differentiation. Deletion of Spi1 in mice results in a fatal loss of B cells and
macrophages17, 18.
Pu.1 is required not only for the maturation of HSCs to CMPs and CLPs (Figure
1), but for the repopulation of HSCs in chimeric mice transplanted with fetal liver cells 16,
19, 20

. SpiI expression is high in HSCs, CMPs, B cells, monocytes and granulocytes, and is

downregulated during erythroid and T cell differentiation21.
The maturation of the CMP to the GMP is controlled by expression of Cebpα
(Figure 1). CCAAT/Enhancer Binding Protein alpha, encoded by the Cebpα gene, is a
basic leucine zipper (bZIP) domain transcription factor that binds in a sequence-specific
manner to DNA to regulate the transcription of myeloid differentiation genes. Cebpα is
expressed in HSCs, myeloid progenitor cells and granulocytes, but is not expressed in
macrophages 22, 23. Genetic knockout of this gene results in normal numbers of CMPs but
a lack of GMPs24, 25, indicating a critical role for this protein in the differentiation of
CMPs to GMPs.
GMPs have the potential to differentiate to granulocytes or monocytes. This
decision is controlled by the expression of interferon-(IFN)-responsive transcription
factor 8 (Irf8)(Figure 1). While the mechanism by which Irf8 controls myeloid
differentiation is not well understood, results from a knockout mouse model highlight the

10

importance of this gene in monocytic versus granulocytic differentiation. Mice null for
Irf8 had increased numbers of granulocytes but fewer macrophages, and developed a
myeloproliferative syndrome resembling human chronic myeloid leukemia (CML)26. Reexpression of Irf8 in myeloid progenitors isolated from the Irf8-/- mice shifted
differentiation back toward macrophages27.
Final maturation from the GMP stage to terminally differentiated granulocytes is
controlled by the expression of Gfi1 and Cebp (Figure 1). Gfi1 is expressed in HSCs,
neutrophils, and early B and T cells

28, 29

. Neutrophil differentiation was completely

blocked in mice lacking Gfi1 expression28, 29. Similarly, Cebp is expressed in myeloid
and lymphoid cells, and mice null for Cebp also exhibited abnormal granulocyte
maturation30.
The divergent branch stemming from the CMP is the MEP, giving rise to
erythrocytes and megakaryocytes (Figure 1). As mentioned above, recent studies have
also supported the emergence of the MEP directly from the ST-HSC, bypassing a shared
progenitor with granulocyte/macrophage potential altogether (Figure 2)15. There are
several major transcription factors involved in the regulation of erythroid/megakaryocytic
differentiation, but the GATA family of transcription factors plays a central role. The
members of this family bind to a consensus DNA sequence through a conserved Cterminal zinc finger motif. A second conserved zinc finger is found at the N-terminus and
stabilizes binding to the DNA.

11

Gata2 is highly expressed in HSCs and early progenitors31-33, but is
downregulated as cells begin to differentiate to erythroid or megakaryocytes. As Gata2
levels decrease, Gata1 levels increase

34

. This is termed the GATA-switch, and is

required for terminal differentiation of the MEP.
The N-terminal zinc finger of GATA1 has been shown to interact with several
proteins including FOG-1 (Friend of Gata-1)35. FOG-1 is also a zinc finger-containing
transcription factor, and exhibits an expression pattern that mimics GATA1. Both
proteins are required for erythroid and megakaryocytic development, as is evident by
knock-out gene studies in mice. Gata1-/- mice are embryonic lethal between E10.5-11.5,
and die of lack of primitive erythropoeisis

36

. Conditional deletion of Gata1 in mice

resulted in thrombocytopenia and a delay in megakaryocyte differentiation 37, as well as a
lack of red blood cells
development

39

38

. Similarly, Fog-null mice exhibit delayed megakaryocytic

. It is the interaction of Gata1 and Fog-1 that is thought to downregulate

expression of Gata2 to initiate terminal differentiation of progenitor cells40. Interestingly,
mutations in the N-terminus of GATA1 that prevent interaction with FOG-1 have been
found in patients with X-linked disorders of megakaryocytic development 41-43.
After the GATA switch occurs, additional transcription factors are necessary to
promote differentiation to erythrocytes or megakaryocytes. While the Gata1/Fog-1
complexes are necessary for lineage specification of both erythrocytes and
megakaryocytes, it is the presence of additional factors that determine the specificity.
Interaction of Gata1/Fog-1 with the Ets family transcription factors Fli1 and Tel are
essential for megakaryopoiesis

44-47

, whereas interaction with zinc finger transcription

12

factor Eklf (Klf1) is essential for erythropoiesis (Figure 1)48. Fli-1 and Eklf directly
interact with and inhibit each other, as Eklf binding to Fli-1 alters the conformation of the
Fli-1 DNA binding domain, preventing it from binding to its target genes 49.
More recent studies have added additional levels of complexity to the
transcriptional regulation of erythroid and megakaryocytic differentiation. Chromatin
immunoprecipitation (ChIP) studies followed by massively parallel sequencing (ChIPseq) in human erythroleukemic cell lines have shown that GATA1 binding most often
occurs not at promoters, but at distal enhancer elements 50-52. Interestingly, studies of the
chromatin occupancy of GATA1-associated transcription factor EKLF indicate the vast
majority of binding also occurs more than 10kb away from known genes, but within 1kb
of GATA1 localization

53

. Further analysis of chromatin conformation using the

circularized chromatin conformation capture (4C) technique suggests that EKLF assists
in localizing actively transcribed chromatin to transcription factories

54

. Additionally,

FOG-1 has been shown to immunoprecipitate with the NuRD chromatin remodeling
complex55, providing yet another mechanism for GATA1-FOG1 complexes to regulate
target gene expression.
Divergent from myeloid differentiation from the MPP is the lymphoid branch of
the hematopoietic hierarchy. MPP differentiation to the common lymphoid progenitor (or
the lymphoid-primed multipotent progenitor according to the Adolfsson model)
correlates with an increase in expression of both Flt3

and of the α chain of the

interleukin 7 receptor (IL-7Rα)56-59, although signaling via IL-7R is not required for the
generation of CLPs. Mice deficient in Flt3 have HSCs that are unable to differentiate to
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myeloid and lymphoid cells, and mice deficient for Il7Rα expression show a three-fold
decrease in the number of CLPs 60, 61(Figure 1).
Additional factors thought to be involved in the maturation to the CLP/LMPP
from the MPP include Pu.1 and Ikaros (Figure 1). As mentioned previously, mice null for
Spi1, the gene encoding the Pu.1 protein, die during embryogenesis or perinatally, and
exhibit defects in myeloid and lymphoid differentiation17,

18

. These mice do not have

detectable T cells in the thymus, nor do they have B cells in the liver, suggesting that
Pu.1 acts at the levels of a progenitor common to both B and T cell development 17, 62.
Ikaros is a zinc finger-containing transcription factor that, like Eklf, is associated
with the NuRD chromatin remodeling complex as well as the SWI-SNF complex
While Ikaros has been shown to be both an activator and a repressor

63, 64

.

65, 66

, its activity is

essential for lymphoid differentiation. Mice lacking Ikaros completely lack B cells and
have impaired fetal T cell development, although adult T cell differentiation is
unaffected67.
B cell differentiation occurs through several steps, each of which requires a
specific transcriptional regulatory program. B cells proceed through a series of
maturation stages, from the early lymphoid progenitor to the pre-pro-B cells, to the pro-B
cells, and finally to the pre-B cell prior to mature B cells. The major player in
commitment to the B cell lineage is Pax5, which is stably expressed throughout all stages
of B cell maturation

68

(Figure 1). Loss of Pax5 expression results in an arrest of B cell

development at the pro-B stage

69

. Pax5 has been shown to both activate target genes
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required for B cell maturation such as Lef1 and Irf8, and to repress target genes including
Flt3, the previously described CLP-associated marker 70, 71.
T lymphopoiesis is equally complex. T-progenitor cells mature in the thymus, and
are marked by expression of CC-chemokine receptor 9 (CCR9), stem-cell antigen 1
(SCA1), and FLT3

72-74

. Early T cell progenitors mature through several steps of

differentiation, from the early T-cell lineage progenitor (ETP), to the double CD4, CD8
negative 2a (DN2a) cells, then to DN2b, DN3a, DN3b, DN4, double CD4, CD8 positive
(DP), to the T cell receptor positive DP cells, and finally to terminally differentiated
CD4+ or CD8+ T cells. Each maturation stage requires expression of a specific
combination of transcription factors, but initiation of the entire T lineage differentiation
program requires Notch signaling (Figure 1). Expression of constitutive Notch leads to T
cell-Acute Lymphoblastic Leukemia (T-ALL) in mice, whereas knockout of Notch target
gene Rbpj results in a loss of all T cell development 75, 76. Additional transcription factors
play important roles at later stages of T cell differentiation, including GATA3, MYB, and
TCF1 77-83.
It is clear that differentiation from hematopoietic stem cell to a terminally
differentiated cell is very complex, involving an intricate network of tightly regulated
transcription factors that turn on and off target genes necessary for lineage maturation.
More recent studies have begun to examine the mechanisms by which gene expression is
controlled at the epigenetic level, or how DNA accessibility affects which genes can be
turned on and off by the above described transcription factors. The mechanisms that
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regulate these epigenetic modifications are as critical as the transcription factors that
control proper hematopoietic development.
Chromatin and Epigenetics
The human body is composed of over 200 different cell types that work in concert
to support a living human being. Each of these cells has 46 chromosomes containing over
3 billion base pairs of DNA. Stretched out end-to-end, the amount DNA in each cell
would reach over two meters. In order to efficiently pack this much DNA within the
nucleus of every cell in the body, a complex organization system has evolved.
Chromatin refers to the packaging of DNA around proteins in the nucleus of a
cell. At the most basic level, approximately 146 base pairs of DNA wrap around a core of
eight histone proteins: two each of histone H2A, H2B, H3, and H4

84

. The DNA wraps

around the octamer core approximately 1.7 times. Between the DNA-wrapped histone
proteins are approximately 20-60 base pairs of DNA that can associate with a fifth
histone protein, the linker histone H1, forming a nucleosome. When viewed by electron
microscopy, this level of DNA organization, approximately 10nm in diameter, resembles
beads on a string with the DNA-wrapped histone octamer being the bead and the spacer
DNA being the string. Nucleosomes further fold upon each other forming 30nm
chromatin fiber up to 300nm fibers.
The extent to which nucleosomes are compacted, and how tightly the DNA is
wrapped around the histone octamer, determines, in part, whether genes are actively
transcribed or not. Only loosely packed, accessible DNA can be targeted by the DNA
transcription machinery and transcribed. Tightly wound, compacted DNA is not
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accessible to the transcription machinery and therefore is not active. These regions are
termed euchromatin and heterochromatin, respectively 85.
Chromatin can be compacted and expanded by ATP-dependent chromatin
remodeling complexes which contain proteins with ATPase enzymatic domains. The
energy from ATP hydrolysis is used to restructure or shift the nucleosome along the
DNA, or to expel nucleosomes altogether to make the DNA accessible to the
transcription machinery.
The stable inheritance of a phenotype resulting from changes in chromosome
structure without alterations in the DNA sequence itself is termed epigenetics 86. Proteins
involved in placing epigenetic marks can be activators that turn on gene expression, or
repressors that turn off gene expression. It is through epigenetics that cells can adopt
specific functions. As discussed above, each cell in the body contains exactly the same
DNA. It is the combination of genes that are expressed and repressed that gives a cell
identity and function.
One mechanism of epigenetic regulation is though modification of the histone
proteins themselves. Histone proteins have flexible N-terminal tails that extend beyond
the octamer core
modifications

84

that can be post-translationally modified by proteins87. Such

include

acetylation,

phosphorylation,

methylation,

ubiquitylation,

sumoylation, and ADP ribosylation. Modification of histone tails can serve different
purposes, from changing the charge in the tail to alter DNA-protein or nucleosomenucleosome interactions, or to providing a binding surface for proteins to localize to the
histone and carry out additional functions.
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The residue of the histone tail that is modified, and the modification itself can
determine the functional outcome

85

. While these marks are vast and varied, a few have

been very well studied. For example, di- or tri-methylation of histone H3 at lysine 9
(H3K9me2/3) within the gene body, and tri-methylation of H3K27 in the promoter region
are associated with transcriptionally repressed genes. Tri-methylation of H3K4 in the
promoters of genes is associated with transcriptional activation88. Understanding the
function associated with these marks, and the proteins that place these marks, is critical
for understanding complex gene regulation.
A second mechanism of epigenetic regulation is DNA methylation. DNA
methylation occurs on the fifth carbon of cytosine rings in CG dinucleotides 89. Cytosines
located 5’ to guanine nucleotides, termed CpG for cytosine-phosphate backbone-guanine,
are represented less than statistically predicted in the genome

90

. Methylated cytosines

can spontaneously undergo a deamination reaction, resulting in a transition mutation to
thymine. This process has been evolutionarily selected against, thus the CG dinucleotide
exhibits a decreased representation throughout the genome.
CpGs are, however, found at an observed-to-expected ratio of >60% in the
promoters of approximately 70% of human protein coding genes

91

. Clusters of CG

dinucleotides making up >50% GC content in a 300-3,000 base pair range of DNA are
termed CpG islands. These clusters are mostly unmethylated, and the genes associated
with these promoter regions are transcribed92. Methylation of these CpGs by DNA
methyltransferase enzymes is associated with transcriptional repression, and these methyl
marks are maintained throughout cell division by maintenance DNA methyltransferase
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enzymes, thus preserving the silencing of the gene 93. DNA methylation is often exploited
by cancer cells, in which the promoters of tumor suppressor genes can be methylated and
therefore silenced. Conversely, the promoters of developmental genes that are silenced as
cells differentiate may become unmethylated, allowing for expression of genes that
should otherwise be turned off.
MLL
The MLL (Mixed Lineage Leukemia) protein is a member of the Trithorax group
of proteins that positively regulate gene transcription by modifying chromatin structure,
among other functions. MLL is an ortholog of the Drosophila melanogaster Trithorax
protein, so named for the transformation of abdominal segments that occurs when the
gene is mutated

94

. Further research identified a role for trithorax in the positive

regulation of homeotic genes that determine the spatial body plan during development 95.
Studies in mice further elucidated a role for Mll in development and
hematopoiesis. A lacZ reporter gene was inserted in-frame in exon 3 of mouse Mll,
located just downstream of the AT-hooks shown to be required for trithorax activity in
Drosophila, resulting in a loss of Mll activity. β-galactosidase staining indicated that Mll
is widely expressed in the developing embryo from the first time point examined (E7.0)
into adulthood, with highest expression levels in found in the nervous system and the
somites that give rise to mature cells of the mesoderm lineage. These regions are
regulated by the expression of Hox genes, indicating an overlap between Mll expression
and regions regulated by Hox genes in the developing mouse 96.
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Wild-type, Mll+/- and Mll-/- mice were generated to study the function of Mll. Mll/-

mice died during embryonic development by E10.5, indicating that expression of Mll is

essential for viability. Further examination of the Mll+/- mice showed that Mll is a
haploinsufficient gene; expression from only one allele does not produce enough protein
product to achieve a wild-type phenotype. These mice were smaller at birth compared to
the wild-type mice and had retarded growth. In addition, the Mll+/- mice also exhibited
skeletal abnormalities. Both anterior and posterior homeotic transformations were
present, similar to those seen in Hox-deficient mice 96.
As Trithorax group (TrxG) proteins are known to positively regulate Hox
expression, whole-mount embryo hybridization and RNA in situ hybridization were used
to assess any alterations in Hox gene expression upon loss of Mll. Reduced boundaries of
expression were evident for Mll targets Hoxc9 and Hoxa7 in the Mll+/- mice, and
expression was absent altogether in E10.5 embryos from Mll-/- mice, indicating that Mll is
required for the proper maintainence of Hox gene expression 96.
Mll+/- mice also exhibited defects in hematopoiesis such as anemia, a reduction in
platelets, and reduced numbers of B-cells 96. The role of Mll in hematopoiesis was further
studied by in vitro differentiation of yolk sac progenitor cells isolated from wild-type,
Mll+/- and Mll-/- mice. Cells lacking Mll produced fewer colonies containing smaller cells
than heterozygous and wild-type controls, indicating that Mll is required for maintenance
of the both the numbers of hematopoietic progenitors and for their proper differentiation
into mature hematopoietic cells, particularly the myeloid and macrophage lineages 97.
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Conditional loss of Mll in the hematopoietic lineage did not alter the steady state
levels of mature blood cells in adult mice. However, when cultured in methylcellulose,
the conditional Mll knockout cells exhibited a reduced ability to form myeloid and
lymphoid colonies compared to control cells

98

. When injected into lethally irradiated

recipient mice, the conditional knockout cells failed to reconstitute the bone marrow,
indicating that Mll is required for adult HSC self-renewal98.
Similarly, hematopoietic lineage-restricted inducible loss of Mll in adult mice
caused rapid and fatal cytopenia within 19 days

99

. Loss of Mll in the hematopoietic

lineage resulted in a loss of hematopoietic stem and early progenitor cells, but more
mature, lineage-committed progenitor cells were unaffected99,

100

. A recent study

identified a network of genes specifically regulated by MLL in HSCs. These genes,
including Prdm16, Pbx1, and Hoxa9, are involved in the self-renewal and proliferative
capacity of HSCs

101

. The results of these studies indicate a critical role for MLL in the

maintenance of hematopoietic stem cells.
MLL Protein Domains
It is thought that MLL regulates expression of genes necessary for development
and hematopoiesis, at least in part, through its chromatin modifying ability. The Cterminus of MLL contains a histone methyltransferase domain with specificity for histone
H3 lysine 4102(Figure 3A). Trimethylation of H3K4 is associated with positive gene
expression, although it is still debated whether the placement of this mark initiates gene
transcription, or if it is just associated with genes that are already being activity
transcribed.
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There are many other important protein domains of MLL that govern its role in
gene regulation (Figure 3A). The MLL gene, located at chromosome 11 band q23,
encodes a full length protein of 3,969 amino acids that is post-translationally cleaved by
taspase-1 into a 320 kilo-Dalton (kDa) N-terminal and 180 kDa C-terminal fragment that
remain associated non-covalently via the FYRN and FYRC domains 103, 104(Figure 3B).
The N-terminus of MLL contains a motif that binds the protein Menin. Menin
directly binds LEDGF, a protein with a PWWP DNA binding domain. MLL, through its
interaction with Menin, is bridged to LEDGF and recruited to target DNA sequences.
Loss of the Menin binding motif of MLL in the context of a MLL fusion protein results
in decreased transformation ability105.
Three A-T hooks are located just downstream from this region. A-T hooks
recognize and bind to bent, A-T rich DNA sequences

106

. This region has been shown to

interact with SET, protein phosphatase 2A (PP2A) and GADD34 proteins

107, 108

. The A-

T hooks precede two speckled nuclear localization domains. These domains are required
for localizing MLL to punctuate structures within the nucleus 109, 110.
The Repression Domain of MLL was identified in a study in which this region of
the protein was shown to have repressive activity in a reporter assay

106

. Additional

studies have found that corepressor proteins such as CtBP, BMI-1 and CBX4 (HPC2)
bind to this region, as does Histone Deacetylase 1/2 (HDAC1/2)111. Recent studies have
shown that the Polymerase Associated Factor (PAF) complex, associated with gene
activation, also binds to this region 112, 113.
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Located within the Repression Domain of MLL is the CXXC domain, so named
for the conserved spacing of eight cysteine resides. The CXXC domain was identified for
its homology to the CXXC domain of the DNA Methyltransferase 1 (DNMT1) protein
114

. Studies from our lab and others have shown that the CXXC domain binds to

unmethylated CpG DNA, protecting it from DNA methylation. The ability of the CXXC
domain to bind unmethylated DNA is required for transformation by the MLL-AF9
fusion protein in MLL leukemia 115, 116.
Downstream of the CXXC domain is an atypical bromodomain and four plant
homodomain (PHD) zinc fingers. The second of the four PHD fingers is involved in
homodimerization of MLL

117

. The third PHD finger has been shown to bind to H3K4

trimethyl marks or the cyclophilin CYP33 in a mutually exclusive manner

118, 119

. The

ability of MLL to both “read” histone marks and “write” the H3K4 methyl mark on
histones is thought to promote the maintenance of histone modifications.
The C-terminus of MLL contains a transactivation domain (TAD) that is
associated with coactivator protein CBP binding120. And, as mentioned previously, the
most carboxy-terminal protein domain in the wild type MLL protein is the SET domain
with H3K4 histone methyltransferase ability. Together, the multiple functional domains
of MLL provide the protein with a multitude of ways to participate in gene regulation,
both with activating and repressive functions.
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Figure 3. Protein Domains of MLL and MLL Fusion Proteins
A

B

C

(A) Domain schematic of the human MLL protein with protein domains and
corresponding amino acids indicated. Alternate names and chromosomal location are
noted. (B) After cleavage by Taspase 1, the N-terminal and C-terminal fragments of MLL
associate through the FYRN and FYRC domains. (C) MLL fusion proteins express the Nterminus of MLL through the breakpoint cluster region and the C-terminus of one of 79
known fusion partner proteins.
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MLL Target Genes
The HOX genes are very well-studied gene targets of MLL. HOX proteins are
DNA-binding transcription factors that bind DNA via a homeodomain located at their Cterminus. HOX proteins function to regulate body segment identity as well as determine
embryonic cell fate. Expression of HOX genes is positively regulated by the Trithorax
group of proteins including MLL, whereas expression is repressed by the Polycomb
group of proteins96, 121, 122.
These genes are highly evolutionarily conserved, so much so that loss of a Hox
gene in Drosophila melanogaster could be rescued by re-expression of the chicken
ortholog123. In humans and mice, the HOX genes are divided into four clusters: A, B, C
and D, located on four separate chromosomes. Within these clusters, there are 13
paralogous groups totaling 39 genes in whole124,

125

. The HOX genes are regulated

spatially and temporally such that the genes located 3’ in the clusters are transcribed
earlier in development and at the anterior end of the organism. Conversely, genes located
5’ in the clusters are transcribed later in development and in the posterior end 124.
HOX genes are also critical regulators of hematopoiesis. Genes in the A, B and C
cluster are highly expressed in hematopoietic stem and early progenitor cells, and
expression of these genes is decreased as the cells differentiate and mature.
Overexpression of HOX genes such as HOXA9 is a characteristic of certain types of
leukemia, and coexpression of Hoxa9 and Meis1 is sufficient to transform normal mouse
myeloid progenitor cells126.
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MEIS1, another target of MLL, is a member of the three amino acid loop
extension (TALE) group of proteins that also contain a homeodomain. Like HOX
proteins, MEIS1 plays a role in development and hematopoiesis, although its role is less
well understood. Similar to HOX genes, MEIS1 expression is highest in early
hematopoietic stem and progenitor cells, and expression decreases as cells differentiate
127

. Meis1-/- mice die at E14.5 and exhibit a lack of megakaryocytes and subsequently,

extensive hemorrhaging128. MEIS1, like HOXA9, is overexpressed MLL-rearranged
leukemias129-131.
In addition to MEIS1 and HOX genes, more recent genome-wide studies have
identified a role for MLL as a potential master regulator of gene transcription. Chromatin
immunoprecipitation studies have examined the binding of MLL at loci throughout the
genome. One of the earliest reports found MLL bound at the promoter of 5,186 genes in
U937 monocytic cells with coincident binding of RNA Polymerase II at 90% of the
genes, and H3K4 trimethylation at 92% of the genes

132

. However, a separate study used

Mll+/+ and Mll-/- murine embryonic fibroblasts (MEFs) to further examine the correlation
between Mll localization, H3K4me3 and gene activation. The authors found peaks of
H3K4me3 at 10,041 genes in the wild type cells, with a loss of H3K4me3 at only 525
promoters, or approximately 5% of genes, in the Mll-/- cells 133. These results suggest that
Mll maybe be responsible for H3K4me3 at only a subset of genes.
Another study comparing the localization of MLL and MLL fusion proteins found
wild-type MLL bound at the promoter and 5’ region of 2,595 genes

134

. While the exact

number of genes regulated by MLL is still being examined, it is clear that MLL plays a
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critical role in regulating specific target genes involved in development and
hematopoiesis.
MLL Leukemia
The transcriptional activation role of MLL is exploited in a specific type of
leukemia termed MLL Leukemia. Patients with MLL leukemia express oncogenic fusion
proteins that result in the aberrant transcription of MLL target genes such as the HOX
genes described above (Figure 3C). Additionally, amplifications of the MLL gene are
found in patients with AML and myelodysplasia, and partial tandem duplication of
amino-terminal exons of MLL are found in approximately 10% of all AML cases 135, 136.
In MLL fusion genes, a double strand break in the DNA occurs within the
breakpoint cluster region (BCR) of the MLL gene. As these breaks are deleterious to a
cell, mechanisms of DNA repair are employed. In this case, non-homologous end joining
(NHEJ) fuses the broken MLL gene to one of over 79 translocation partner genes
3

(Figure 3C). The cause for breakage of MLL within the BCR, as well as the cause for

breakage within the fusion partner, is not well understood. While there is little sequence
homology within the breakpoint cluster regions of both MLL and the known fusion
partners, the BCRs share several structural elements including topoisomerase II cleavage
sites, DNAse I hypersensitivity sites and scaffold attachment regions that serve to
associate proteins involved in transcription and replication137-140. These regions may be
more susceptible to breakage and subsequent aberrant repair by NHEJ.
MLL translocations are found in approximately 10% of all Acute Myeloid or
Lymphoid Leukemias diagnoses, but the incidence of MLL leukemia is higher in infants.
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Approximately 70% of infant ALL and 35-50% of infant AML patients express MLL
fusion genes

141

. While the five year event free survive (EFS) in infants with ALL

without MLL recombination is 74-96%, infants with ALL with a MLL recombination
have a five year EFS of only 19% 2.
MLL fusions are also present in a subset of leukemias that arise after treatment for
a primary cancer, termed therapy-related MLL leukemia142. Cells require expedient
replication of DNA for cell division to occur. As the double helix unwinds to separate the
strands for replication, tension builds in the DNA proximal to the replication fork and if
not relieved, would halt the DNA polymerase. Topoisomerase enzymes introduce breaks
in the DNA phosphodiester backbone to allow for unwinding of the DNA to alleviate the
tension, and then reanneal the cut DNA back together. Topoisomerase enzymes play a
similar role in RNA transcription.
Topoisomerase II inhibitors such as etoposide, doxorubicin and daunorubicin are
often administered to cancer patients to block the activity of the topoisomerase enzyme in
rapidly dividing cancer cells, notably preventing the reannealing of broken DNA strands.
This triggers the DNA damage response pathway and induces apoptotic cell death. The
11q23 locus has been shown to be highly susceptible to double strand breaks, and
inhibition of topoisomerase enzymes prevents repair at this locus

143, 144

. Aberrant repair

of the broken DNA by NHEJ can then result in the production of oncogenic fusion
proteins. Approximately 5-10% of all MLL leukemias are therapy-related, almost all of
which are AML141.
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While almost 80 MLL fusion partners have been characterized, over 85% of all
MLL leukemias involve one of 6 partner genes3: AF4, AF9, ENL, AF10, ELL and AF6.
These proteins belong to one of three gene families, all of which are involved in
transcription regulation. Of note, new nomenclature has been instituted for genes in these
families: AF4/AFF1, AF9/MLLT3, ENL/MLLT1, AF10/MLLT10, and AF6/MLLT4.
However, as much of the literature regarding these genes references the original gene
names, they will be used throughout this dissertation.
Results from several studies support the hypothesis that the fusion partner dictates
the leukemic phenotype. For example, MLL-AF9 fusion proteins are highly associated
with AML, whereas MLL-AF4 fusions often given rise to ALL or acute biphenotypic
leukemia (ABL). Retroviral transduction of MLL-AF9 transforms both early
hematopoietic progenitors

145

and committed myeloid progenitors

146

, and when

transplanted into mice, results in proliferation and accumulation of myeloblasts.
Similarly, a knock-in MLL-AF9 mouse model in which expression of the MLL-AF9
fusion protein is under control of the endogenous Mll promoter also leads to development
of acute myeloid leukemia in the majority of the mice 147, 148.
Conversely, knock-in of the MLL-AF4 fusion resulted in mice with a mixed
lymphoid and myeloid phenotype, with a predominance of B220+ or CD19+ B lymphoid
cells148. These mice developed hematologic malignancies with a median of 520 days
compared to 220 days for mice with a knock-in of the MLL-AF9 fusion 148. These results
support the hypothesis that the fusion partner is responsible for dictating the leukemic
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phenotype. However, additional studies suggest that the microenvironment is the critical
regulator of myeloid versus lymphoid leukemic fate.
Wei et al examined the leukemic phenotype of MLL-AF9-transduced CD34+
human cord blood cells cultured under myeloid or lymphoid cytokine conditions in vitro
and in vivo. When cultured in the presence of myeloid cytokines, cells expressed
myelomonocytic surface markers. However, switching these myeloid-conditioned, long
term-cultured MLL-AF9 cells to media promoting erythroid or lymphoid development
failed to differentiate the cells, as indicated by decreased surface marker expression of
lienage-specific markers compared to control CD34+ cells

149

. Interestingly, when MLL-

AF9 transduced CD34+ cells were cultured under conditions to promote B cell
differentiation, the cells exhibited a mixed lineage phenotype, suggesting that the
cytokine environment plays a critical role in determining the leukemic phenotype of these
cells 149.
To examine the role of the microenvironment on leukemogenesis in vivo¸ MLLAF9-expressing CD34+ cells were either directly injected after retroviral transduction
into mice, or were cultured for an extended period of time in the presence of myeloid or
lymphoid cytokines prior to injection into mice. Non-obese Diabetic/Severe Combined
Immunodeficiency (NOD-SCID) or NOD-SCID β2-microglobulin-/- mice injected with
MLL-AF9-transduced cells cultured under myeloid conditions only developed AML with
a latency of 10 weeks. Injection with cells cultured under lymphoid conditions resulted in
mice with AML, B-ALL or Acute Biphenotypic Leukemia (ABL) with a latency of
approximately 13.5 weeks. Direct injection of newly-transduced cells caused mice to
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develop B-ALL or ABL, but no mice developed AML. However, injection of these same
cells into mice transgenic for IL-3, SCF and GM-CSF expression resulted in only AML
development in mice within 7 weeks. Similarly, injection of MLL-AF9 cell lines cultured
under myeloid or lymphoid conditions into these transgenic mice resulted in development
of AML exclusively within 5 weeks. These results suggest that it is not the fusion partner
per se, but the microenvironment in which the fusion-expressing cell is located that
determines the leukemic phenotype 149.
While the interplay between the function of the partner brought into MLL fusion
genes and the microenvironment in which they are expressed is still being elucidated, it is
clear that MLL fusion proteins are key drivers of leukemogenesis. MLL-AF9 fusions in
particular are highly leukemogenic, and understanding the mechanism by which AF9
functions in wild-type cells is necessary understanding how it contributes to misregulated
hematopoiesis in MLL leukemia.
AF9
The AF9 gene, located at chromosome band 9p22, is fused to MLL in
approximately 25% of de novo AML in children and 2-5% of all AMLs4. Patients with
MLL-AF9 translocations have a median survival of four years4. Understanding the
function of AF9 is necessary to understanding its role in MLL leukemia in order to
develop efficacious therapeutics.
AF9 is a member the YEATs (Yaf9, ENL, AF9, Taf1, Sas5) domain-containing
family of proteins, so named for the conservation of the domain in both yeast (Yaf9,
Taf1, Sas5) and mammalian (AF9, ENL) proteins. AF9 and ENL are highly homologous
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to each other, sharing approximately 50% amino acid identity overall and 80% identity in
conserved N and C terminal regions150, but these proteins show little homology to other
mammalian gene families (Figure 4A).
The YEATs domain is located at the N-terminus of both AF9 and ENL (Figure
4A, B). This domain is often found in proteins with chromatin-modifying ability151. As is
further discussed in the review on transcription elongation, the YEATS domain of AF9
and ENL interact with the Polymerase Associated Factor complex (PAFc), which recruits
the Super Elongation Complex (SEC) to poised polymerases, facilitating productive
elongation of nascent RNA 152, 153.
A nuclear localization signal (NLS) is located downstream of the YEATs domain
and allows for translocation of the protein from the cytoplasm to the nucleus. This region
is also proximal to a serine/proline rich region. The C-terminus of AF9 encodes a 94
amino acid AHD domain [actin non-complementing gene 1 budding yeast (Anc1)
homology domain] involved in protein-protein interactions154. This region of AF9 is
highly conserved with ENL, and to a lesser degree, to the yeast ANC1

155

. It has been

shown to interact with at least four other proteins: AF4, DOT1L, CBX8 and BCoR in
mammals8-11(Figure 5).
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Figure 4. Protein Domains of AF9 and ENL
A

B

C

D

Protein domain schematic of (A) AF9 and (B) ENL with alternate names and
chromosomal location noted. Lines below the protein structure indicate the approximal
fragment of the protein present in MLL fusions. (C) ) Solved NMR structure of AF4
peptide in complex with the C-terminal AHD of AF9 (figure from Leach 2013). (D)
Amino acid sequence of a segment of the AF9 region known to interact with AF4,
DOT1L, CBX8 and BCoR is highly conserved in homolog ENL. The bolded aspartic
acid mediates an electrostatic interaction with AF4 family members.
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Recent studies by Leach et al showed that the AHD of AF9 is highly disordered
with a structure that is almost entirely random coil with a minimal beta structure in its
unbound state156. The addition of an AF4 peptide corresponding to the known AF9interacting sequence

157

resulted in a structural rearrangement of the AHD, forming the

alpha-beta structure shown in Figure 4C. A beta strand in AF4 residues 761-766 is
located next to the beta hairpin of AF9 residues 535-546, together forming a threestranded antiparallel beta sheet. AF9 also forms three alpha helices around the AF4
peptide156(Figure 4C).
At least one electrostatic interaction between AF9(D544) and AF4(K764) exists
(Figure 4D, 6B). This interaction is the focus of further studies presented in this
dissertation. The interface between AF9 and AF4 is otherwise primarily hydrophobic,
mediated by several aliphatic residues within the region. Interestingly, while the
sequences of the proteins that interact with AF9 are highly dissimilar, DOT1L, CBX8
and BCoR proteins all have conserved spacing of the aliphatic residues present in AF4
that mediate the AF4-AF9 interaction. Coexpression of AF9 and any one of the four
binding partners resulted in highly similar chemical shifts, suggesting that AF9 adopts a
similar structure when bound to any of the four proteins, and that the binding partners all
share a common binding site on AF9 156. These results support the hypothesis that the Cterminus of AF9 remains highly disordered until binding to a partner protein. As the
binding partners of AF9 are considered both transcriptional activators (AF4, DOT1L) and
repressors (CBX8, BCoR), it is plausible that the interaction of AF9 with one of these
proteins may allow for differential regulation of genes targeted by AF9.
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Figure 5. AF9-Containing Protein Complexes

The AHD of AF9 has been shown to interact with at least four known proteins: CBX8,
DOT1L, BCoR and AF4/AF5q31. Shaded regions of the interacting protein denote
approximate region of AF9 interaction. CBX8 is a member of the PRC1 repressive
complex. DOT1L is the only known H3K79 histone methyltransferase. BCoR has been
shown to associate with BCL-6 to repress gene targets. AF4/AF5q31 are associated with
P-TEFb, and with additional proteins (not shown) form the Super Elongation Complex
(SEC).

To further investigate the functional role of Af9, a constitutive knockout mouse
was engineered by disrupting the second exon of Af9 with a lacZ-neo cassette. Af9+/- mice
were normal and fertile158. Breeding with these mice produced homozygous offspring at
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the expected ratio, indicating that the homozygous null Af9 mice survive embryogenesis.
However, 50% of these Af9-/- mice were found dead at birth or died within hours after.
The remaining surviving mice were severely runted and died within two weeks. These
mice did not exhibit any gross external malformations, nor did they have internal changes
in organ structure. Hematopoiesis appeared normal in the Af9-/- mice as assessed by
histology and flow cytometry158.
Further examination of whole-skeleton preparations showed that the homozygous
mutants exhibited axial skeletal abnormalities, lacking a pair of floating ribs and the
associated vertebrae. The Af9-/- mice also had deformed sternums, and often had extra
cervical vertebrae compared to wild type controls. These malformations, in addition to
other subtle changes, indicated that anterior homeotic transformation of the axial skeletal
had occurred in mice lacking Af9 expression comparable to the phenotype of Mll+/- mice
96

. Lumbar and caudal vertebrae, and the appendicular skeleton were normal158.
β-galactosidase staining of embryos taken from heterozygous mice between E10.5

and E14.5 indicated widespread Af9 expression in the mouse including the skeletal
system, neural system, gut, forming genital organs, in the caudal hindbrain and at the
midbrain-hindbrain border. Slight differences in the expression pattern of Bgalactosidase were seen in the homozygous null embryos, with decreased staining at the
anterior cervical region compared to the heterozygous embryos, as well as more broad
lateral expression in this region compared to the Af9+/- embryos158.
The widespread expression pattern of Af9 in developing tissues and the homeotic
transformations seen upon loss of Af9 suggested a role for Af9 as a master regulator of
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early embryonic development, similar to Mll. As proper expression of Hox genes is
critical for normal development, the authors examined the expression patterns of several
Hox genes in wild-type, heterozygous and homozygous null Af9 embryos. The expression
of Hoxd4 in Af9-/- embryos was reduced and did not reach the anterior boundary
compared to wild-type or Af9+/- E9.5 embryos. This altered expression pattern was not
seen with other Hox genes158. From this study, the authors concluded that Af9 is required
for normal embryonic development, at least in part by Hox gene regulation.
Pina and colleagues sought to further elucidate the role of Af9 in hematopoietic
development. Global transcriptome analysis of long term culture-initiating cells (LTC-IC)
was performed, and identified AF9 as one of the most highly upregulated genes in the
quiescent human LT-HSC159, consistent with other published microarray data

160-162

. The

expression of AF9 was further analyzed in the various progenitor compartments of
human cord blood. Results indicated that AF9 expression was highest in the HSC, and
that expression diminished at each stage of differentiation with a 2-3 fold reduction from
HSC to CMP and again to GMP, suggesting a role for AF9 in early lineage commitment
159

.
Forced expression of AF9 by lentiviral transduction in human CD34+CD38- cord

blood cells resulted in an increase in erythroid progenitors (BFU-E) at the expense of the
granulocyte/macrophage progenitors (CFU-GM). The earlier multipotent CFU-GEMM
population that gives rise to the CFU-GM was unaffected. Overexpression of AF9
proteins lacking the YEATS domain or AHD, respectively, produced colony numbers
similar to vector control, indicating that the entire full-length protein is necessary to
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mediate

the

expansion

of

the

erythroid

progenitor

compartment.

Similarly,

overexpression of AF9 resulted in an increase in CD41+ colonies in a megakaryocyteCFC assay. Conversely, knockdown of AF9 with short hairpin RNAs produced an almost
complete loss of BFU-E and CFU-GEMM and a reduction in CD41+ colonies, suggesting
that AF9 plays a critical role in early erythroid/megakaryocyte (E/Meg) lineage fate
determination159.
To test the effect of AF9 overexpression in vivo, the authors injected NOD/SCID
β2-microglobulin-/- mice with CD34+ cord blood cells transduced with lentivirus
encoding GFP-tagged AF9. Two weeks after intratibial injection, engraftment of GFPpositive

cells

within

the

erythroid

(CD71+),

megakaryocyte

(CD41+)

and

lymphoid/myeloid (CD45+) compartments was examined. The results correlated with the
in vitro data, indicating an increase in GFP-positive cells in the erythroid and
megakaryocytic populations upon forced expression of AF9 with a concurrent decrease in
GFP-positive cells in the lymphoid/myeloid compartments159.
Expression of transcription factors associated with the E/Meg lineage such as
GATA1 and GATA2 were increased upon overexpression of AF9 in CD34+ cord blood
cells, while expression of transcription factors associated with the GM lineage (PU.1,
CEBPA, GFI1) were decreased upon forced expression of AF9159. Together, the results of
this study support a role for AF9 in early hematopoietic commitment to the erythroid and
megakaryocytic lineage.
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AF9 Homolog ENL
Interestingly, the AF9 homolog ENL (MLLT1) shows an opposing pattern of
expression despite highly conserved sequence similarity throughout regions of the
protein. ENL is expressed in most tissues with the exception of the liver, with the highest
expression levels found in the testis and brain. In terms of hematopoietic expression,
ENL is highly expressed in lymphoid cells but not in myeloid cells, the opposite pattern
of AF9 150.
The ENL protein is structurally very similar to AF9, sharing 50% of amino acid
sequence overall, with an increase to 80% identity within the YEATS and AHD domains
(Figure 4B, 4D). However, the 5’ regulatory region of Enl shows no sequence similarity
to the Af9 promoter region, suggesting that the expression of these genes is distinctly
regulated. The 5’ regulatory region of Enl does not contain a consensus TATA element,
but includes several Sp1 binding sites as well as potential N-myc, c-Ets, c-Rel and GATA
binding sites

150

.

Enl-deficient mice were engineered by insertion of a neomycin-resistance cassette
with a stop codon in reverse orientation into exon six of Enl, resulting in a protein less
than 40% of full length150. Heterozygous mice did not exhibit any developmental defects;
however, crosses with these mice did not yield any homozygous null offspring, indicating
an essential role for Enl in embryonic development. Genotyping analysis of developing
embryos using timed matings indicated the absence of Enl-/- mouse embryos as early as
E8.5, the earliest time point examined150.
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Drosophila melanogaster express a gene called ear (Enl/Af9-related) that is
equally homologous to both human AF9 and ENL, suggesting that these genes arose from
a common ancestor. Like AF9 and ENL, ear is highly expressed in early Drosophila
embryos, consistent with the role of this protein and the human homologs in early
transcriptional regulation

163

. However, it is possible that AF9 and ENL diverged from a

single gene to fulfill separate roles in development.
AF9 and ENL in Transcriptional Elongation
Both AF9 and ENL are found in protein complexes associated with transcriptional
elongation

5-7

. During transcription, RNA Polymerase II (Pol II) is recruited to target

gene promoters and initiates transcription of approximately 12 nucleotides before it
becomes paused (promoter-proximal pausing)164. Elongation is halted by two factors:
DSIF [5,6-dichloro-1--ᴅ-ribofuranoslbenzimidazole (DRB) sensitivity-inducing factor]
and NELF (negative elongation factor)

165, 166

. Genome-wide ChIP-seq studies have

shown that the major peak of Pol II is at about +50bp, with Pol II also found at low levels
downstream of the poised promoter peak, and absent in the -2000 to -10,000 region167.
The distribution of DSIF follows that of Pol II, and indeed DSIF has been shown to track
along the gene with Pol II. NELF is primarily found only at the poised Pol II peak 167.
Association of Pol II with DSIF and NELF has been shown to significantly reduce the
elongation rate of Pol II in in vitro transcription assays168.
Poised Pol II can be released to initiate productive elongation through the
association with P-TEFb169. P-TEFb is composed of CDK9 and a cyclin T1/2 subunit.
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Binding of cyclin T1/2 to CDK9 induces a conformational change in CDK9 that, along
with phosphorylation of CDK9 threonine 186, is required for activation of the kinase170.
P-TEFb then phosphorylates the serine 2 residue of the C-terminal domain (CTD) of the
largest subunit of Pol II171, as well as the hSpt5 subunit of DSIF172, 173 and the E subunit
of NELF174 to release inhibition by DSIF and NELF allowing for productive elongation
169, 172, 174

. At this point, additional factors associated with Pol II act to stabilize the

complex and promote elongation at a rate of 3.8kb/min for up to 2 million base pairs 175.
These factors include transcription factor IIS (TFIIS), which helps Pol II restart after
backtracking on the DNA176, TFIIF and ELL 1-3, which stimulate the elongation rate of
Pol II177, as well as the PAF complex and the Super Elongation Complex (SEC) defined
below178.
The members of the SEC were first identified through studies of viral gene
activation upon HIV infection. P-TEFb, prior to recruitment to Pol II, is sequestered by
binding to the 7SK snRNP. In HeLa cells, approximately 90% of P-TEFb is bound in an
inactive form to the 7SK snRNP complex179-181. This complex includes the RNA-binding
protein HEXIM 1 or 2, the La-related protein LARP7, and the 7SK methyl phosphate
capping enzyme (MePCE). HEXIM1/2 binds the 7SK snRNP as well as P-TEFb, and
LARP7 and MePCE act to stabilize this complex. The HIV Tat protein releases P-TEFb
from the 7SK snRNP and recruits it to the poised Pol II at the HIV LTR through a
mechanism not yet well understood182. Tandem affinity purification of CDK9 and Tat
first identified SEC components AF9, ENL, ELL2, and AF5q31183, all of which are
known fusion partners in MLL leukemia.
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Subsequent biochemical analyses using different methologies have identified
additional components and distinct complex formations composed of the proteins in the
SEC. Biswas et al biochemically purified proteins associated with AF9, AF4 and ELL
and identified the associated proteins by mass spectrometry. Reconstitution of these
complexes using purified proteins lead the authors to identify distinct complexes
involved in transcription regulation. First, AF4 or AF5q31 directly interact with Cyclin
T1 of P-TEFb. AF4/AF5q31 then recruits AF9, an interaction that will be further
discussed. P-TEFb links ELL and ELL-Associated Factors 1 and 2 (EAF1/2) to the AF4P-TEFb complex. DOT1L was shown to interact with AF9 in a complex distinct from the
AF4-P-TEFb complex, which aligns with the finding that DOT1L and AF4 bind to the
same region of AF96(Figure 5).
A separate study by Yokoyama and colleagues purified endogenous AF4 from
leukemic K562 cells and identified AF5q31, ENL, CDK9 and Cyclin-T1 in the
immunoprecipitates. The authors termed this complex the AEP for AF4 family/ENL
family/P-TEFb complex7. Unlike the Biswas study, DOT1L was not found to be present
in this complex.
A third study by Mueller et al immunoprecipitated Flag-ENL in HEK293 cells
and detected 15 associated proteins with ENL. These included CDK9, Cyclin T1,
AF5q31 and AF4, as did the other studies. Additional associated proteins included BCoR
and CBX8 which will be further discussed, as well as nine other proteins. This complex
was termed the EAP for ENL Associated Proteins5.
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While the techniques used and the final components identified between these
studies have some differences, it is clear that multi-protein complexes including AF9 are
involved in the intricate regulation of RNA transcription. Understanding the role of AF9,
and those proteins with which AF9 interacts, is necessary for understanding the
regulation and misregulation of gene expression in normal and neoplastic development.
AF9 Interacting Proteins
As indicated earlier, multiple proteins have been shown to interact with AF9,
including AF48, DOT1L9, CBX810 and BCoR11. These interactions are mediated by the
C-terminal AHD of AF9 which is retained in MLL-AF9 fusion proteins.
AF4
AF4 (AFF1) is a member of the AFF/ALF family of nuclear proteins including
AF5q31, LAF4, and FMR2. These proteins contain conserved N and C-terminal
homology

domains,

a

serine/proline-rich

transactivation

domain

and

an

AF4/LAF4/FMR2 (ALF) homology domain (Figure 6A). The ALF domain, specifically
residues 273-289, interacts with E3 ubiquitin ligase proteins of the Drosophila seven in
absentia (sina) homologues (Siah)-1a and Siah-2a family184, 185.
A specific mutation in the Siah-binding motif of Af4 was identified in a screen of
chemically mutagenized mice186. Male mice were injected with N-ethyl-N-nitrosurea
(ENU) which targets spermatagonial stem cells. These mice were then bred, and
offspring with dominant motor phentoypes were screened to identify the mutated gene.
Mice with jerky, ataxic gaits, termed “robotic mice” were found to express Af4 protein
with a V280A mutation in the Siah-binding motif of Af4. These mice also exhibited a
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rapid loss of Purkinje cells in the cerebellum and developed complete, bilateral
cataracts186. The mutation expressed in the robotic mouse reduces binding between AF4
and the SIAH E3 ubiquitin ligases, significantly decreasing AF4 protein turnover and
subsequently leading to an accumulation of AF4 protein. This mouse has therefore acted
as a useful model of AF4 overexpression.

Figure 6. Protein Domains of AF4

A

B

(A) Protein domain schematic of AF4 with alternate names and chromosomal location
noted. Line below the protein structure indicates the approximal fragment of the protein
present in MLL fusions. (B) The AF9 interacting sequence is highly conserved among
AF4 family members. A conserved lysine (indicated in bold) mediates an electrostatic
interaction with AF9 residue D544.
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As previously discussed, AF4 directly interacts with both the kinase and cyclin
subunits of P-TEFb5, 187. Specifically, AF4 residues 1-308 are necessary for binding to
Cyclin T1188. AF4 is a direct phosphorylation target of P-TEFb, a modification which
was shown to decrease the transcriptional activity of AF4 in a reporter assay187. Recent
studies have shown that AF4 is also present in the 7SK snRNP complex that sequesters
inactive P-TEFb, as well as a member of the P-TEF-b-AFF1(AF4)-BRD4 (PAB)
complex that delivers active P-TEFb to target genes188. These authors argue that AF4
should be considered a member of all P-TEFb complexes, not just the P-TEFb-associated
SEC.
AF4 residues 766-779, highly conserved in all AF4 family members, interact with
AF9 and ENL (Figure 6B). Binding to either one of these proteins protects AF4 from
SIAH-mediated degradation187. Inhibition of the AF4-AF9 interaction by a synthetic AF4
mimetic peptide results in necrotic cell death of MLL leukemia cells, the mechanism of
which is not yet understood157, 189.
Isnard and colleagues engineered a constitutive Af4 knockout mouse to examine
the role of Af4 in development190. Mice heterozygous for the null allele appeared normal
and were fertile. Homozygous mice were born at the expected proportion and 80% of
those Af4-/- mice appeared normal. The remaining 20% were significantly smaller, the
smallest of which did not survive beyond ten days. These mice exhibited defects in
lymphoid development with decreased thymic cellularity, a reduction in CD4+CD8+ T
cells, and a reduction in pre-B and mature B cells. All other hematopoietic compartments
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appeared normal. Interestingly, MLL-AF4 leukemias are of lymphoid phenotype in 95%
of the cases191, further supporting a role for AF4 in lymphoid development.
DOT1L
The DOT1L (Dot1-like, KMT4) protein was identified through its N-terminal
sequence homology to the yeast Dot1 protein, which was discovered in a genetic screen
as a suppressor of telomeric silencing (Dot1, disruptor of telomere silencing)192. This
region of shared homology encodes a conserved methyltransferase domain. DOT1L is the
only member of the class I methyltransferase family, in contrast to all other known
histone

methyltransferases

(HMTs)

of

the

class

V

family.

The

Class

V

methyltransferases, including MLL, contain a conserved SET domain at the C-terminus
and target residues on the protruding histone tail193, 194. DOT1L is the only identified nonSET domain-containing HMTase and exhibits specificity for methylation of histone H3 at
lysine 79 (H3K79), a residue located within the globular structure of the H3 protein195197

(Figure 7). DOT1L is also the only enzyme identified thus far that methylates H3K79,

and knockout of Dot1 in yeast and Drosophila, and Dot1l in mice all result in a global
loss of H3K79 methylation197-199.
Studies in yeast suggest that Dot1 is a distributive enzyme—depositing both
mono-, di-, and tri-methyl marks on H3K79 after one round of catalysis200. Most of the
class V methyltransferases are processive enzymes, requiring methyl marks to be placed
sequentially from mono to di to trimethyl201. These results also suggest that all
methylation states of H3K79—mono, di and trimethyl—mark loci of active
transcription200. Genome-wide studies support the association of H3K79 methylation with
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highly transcribed genes202, with hypomethylation of H3K79 associated with regions of
repressed chromatin195, 197.

Figure 7. Protein Domains of DOT1L

Protein domain schematic of DOT1L with alternate names and chromosomal location
noted.

However, there are specific examples in which H3K79 marks repressed genes,
including transcription factors Tbr1 and CTGF, and the epithelial sodium channel gene
ENaCα. Overexpression of AF9, which binds to DOT1L residues 479-1222, results in
hypermethylation of H3K79 in the promoter region of ENaCα and reduced ENaCα
expression. The requirement of the Af9-Dot1l interaction in ENaCα promoter H3K79
methylation was further supported by knock-down of Af9, which resulted in a decrease in
H3K79 methylation at the ENaCα promoter region and subsequent increase in gene
transcription9.
Dot1l expression is ubiquitous and essential for development, as Dot1l-/- mice do
not survive beyond E10.5. These embryos exhibit cardiovascular defects including an
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enlarged heart and decreased vasculature199. Conditional cardiac-specific deletion of
Dot1l caused dilated cardiomyopathy, at least in part due to the loss of Dot1l-mediated
H3K79 methylation and decreased expression of dystrophin, a protein necessary for
supporting cardiac smooth muscle cells from mechanical stress during contraction203.
Embryos from Dot1l-/- mice also exhibit severe anemia, indicating a role for Dot1l
in erythropoiesis204. Loss of Dot1l expression resulted in delayed development of
erythroid, but not myeloid or lymphoid, progenitor cells. Expression of Gata2, which as
discussed previously is required for maturation of the HSC to the CMP, was
downregulated in Dot1l-deficient mice. Pu.1 expression, associated with myeloid lineage
differentiation, was significantly increased in Dot1l null mice204. These results suggest
that H3K79 methylation by Dot1l regulates the lineage commitment of early progenitor
cells. In a separate study, conditional loss of Dot1l resulted in pancytopenia, including
loss of HSCs and lineage progenitor cells205.
Additionally, DOT1L has been shown to play a role in regulating heterochromatin
formation at telomeres206. DNA silencing at telomeres is mediated by the recruitment of
Sir (silent information regulator) proteins207. These proteins bind only to unmethylated
H3K79, and methylation at this histone residue precludes Sir binding and affects
heterochromatin formation.
DOT1L is also involved in DNA double strand break repair208. The DNA damage
response protein 53BP1 binds to methylated H3K79 at DNA double strand breaks, and
either mutation of the H3K79 residue or knockdown of DOT1L inhibits recruitment of
53BP1 to sites of DNA damage. In regard to cell cycle progression, DOT1L H3K79
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methylation levels have been shown to fluctuate during the cell cycle in both yeast and
humans204,

209

. Dot1l-null embryonic stem cells show defects in proliferation and are

blocked in the G2/M phase of the cell cycle210. DOT1L is also involved in transcriptional
elongation. As previously discussed, Dot1l has been found to be in complex with proteins
associated with the P-TEFb elongation complex5, 187 including AF9. Studies by Biswas
suggest that the DOT1L-AF9 complex is mutually exclusive of the AF9-P-TEFb
complex6.
In MLL leukemias expressing the MLL-AF9 fusion, it is hypothesized that the
AF9-DOT1L interaction aberrantly recruits the histone methyltransferase to MLL target
genes, promoting H3K79 methylation and productive elongation of MLL target genes
associated with leukemogenesis such as Hoxa9 and Meis1. Indeed, loss of Dot1l
expression in MLL-AF9 transformed bone marrow cells results in a loss of colony
formation and Hoxa9 expression compared to wild-type cells211.
This finding extends beyond MLL-AF9 fusions to other MLL-rearranged fusion
proteins; loss of Dot1l in MLL-GAS7 or MLL-AFX, but not E2a-PBX-transformed cells
also results in a decrease in colony formation, although not as dramatically as with the
MLL-AF9 expressing cells211. Genome-wide ChIP-seq studies indicate that of 139 genes
targeted by the MLL-AF9 fusion protein, 120 genes are enriched in H3K79
dimethylation212. Loss of Dot1l in MLL-AF9 leukemia cells resulted in a specific
decrease in expression of genes targeted by MLL-AF9, and these cells were unable to
induce leukemia when transplanted into mice212.
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Targeting DOT1L has thus been identified as a potential therapeutic approach in
patients with MLL-rearranged leukemias. Several inhibitors have been developed,
including one compound engineered by Epizyme Inc. This inhibitor, EPZ004777,
competes for binding with the DOT1L cofactor S-adenyosylmethionine (SAM) to a
specific pocket in the DOT1L structure. SAM is the substrate for DOT1L; upon binding,
DOT1L catalyzes the methylation of lysine 79 at histone H3 and releases S-adenosyl-Lhomocysteine (SAH) as the product. Inhibitors that prevent SAM binding to the DOT1L
SAM-binding pocket would thus prevent methylation of target residues by DOT1L.
While all histone methyltransferases use SAM as the methyl group donor, EPZ004777 is
highly selective for DOT1L over other histone methyltransferases213.
Treatment of leukemic cell lines with EPZ004777 resulted in a specific decrease
in H3K79 dimethylation without altering other histone modifications. Expression of MLL
target genes HOXA9 and MEIS1 were reduced in treated cells compared to control,
whereas genes associated with hematopoietic differentiation were increased. Mice
injected with leukemic MV4-11 cells harboring the MLL-AF4 fusion gene exhibited a
significant increase in median survival when treated with the DOT1L inhibitor compared
to control treated mice213. A derivative of this compound is now in phase I clinical trials.
CBX8
AF9 was also shown to interact with Polycomb group (PcG) protein CBX8
(HPC3) in a yeast two-hybrid screen and subsequently validated by other techniques10.
Further characterization of this interaction mapped amino acids 202-333 of Cbx8 binding
to the C-terminal 94 amino acids of AF9 (Figure 8). Members of the CBX family encode
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a conserved N-terminal chromodomain and a C-terminal C-box involved in interaction
with other proteins such as RING1A/B

214-216

. The AF9 interacting region is located

between these two domains, in a region of the Cbx8 protein that shows no homology to
other Cbx family members10.

Figure 8. Protein Domains of CBX8

Protein domain schematic of DOT1L with alternate names and chromosomal location
noted.

The Polycomb group (PcG) of proteins act to silence gene targets in opposition to
the activating Trithorax group of proteins, which includes MLL. Polycomb proteins exert
their function through two complexes: the Polycomb Repressive Complex (PRC) 1 and
PRC2. In the canonical model of PRC-mediated repression, PRC2 containing EED,
SUZ12 and EZH2 is recruited to target genes. EZH2, a SET-domain containing histone
methyltransferase, then catalyzes methylation of histone H3 lysine 27. This mark,
associated with gene repression217-219, then provides a docking site for PRC1 which is
composed of PHC, RING1A/B, BMI1 or MEL18, and a CBX protein (CBX 2, 4, 7 or
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8)220,

221

specific

. The exact composition of this complex is tissue-and differentiation-stage
222-224

. RING1 is an E3 ubiquitin ligase that catalyzes mono-ubiquitination of

H2A at lysine 119, which is a mark associated with transcriptional repression. Additional
proteins such as DNA methyltransferase (DNMTs) or histone deacetylases (HDACs) can
also be recruited to mediate additional silencing.
Maintaining the proper balance between the activity of the Trithorax group of
proteins and the Polycomb group of proteins is necessary for appropriate self-renewal and
differentiation of tissues219. The HOX genes, as previously described, are very well
studied targets of TRX and PcG. The promoters of these and other genes involved in
development are often marked by both the TRX-associated H3K4 methylation and
PRC2-associated H3K27 methylation marks. These bivalent genes are poised for either
rapid activation or repression following removal of one of the two marks. Polycomb
group proteins also play a role in cell cycle checkpoints. For example, members of both
PRC1 and PRC2 bind to and repress the p16Ink4a/p19Arf locus at the G1/S checkpoint220.
Studies have also identified roles for PcG proteins in the DNA damage response pathway,
as H2AK119Ub accumulates at DNA damage foci225, 226. As both PcG and TRX proteins
play critical roles in development and homeostasis, it is not surprising that PRC and TRX
proteins are often mutated in cancer.
The role of CBX proteins in hematopoiesis and leukemogenesis has been a
rapidly emerging area of study. Klauke and colleagues showed the overexpression of
Cbx7 enhances the self-renewal of hematopoietic stem cells and leads to leukemia,
whereas overexpression of Cbx 2, 4, or 8 leads to stem cell exhaustion. PRC complexes
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containing difference Cbx proteins are differentially recruited to a subset of target
genes227.
In regard to MLL leukemias, CBX8 has been shown to be required for MLL-AF9
mediated transformation and leukemogenesis. Tan and colleagues retrovirally transduced
bone marrow cells with MLL-AF9 fusion proteins encoding mutations that prevented
binding to Cbx8. Cells expressing these mutants were unable to serially replate in a
colony forming assay compared to the wild-type MLL-AF9 fusion228. These results were
further confirmed by expressing the MLL-AF9 fusion in bone marrow isolated from
wild-type or conditional Cbx8 knockout mice. Loss of Cbx8 resulted in a loss of colony
formation of MLL-AF9 transformed cells compared to control cells still expressing Cbx8.
Loss of transformation ability was associated with a decrease in activation of a luciferase
reporter gene under the control of the Hoxa9 promoter. While CBX8 is generally thought
to be a repressive protein, these results support a role for CBX8 in transcriptional
activation in MLL leukemia, possibly through association with the histone
acetyltransferase (HAT) TIP60228.
AF9 has also been shown to be present in a complex with additional members of
the PRC1 family. Immunoprecipitation of FLAG-tagged AF9 in HEK293 cells showed
association with endogenous PRC1 proteins CBX8, RING1A, RING1B and BMI1.
Knockdown of CBX8 with shRNA resulted in decreased association of AF9 with
RING1B and BMI1, indicating that interactions are mediated by the AF9-CBX8
complex229.
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Gel filtration experiments indicated that other AF9 binding partners, such as
DOT1LL, AF4 and BCoR, are not present in the AF9-PRC1 complex. Overexpression of
CBX8 results in decreased recruitment of DOT1LL to the ENaCα locus, which as
discussed, is mediated by AF9. As H3K79 methylation is associated with repression of
this gene, overexpression of CBX8 resulted in increased expression of ENaCα. Cooverexpression of CBX8 with AF9 restored levels to control. Conversely, shRNAmediated knockdown of CBX8 resulted in a decrease in ENaCα expression229. These
results highlight the importance of the distinct functions of AF9 that depend on the
proteins with which it is associated, the last known of which is BCoR.
BCoR
The BCL-6 Corepressor (BCoR) protein was identified as a transcriptional
repressor through its interaction with the oncoprotein BCL-6230(Figure 9). In a reporter
gene assay, coexpression of BCoR and BCL-6 resulted in potentiation of the
transcriptional repression mediated by BCL-6230. These proteins are found to localize at
the same BCL-6 target genes in germinal center B cells231.
BCoR itself is widely expressed throughout mouse and human cells, in both
embryonic development and in adult tissues230, 232. High levels of expression are present
in the developing tooth primordium, eye, limb buds, branchial arches and nervous system
tissues232, all of which are abnormal in patients with X-linked Oculofaciocardiodental
Syndrome (OFCD) characterized by mutations in BCoR233, 234.
Whole exome sequencing of a patient with acute myeloid leukemia with a normal
karyotype (CN-AML) identified a clonal somatic mutation in BCoR235. Further analysis
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of 553 CN-AML patients found that BCoR mutations were present in 3.8% of the cases.
These mutations often resulted in reduction or loss of BCoR expression. AML patients
with BCoR mutations had 7.5% Event Free Survival (EFS) compared to 41.4% of
patients with wild-type BCoR, with 25.6% and 56.7% Overall Survival, respectively235.

Figure 9. Protein Domains of BCoR

Schematic of domains in BCoR. Alternate names and chromosomal location are noted.

A yeast two-hybrid screen seeking to identify proteins that interact with the Cterminal 94 amino acids of AF9 identified BCoR as a potential interacting protein10.
Further analysis identified the minimal AF9 binding domain to be located at BCoR amino
acids 1127-1251(Figure 9). Within this region is a stretch of 34 amino acids that is
present in two, but not all four mouse BCoR splice variants. Only isoforms containing
this region were able to bind to AF9, whereas all isoforms can bind to BCL-6 as the
regions affected by alternative splicing are located downstream of the BCL-6 binding
domain. These results suggest that the interaction of specific BCoR isoforms with AF9
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can modulate the transcriptional activation activity of AF9, both in the context of the full
length protein and perhaps in the context of MLL-AF9 fusions.
Collectively these studies all indicate a critical role for AF9 and AF9 interacting
partners AF4, DOT1LL, CBX8 and BCOR in gene regulation and development (Figure
5). The function of interactions mediated by AF9 is less well understood. Here, we seek
to elucidate the role of AF9 and AF9-mediated interactions in normal hematopoiesis and
leukemogenesis.

CHAPTER THREE
METHODS
Cloning of Full-length AF9
To clone full-length AF9 into a FLAG vector, the 3XFLAG tag was PCR
amplified from the p3xFLAG vector (courtesy of Dr. C. Hemenway) with the high
fidelity Phusion polymerase (Finnzymes/Thermo Scientific) using a forward primer
including a Xho1 site and a reverse primer with Xba1 and BamHI sites, as well as a stop
codon sequence (1U/50μl reaction Phusion Polymerase, 10mM dNTPs, 10uM each
forward and reverse primer, 5x HF Buffer)(Table 1). The amplicon was digested with
XhoI overnight in NEB Buffer 4, followed by digestion with BamHI the next day for an
additional two hours. The digested amplicon was then purified by gel extraction with the
Qiaex II Gel Extraction kit (Qiagen). The pMSCV.YFP vector (courtesy of Dr. J. Zhang)
was digested in parallel with the insert with XhoI overnight in NEB Buffer 3, followed by
a two hour digestion the next day with BglII. The digested vector was treated with 2μl
calf intestine alkaline phosphatase (CIP) enzyme (NEB), incubated at 37°C for 30
minutes and gel purified.
The 3xFLAG fragment was ligated into the digested MSCV.YFP vector overnight
at 14°C at a 3:1 insert-to-vector molar ratio. The following day, 1μl of the ligation
reaction was transformed into DH5α chemically competent cells. The ligation mix was
added to 50μl of cells on ice, gently flicked 5-6 times, and placed on ice for 30 minutes.
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Bacteria were heat shocked at 42°C for 30 seconds and returned to the ice for 5
minutes. 950μl of room temperature SOC was added to the cells, and they were incubated
at 37°C, rotating at 225 rpm for 1 hour. The transformed bacteria were plated on LB
plates containing 100μg/mL ampicillin and placed in a 37°C incubator overnight.
The following day, isolated transformants were inoculated into 5mL of LB broth
containing ampicillin (100μg/ml) and were grown overnight shaking at 225 rpm, 37°C.
The plasmid DNA was isolated from the bacteria using the GeneJet Therrmo Scientific
Miniprep Kit and was screened by PCR using the MSCV vector forward sequencing
primer and the reverse primer used for cloning. Positive clones verified by sequencing.
Full length AF9 was PCR amplified from the p3xFLAG.AF9 vector (courtesy of
Dr. C. Hemenway) with a forward primer containing an EcoRI restriction site and a
reverse primer including a XhoI restriction site (Table 1). The PCR product was digested
sequentially with XhoI overnight followed by the addition of EcoRI enzyme the next day
for an additional two hours. The enzymes were heat inactivated for 10 minutes at 65°C
and the PCR product was purified by gel extraction (Qiagen Gel Extraction Kit).
Table 1. Primer Sequences for Cloning of MSCV.YFP.AF9.3xFLAG
Amplicon
Primer Sequence (5’3’)
Forward: CCGCTCGAGGACTACAAAGACCATG
3xFLAG
Reverse: CGGGATCCTCTAGACTAGTCATCGTCATC
Forward: GGAATTCCATGGCTAGCTCG
AF9
Reverse: CCGCTCGAGGGATGTTCCAGATG

To clone full length AF9 into the newly constructed MSCV.YFP.3xFLAG vector,
the above mentioned digested AF9 was ligated into MSCV.YFP.3xFLAG vector digested
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with

EcoRI

and

XhoI

as

previously

described,

yielding

the

final

MSCV.YFP.AF9.3xFLAG vector. The final construct was screened by digestion with
EcoRI, and positive clones were verified by sequencing.
Site-Directed Mutagenesis to Introduce Mutations into Full-length AF9
Primers were designed according to the Agilent Quik-Change Site Direct
Mutagenesis kit recommended protocol to introduce one of eight single amino acid
changes in full length AF9. The MSCV.YFP.AF9.3xFLAG plasmid was used as a
template in a PCR reaction containing 1μl of each site directed mutagenesis primer
(Table 2), 5μl 10x reaction buffer, 1μl dNTP mix, 1μl PfuTurbo and water to 50μl total
volume. A control reaction using pWhiteScript template and provided primers was
assembled in parallel. The reactions were incubated in a ThermoHybaid PCR Express
Thermocycler for one cycle at 95°C for 30 seconds, followed by 12-18 cycles of 95°C
for 30 seconds, 55°C for 1 minute, and 68°C for 8 minutes or 5 minutes for the
mutagenized construct and the pWhiteScript control, respectively. After the PCR was
completed, the samples were cooled to 37°C followed by digestion with Dpn1 for 1 hour
at 37°C.
Dpn1-treated mutagenized DNA (1μl) was transformed into 50μl XL1-Blue cells
(Agilent). The mixture was swirled and incubated on ice for 30 minutes. The samples
were then heat shocked at 42°C for 45 seconds and returned to the ice for 2 minutes.
500μl pre-warmed SOC was added to the reaction and incubated at 37° C, shaking at 225
rpm. After 1 hour, the transformed bacteria were plated on LB plates containing
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100μg/mL ampicillin supplemented with 2% X-Gal and IPTG for blue-white selection.
Plates were placed in the 37°C incubator overnight.
The next day, 5ml of LB broth containing ampicillin was inoculated with a single
colony and grown overnight at 37°C shaking at 225rpm. After 12-16 hours of growth,
DNA was extracted from the transformants and screened by double digestion with Xho1
and EcoR1 to digest AF9 from the vector. Clones were sent for sequence verification.
After confirming the presence of the desired mutation, AF9 was cut out of the
vector and ligated into the MSCV.YFP.3xFLAG backbone. The plasmid DNA was
incubated with XhoI enzyme, BSA and NEBuffer 4 in a 50μl reaction overnight at 37°C.
The following day, EcoRI enzyme was added to the reaction mixture and the digestion
proceeded for 2 hours at 37°C. The digested product was run on a 2% gel and extracted.
The digested mutant AF9 was ligated into MSCV.YFP.3xFLAG vector digested
with XhoI and EcoRI, CIP-treated and gel extracted as described previously. The mutant
full-length AF9 was ligated into MSCV.YFP.3xFLAG in a 2μl insert:1μl vector 10μl
total reaction. Ligation reactions were placed in a 16°C water bath overnight.
The following day, 1μl of the ligation reaction was transformed into DH5α
chemically competent cells as previously described. Transformants were selected and
inoculated into 5ml LB broth containing ampicillin. Cultures were grown at 37°C shaking
at 225rpm overnight. After 12-16 hours of growth, DNA was extracted from the bacteria.
Clones were screened by EcoRI restriction enzyme digestion and sent for sequencing
using the MSCV Reverse primer.
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Table 2. Primer Sequences for Site Directed Mutagenesis
Nucleotide
Mutation
Primer Sequence
Change
E506R

GAAAGA

I538A

ATCGCC

D544R

GATCGT

D546R

GATCGT

K557E

AAAGAA

L526A

CTGGCG

S565A

TCTGAT

S565D

TCTGCT

Sense:
tgaatgtgacaaggcatacctagatagactggtagagcttcac
Antisense: gtgaagctctaccagtctatctaggtatgccttgtcacattca
Sense:
tgaaccttatagaagaaactggacactttcatgccacaaacacaacatttg
Antisense: caaatgttgtgtttgtggcatgaaagtgtccagtttcttctataaggttca
Sense:
acactttcatatcacaaacacaacatttcgttttgatctttgctcgctggac
Antisense: gtccagcgagcaaagatcaaaacgaaatgttgtgtttgtgatatgaaagtgt
Sense:
ctttcatatcacaaacacaacatttgattttcgtctttgctcgctggac
Antisense: gtccagcgagcaaagacgaaaatcaaatgttgtgtttgtgatatgaaag
Sense:
gacaaaaccacagtccgtgaactacagagttacctgg
Antisense: ccaggtaactctgtagttcacggactgtggttttgtc
Sense:
ccgtaaactacagagttacgcggaaacatctggaacatcc
Antisense: ggatgttccagatgtttccgcgtaactctgtagtttacgg
Sense:
cgtaaactacagagttacctggaaacagatggaacatccctcg
Antisense: cgagggatgttccatctgtttccaggtaactctgtagtttacg
Sense:
agagttacctggaaacagctggaacatccctcgag
Antisense: ctcgagggatgttccagctgtttccaggtaactct

Cloning of the MSCVneoMLL-AF9(D546R) Fusion Protein
The region containing amino acids 376-568 of AF9(D546R) was amplified using
the full length MSCV.YFP.AF9(D546R).3xFLAG construct as a template. The forward
primer contained a SalI restriction site, and a reverse primer contained a BamHI
restriction site (Table 3). The PCR amplicon was gel purified and digested with SalI
overnight. The following day, BamHI enzyme was added to the digestion reaction and
the digested AF9 fragment was gel extracted. The MSCVneo vector was digested with
EcoRI and BglII for two hours, CIP-treated to prevent re-ligation and gel extracted. The
5’ fragment of MLL (amino acids 1-1403 corresponding to the fragment found in MLL
fusions) was cut out of MSCVneoMLL-AF9 plasmid with EcoRI and SalI for two hours.
1μl MSCVneo vector, 2μl 5’ MLL and 3μl 3’ AF9(D546R) were ligated with 1μl DNA
ligase enzyme and buffer at 14°C overnight. The following day, 1μl of the ligation
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reactions was transformed into DH5α electrocompetent cells by electroporation.
Transformants were screened by PCR with primers amplifying the MLL-AF9 fusion
junction, and positive clones were verified by sequencing.
Table 3. Primer Sequences for Cloning of MSCVneoMLLAF9(D546R)3xFLAG
Primer
Primer Sequence (5’3’)
AAAGCGGTCGACTTTAAGATTCTTGAAGTGAAAAGTCCAATAAAG
AF9 Forward
1x FLAG Reverse

AAAGGATCCTCACTTGTCGTCATCGTCTTTGTAGTCGGATGTTCCAG
ATGTTTCCAG

Cloning of AF9(D546R) 376-568 and 470-568 into pCMV3xFLAG
The region containing amino acids 376-568 and 470-568 of AF9 were PCR
amplified from MSCV.YFP.AF9(D546R) with an AF9 forward primer containing an
EcoRI restriction site and a reverse AF9 primer containing a KpnI restriction site (Table
4). Digested amplicons were isolated by gel purification and ligated into the
pCMV3xFLAG vector (courtesy of Dr. C. Hemenway) digested with EcoRI and KpnI for
two hours followed by CIP treatment, heat inactivation and gel purification. Ligation
reactions and transformations were performed as described above. Transformants were
screened using EcoRI digest, and positive clones were sent for sequencing for
verification.
Table 4. Primer Sequences for Cloning AF9(D546R) 376-568 and 470-568
Primer
Primer Sequence (5’3’)
AF9(376-568) Forward
GCGAATTCATCTGAACAACCCAGTCCT
AF9(470-568) Forward
GCGAATTCATTACTAAAAACCAACAAC
AF9 Reverse
ATGGTACCTCAGGATGTTCCAGATGT
Retrovirus Production, Concentration, and Titering
Five 10cm tissue culture dishes of Phoenix Ecotropic cells were seeded at 2 x106
cells

in

DMEM

supplemented

with

10%

fetal

bovine

serum

and

1%
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penicillin/streptomycin for each retrovirus construct. The following day, the media was
changed 2-3 hours before calcium phosphate transfection with 22.5μg retroviral construct
and 2.5μg pCL-Eco packaging plasmid following the manufacturers’ protocol
(ClonTech). Sixteen hours post-transfection, the transfection media was removed and 7ml
of DMEM + 10% FBS was added. Cells were placed at 32°C, 5% CO2 overnight. The
following day, the supernatant was collected, 7ml of fresh media was added and the cells
were returned to the 32°C incubator. The viral supernatant was again harvested the
following day and pooled with the previously collected supernatant. The supernatant was
spun to pellet any cell debris and concentrated 6x using Centricon Plus 70 filters
(Millipore) by centrifugation at 1640rpm, 33°C in a swing bucket JS 75 rotor for
approximately two hours. Concentrated virus was aliquoted, snap frozen, and stored at 80°C.
To determine titer of the prepared retroviruses, 2.5x104 Rat1a cells were seeded
per well of a 6-well tissue culture plate. The following day, the virus preparation was
serially diluted 1:2 up to 1:1x106 in DMEM + 10% FBS supplemented with 16μg/mL
polybrene and added to the cells where they were incubated at 37°C, 5% CO2. After two
hours, an additional milliliter of DMEM + 10% FBS was added to the cells to bring the
final volume to 2ml and cells were returned to the 37°C incubator. The following day, the
media was removed and replaced with 2ml DMEM 10% FBS.
For cells transduced with plasmid encoding a neomycin resistance gene, media
was supplemented with 0.5mg/ml G418. Selection was maintained for ten days at which
time media was removed, the cells were washed with PBS and stained with methylene
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blue (0.1g of methylene blue in 60ml methanol) for 5 minutes. Plates were rinsed in
diH20 and air dried, after which colonies were enumerated.
Cells transduced with plasmid encoding yellow fluorescence protein (YFP) and an
untransduced control were removed from the plate by trypsinization 48 hours after
retroviral transduction and resuspended in PBS + 2% FBS. The cell suspension was
passed through a mesh filter to achieve a single-cell suspension, and the percentage of
YFP+ cells was assessed using flow cytometry.
Immunoprecipitation and Western Blot Analysis
Phoenix Ecotropic cells transfected with full-length AF9 point mutants to prepare
virus as described above were harvested four days after transfection. Cell pellets were
lysed in 1x SDS Sample Buffer and boiled at 95°C for 5 minutes. Protein lysates were
resolved on a 10% separating, 4% stacking SDS-PAGE gel at 150 Volts. Proteins were
transferred onto a nitrocellulose membrane using the Bio-Rad Trans-Blot Turbo Transfer
System, 1.5mm gel transfer program. Membranes were blocked in 5% milk in Tris
Buffered Saline + 0.05% Tween (TBS-t) for a minimum of one hour. AF9 proteins were
detected using a mouse anti-FLAG M2 antibody (Sigma) at a 1:3000 dilution in 5% milk
for one hour to overnight at 4°C. Membranes were washed four times for five minutes
each in TBS-t, and then incubated with secondary anti-mouse or anti-rabbit antibody (GE
Healthcare Life Sciences) at a 1:8000 dilution in milk for two hours. Membranes were
washed as described and developed using ECL Substrate (Thermo).
MLL-AF9-transformed c-kit+ bone marrow cells frozen from colony assay
experiments (as subsequently described) at the end of week one were thawed and plated
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in RPMI + 10% fetal bovine serum, 10ng/ml IL-3, 10ng/ml IL-6, 100ng/ml SCF and
10ng/ml GM-CSF overnight. The following day, cells were lysed in 1x SDS sample
buffer followed by boiling at 95°C for 5 minutes. Lysates were resolved on an 8% SDSPAGE gel at 150 volts and transferred on the BioRad Trans-Blot Turbo Transfer System
using the program for high molecular weight proteins. Membranes were blocked for two
hours and incubated with primary mouse anti-FLAG M2 antibody overnight, and
secondary anti-mouse antibody for two hours the following day as described above.
Membranes were developed using Super-Signal West Dura substrate (Thermo).
For coimmunoprecipitation experiments, HEK293 cells were cotransfected with
plasmids encoding either FLAG-tagged full length AF9 or C-terminal fragments of AF9
(wild type or D546R mutant, amino acid residues 376-568 or 470-568) and one of five
GFP-tagged proteins: full length murine Dot1L, murine Dot1L amino acids 479-659,
human DOT1L amino acids 828-1095, human AF4 RI3A- fragment, corresponding to
amino acids 647-871 of AF4 or human AF4 amino acids 755-777 using calcium
phosphate transfection according to the manufacturer’s protocol (ClonTech). Cells were
harvested 72 hours after transfection and lysed in 1ml IP lysis buffer (500mM Tris-HCl
pH 7.4, 150mM NaCl, 0.5% Triton-X 100 (v/v) and freshly added Protease Inhibitor
Cocktail and 1μM DTT). Lysates were sonicated with five pulses at output four, twice,
before centrifugation at 12,000rpm for 20 minutes to remove the insoluble fraction. 950μl
of prepared lysate was incubated with 20μl slurry FLAG M2 beads (Sigma) blocked in ZBuffer

(25mM HEPES pH 7.5, 12.5mM MgCl2, 150mM KCl, 0.1% NP-40 20%

Glycerol, BSA [1mg/mL], and freshly added Protease Inhibitor Cocktail 1:1000)
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overnight, rotating at 4°C. The remaining 50μl were saved for Western Blot to determine
input amounts. The following day, the bead-bound proteins were pelleted by
centrifugation at 1500 rpm, 4°C for one minute, followed by four-30 second washes with
1mL NETN buffer (100mM NaCl, 1mM EDTA, 0.5% NP-40, 20mM Tris-HCl pH 8.0,
and freshly added Protease Inhibitor Cocktail 1:1000). Proteins were eluted by boiling the
beads in SDS sample buffer at 95°C for 5 minutes. After a brief centrifugation to pellet
the beads, the eluate was resolved on a 10% gel as described above.
RNA Isolation and cDNA Synthesis
RNA was isolated from cells using TriReagent following the manufacturers’
protocol (Sigma). RNA was treated with DNAseI to remove any genomic DNA
contamination according to the manufacturers’ protocol (Fermentas). Complimentary
DNA was synthesized using the ABI High Capacity cDNA Synthesis kit (Applied
Biosystems/Life Technologies). Up to 2μg of RNA was reverse transcribed in a reaction
following the manufacturers’ protocol. cDNA was stored at -20°C.
Reverse Transcription-PCR
RNA was isolated from cells expressing combinations of MLL-AF5(WT or
K717D) and AF9(WT or D544R) in the genetic complementation experiments
(subsequently described) at the end of week four, and cDNA was prepared as described.
RT-PCR followed by sequencing was performed to verify the presence or absence of the
mutation in these cells. Primers used to amplify these regions are in Table 5. PCR
reactions were prepared with 1x Buffer, 1x Q Solution, 200μM dNTPs, 0.2μM forward
and reverse primers, 0.25U/50μl Taq Polymerase and 100ng of cDNA template or 10ng

66

plasmid control. PCR cycling conditions were as follows: 95°C 2 minutes, followed by
30 cycles of 95°C 30sec/58.3°C 1 min/72°C 1 min, and final extension at 72°C for 10
min. PCR products were resolved on a 0.8% agarose gel at 90V. Products were sent for
sequencing with their respective forward primers after clean-up using the Qiagen PCR
Clean-up Spin Column kit.
Table 5. Primer Sequences for Amplification of AF5 and AF9 Mutant Sequence
Amplicon
Primer Sequence (5’3’)
F: AAAGCGGTCGACTTTAAGATTCTTGAAGTGAAAAGTCCAATAAAG
AF9
(WT or D544R) R: AAAGGATCCTCAATCACCGTCATGGTCTTTGTAGTC
F: CTTCCTTCCTCACAAACTC
AF5
(WT or K717D) R: CGTCTCCTTGTTGCTGTTACT
Quantitative Reverse Transcription-PCR (qRT-PCR)
TaqMan probe technology was used to assess expression of murine Hoxa9, Meis1
and Hprt control gene expression (Hoxa9: Mm00439364_m1, Meis1: Mm00487664_m1,
Hprt: Mm01545399_m1; Applied Biosystems/Life Technologies). Reaction mixtures
containing 1μl 20x Gene Expression TaqMan probe, 10μl of 2x Gene Expression Assays
master mix (Applied Biosystems/Life Technologies), 2μl of undiluted prepared cDNA
and water to 20μl volume were prepared for each sample in triplicate. qRT-PCR was
performed on an Applied Biosystems 7300 Real Time PCR System using the standard
cycling program of one cycle at 50°C for 2 minutes, one cycle at 95°C for 10 minutes,
and 40 cycles of 95°C for 15 seconds/60°C for 1 minute. Data were analyzed using the
ABI Prism 7300 software. Relative target gene expression was normalized to Hprt
expression using the 2-∆∆Ct method236. Experiments were repeated a minimum of three
times, and data are shown as an average of all experiments with the standard error of the
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mean. Student’s t-test was performed to determine statistical significance using GraphPad
Prism software.
Levels

of

mRNA

encoding

transcription

factors

associated

with

erythroid/megakaryocyte (Gata1, Gata2) and granulocyte/macrophage (PU.1, Cebpa)
lineages were assessed using SYBR Green technology (Table 6). Reaction mixtures
containing 10μl SYBR Green Mix (BioRad), 1μl 10uM forward primer, 1μl 10uM
reverse primer, 1μl cDNA diluted 1:3 in H20 to 20μl total volume were prepared in
triplicate for each sample. The standard cycling protocol was used with the addition of
the dissociation step. Target gene expression was normalized to Gapdh expression and
analyzed as described above.
Table 6. Primer Sequences for Erythroid and Myeloid Lineage Transcription
Factors
Amplicon
Primer (5’3’)
Forward: GTGAGGCCGGTGCTGAGTAT
Gapdh
Reverse: TCATGAGCCCTTCCACAATG
Forward: TCACAAGATGAATGGTCAGA
Gata1
Reverse: TGGTCGTTTGACAGTTAGTG
Forward: CCCAAGCGGAGGCTGTCT
Gata2
Reverse: TCAGACGACAACCACCACCTT
Forward: CCCCACACCGGCCTCAGTCACCAG
Pu.1
Reverse: GAGGTGCTGGGCCGTGGGGG
Forward: GTAACCTTGTGCCTTGGATACT
Cebpa
Reverse: GGAAGCAGGAATCCTCCAAATA
Gata1 primer sequence237, Gata2 and Pu.1 primer sequences52

Expression of Meis1 was analyzed using primers specifically designed to amplify
the 5’ exon 1, exon 8/9, and 3’ exon 12 (Table 7). The protocol for qRT-PCR with SYBR
Green as described above was followed. Additionally, the Meis1 TaqMan probes
described were also used in this assay to amplify exons 6/7.

68

Table 7. Primer Sequences for Exon 1, Exon 8/9 and Exon 12 of Meis1
Amplicon
Primer (5’3’)
Forward: CCTGTGCAACACACACTTTAC
5’ Meis1 (Exon 1)
Reverse: GGGAGATTAGAGAGGAGGGTTA
Forward: GTGACGATGATGACCCTGATAA
Meis1 Exons 8/9
Reverse: CAGAAGGGTAAGGGTGTGTTAG
Forward: CTCTCTCTCTCTCTCTCTCTTCTC
3’ Meis1 (Exon 12)
Reverse: TTCCCATCCTTCCCGATTTAC
Genomic DNA isolation
Genomic DNA was isolated from cell pellets using the Puregene Genomic DNA
Purification Kit (Gentra) according to the manufacturers protocol. DNA pellets were
resuspended in 50-250μl DNA Hydration Solution and incubated at 65°C for 1 hour,
followed by continued hydration overnight at room temperature. Genomic DNA was
stored at -20°C.
Af9 Genotyping PCR
To assess in vitro 4-OHT-mediated deletion of floxed Af9 in the hematopoietic
progenitor colony forming cell (CFC) assays, polymerase chain reaction was performed
using primers that anneal to genomic DNA sequences located up and downstream of the
flanked loxP sites in the Af9fl/fl mouse (Table 8). Approximately 100ng of genomic DNA
was amplified in a 25μl reaction containing 1X Buffer, 200μM dNTPs, 0.25μM each
primer, and 1U/50ul Taq Polymerase. The PCR reaction was cycled at 94°C for 5 min,
followed by 40 cycles of 94°C for 30 seconds, 57°C for 30 seconds, and 72°C for 90
seconds. A final 10 minutes extension at 72°C completed the reaction. PCR products
were resolved on a 0.8% agarose gel at 90V.
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Table 8. Primer Sequences for Genotyping of Af9 Mice
Primer
Sequence (5’3’)
AAACAATAGCTTTGGCAGCG
Af9 Forward
CCTAGGCAGCGAGGAAGTTT
Af9 Reverse
Primary Mouse Bone Marrow Isolation
C57Bl/6, Af9(Mllt3)fl/fl, or Af9(Mllt3)fl/fl B6.129-Gt(ROSA)Sortm1(cre/ERT2)Tyj/J mice
were sacrificed by CO2 inhalation. Femurs and tibias were collected in RPMI + 10%
FBS. Bone marrow was flushed from the bones using a 25g 1.5” needle into a 6-well
plate containing additional RPMI + 10% FBS. Bones were flushed until all bone marrow
had been removed and bones appeared white. Bone marrow was collected in a conical
tube and centrifuged at 1500 rpm for 5 minutes.
c-kit Positive Selection of Mouse Bone Marrow Progenitor Cells
Isolated bone marrow cells were resuspended in 2ml PBS + 2% FBS at 100x106
cells/ml in 5ml polypropylene tubes for c-kit+ selection using the Stem Cell EasySep
Mouse CD117 Positive Selection kit. All antibody incubations were conducted in the
tissue culture hood at room temperature for the indicated amounts of time.
CD117 antibodies were added to the cells at 70μl/ml and incubated for 15
minutes. EasySep PE Selection cocktail was then added at 70μl/ml for an additional 15
minutes. Magnetic nanoparticles were mixed by pipeting five times, and were then added
at 50μl/ml to the cell suspension for 10 minutes. After the final incubation, the cells were
brought to a total 2.5ml volume with PBS + 2% FBS. Cells were gently mixed by
pipeting 2-3 times and then placed in a chilled EasySep magnet without the cap for 5
minutes. While holding the tube in the magnet to retain nanoparticle-bound cells, the tube
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was inverted and the supernatant was poured off. The tube was removed from the magnet
and 2.5ml PBS + 2% FBS was added. Cells were resuspended by gently pipeting 2-3
times and replaced back in the magnet for 5 minutes. The separation protocol was
repeated for a total of four-5 minute separations. After the final separation, cells were
counted and plated overnight in a round-bottom 96 well plate in RPMI + 10% FBS, 1%
penicillin/streptomycin supplemented with 0.05mM -mercaptoethanol, 100ng/ml SCF,
10ng/ml IL-3 and 10ng/ml IL-6.
Retroviral Transduction
c-kit+ cells were transduced with retroviruses in RPMI 10% FBS supplemented
with 100mM HEPES and 4μg/mL polybrene by centrifugation at 3000 rpm, 33°C for four
hours on one or two days. The specific protocol was adjusted based on the experimental
design as described below.
Colony Replating Assay
For MLL-AF9 point mutants, 30,000 c-kit+ cells were transduced with 750μl high
titer MSCVneoMLL-AF9(wild type or mutant) virus in a 1mL total volume (750μl viral
supernatant, 7.5mM HEPES, 4μg/ml Polybrene and RPMI 10% FBS to volume) for two
consecutive days. After the first spinoculation, cells were plated overnight in RPMI +
10% FBS, 1% penicillin/streptomycin supplemented with 0.05mM -mercaptoethanol,
100ng/ml SCF, 10ng/ml IL-3 and 10ng/ml IL-6 in 96 well plates. The spinoculation
procedure was repeated on the second day, after which cells were plated at 10,000
cells/1.1mL in methylcellulose supplemented with glutamine, 100ng/ml SCF, 10ng/ml
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IL-3, 10ng/ml IL-6, 10ng/ml GM-CSF, 1.25mg/ml G418 and RPMI in 35mm dishes. The
dishes were placed in a larger 15cm dish humidified with an uncovered 35mm dish
containing H20 and placed in a 37°C, 5% CO2 incubator for seven days. After one week,
colonies were counted using a Leica DMIL model microscope (Wetzlar, Germany) and
enumerated as colonies/10,000 cells. Photographs of the colonies were taken using a
Nikon Diaphot inverted fluorescence microscope with an Olympus DP21 digital camera.
For replating, the cells were collected in tubes containing 20mL of 1x PBS,
washed one time, resuspended at an appropriate volume and counted. One-to-ten
thousand cells were replated as described above for a total of four times. Experiments
were repeated three to six times and statistical significance was assessed using a
Student’s t-test with p<0.05.
Genetic Complementation Assay
c-kit+ bone marrow progenitors were isolated from C57Bl/6 mice as described
above. 50,000 cells were retrovirally transduced with a combination of AF9(WT or
D544R) and MLL-AF5(WT or K717D) virus in a 2ml total transduction volume, three
tubes per construct. Each spinoculation tube contained 50,000 cells, 750μl of
MSCVYFPAF9 virus, 750μl MSCVneoMLL-AF5 virus, polybrene and HEPES as
described. The virus combinations were as follows: MLL-AF5(WT) + AF9(WT), MLLAF5(K717D) + AF9(WT), MLL-AF5(WT) + AF9(D544R), or MLL-AF5(K717D) +
AF9(D544R).
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Cells were centrifuged at 3000rpm, 33°C for four hours on two consecutive days.
At the end of the last spin, cells were plated in methylcellulose with G418 for one week
to select for cells expressing the MSCVneoMLL-AF5(WT or K717D) construct.
After one week, cells were harvested from methylcellulose and sorted for YFP+
using the FACsAria III instrument (BD Biosciences). The YFP+G418R cells were
divided evenly and plated in methylcellulose for a colony replating assay as described
above.
Murine Colony-Forming Cell (CFC) Assays
CFC Assays with Af9fl/fl c-kit+ Bone Marrow Progenitor Cells
For experiments using untransduced c-kit+ bone marrow cells, cells were
harvested and immediately pre-treated with 200nM 4-hydroxytamoxifen (Sigma) or
ethanol control in a 96-well plate for four hours at 37°C. After the four hour pretreatment, cells were plated for myeloid, erythroid or megakaryocytic lineage
differentiation.
For erythroid lineage differentiation, 10,000 cells in RPMI + 2% FBS
supplemented with 10ng/ml IL-3, 50ng/ml SCF, 3U/ml rhEPO, 1% P/S, 100nM 4-OHT
or ethanol control, were plated in 2.4mL aliquots methylcellulose (M3234, Stem Cell) to
a total volume of 3.3mL. 1.5mL, or approximately 4,500 cells, were plated in two-35mm
dishes and placed in a covered 15cm plated with a 35mm uncovered dish of water for
humidity. Erythroid colonies were enumerated per 10,000 cells plated and photographed
at day four.
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For myeloid lineage differentiation, cells were plated in 900μl RPMI + 10% FBS,
10ng/ml IL-3, 10ng/ml IL-6, 50ng/ml SCF, 10ng/ml GM-CSF, and 100nM 4-OHT or
ethanol control.

The cell suspension was added to 2.4ml methylcellulose aliquots

supplemented to yield a total volume of 3.3ml. 1.1ml of the methylcellulose suspension
containing approximately 6,800 cells was plated in 35mm dishes. Cells were placed along
with an uncovered 35mm dish of water in a 15cm plate in a 37°C incubator for 12 days.
Colonies were enumerated per 10,000 cells plated.
For megakaryocytic lineage differentiation, 11,000 cells in 300μl IMDM
containing 100nM 4-OHT or ethanol control were added to a 1.7mL Megacult-C medium
containing 50 ng/ml rhTPO, 10ng/ml rmIL-3, and 20ng/ml rhIL-6 (Stem Cell). 1.2ml
cold collagen was added to the Megacult-C cell suspension and quickly mixed. 750μl of
the suspension, or approximately 2500 cells, was added per chamber of a double chamber
slide (Stem Cell Double Chamber Slide Kit #04963). The slides were placed in a 15cm
plate along with an uncovered 35mm dish of water for humidity in a 37°C, 5% C02
incubator for 7-10 days.
At the end of the incubation period, the slides were removed from the incubator
and dehydrated using filter paper layered on top of mesh spacers (Stem Cell Double
Chamber Slide Kit #04963). After the filter paper was fully saturated, it was removed and
the slides with mesh spacer were placed in a container of ice cold acetone for five
minutes, gently releasing the mesh from the slide with slight agitation. Slides were air
dried for 15 minutes and either stained immediately or stored in the dark at 4°C for up to
a month.
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If refrigerated, slides were brought to room temperature prior to staining.
Acetylcholinesterase stain was prepared by dissolving 10mg of acetyhiocholiniodide
(Sigma #A5751) in 0.1M sodium phosphate buffer, pH 6.0. Under constant stirring, the
following were added in order: 1ml 0.1M sodium citrate, pH 6.0; 2ml 30mM copper
sulphate, pH 6.0; 2ml 5 mM potassium ferricyanide solution (ACS Reagent #244023).
Slides were completely covered with the staining solution and incubated for 5 hours at
room temperature in a covered chamber. The staining solution was removed and slides
were fixed in 95% ethanol for 10 minutes, followed by rinsing with lukewarm water. The
slides were then air dried before counterstaining with Harris’ hematoxylin solution
(Sigma 107K4356) for 30 seconds. Slides were rinsed with lukewarm water, air dried,
and stored in covered containers at room temperature. Achetylcholinesterase-positive
colonies were counted, and slides were photographed using an AMG Evos XL Core
microscope (Fischer Scientific).
CFC Assays with YFP-AF9 Transduced Af9fl/fl Bone Marrow Progenitor Cells
For CFC assays requiring expression of YFP-tagged AF9 constructs, 300,000 ckit+ cells were transduced with 750μl MSCV.YFP, MSCV.YFP.AF9(WT) or
MSCV.YFP.AF9(mutant) virus in a 1mL total volume as described above. Cells were
centrifuged at 3000 rpm, 33°C for 4 hours, and plated at 106 cells/ml in RPMI + 10%
FBS, 1% penicillin/streptomycin supplemented with 0.05mM -mercaptoethanol,
100ng/ml SCF, 10ng/ml IL-3 and 10ng/ml IL-6 in 96-well plates overnight.
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Approximately 30 hours later, cells were collected in PBS + 2% FBS and sorted for
YFP+ cells using the FACS Aria Instrument (Becton Dickinson).
Immediately after sorting, YFP+ cells were plated in cytokine-supplemented
media with 200nM 4-hydroxytamoxifen (Sigma) or ethanol control in a 96-well plate for
four hours at 37°C. After the four hour pre-treatment, cells were plated for myeloid,
erythroid or megakaryocytic lineage differentiation as described above.
Cytospins and Staining
Cells were harvested from methylcellulose, washed and resuspended at 20,000
cells/200ul in 1x PBS. Cells were spun at 1000rpm for 4 minutes using the CytoSpin4
ThermoSci cytospin onto charged microscope slides (Premiere, CA Scientific Co). The
cells were air dried and stained with Hema 3 (Fisher Scientific).
Surface Marker Staining by Flow Cytometry
Cells collected from CFC assays for myeloid or erythroid lineage were
resuspended in 500μl PBS + 2% FBS, and divided amongst two polystyrene FACs tubes.
A separate tube of approximately 50,000 cells was resuspended in 200μl PBS + 2% FBS
for an unlabeled control. Compensation controls were prepared by adding one drop of
either α-Rat α-Hamster Igκ positive or negative compensation beads (BD Bioscience) to
100μl 1x PBS. Specific antibody dilutions were prepared, and master mixes were
prepared to assess surface marker expression of erythroid and myeloid lineage markers
(Table 9).
1μl of each antibody (eBioscience) was added to the appropriate compensation
tubes, and the antibody cocktails were added to the samples. Tubes were kept on ice in
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the dark for 20 minutes. 500μl of PBS + 2% FBS was added to each tube, gently mixed,
and centrifuged at 1500 rpm for 7 minutes. The supernatant was carefully decanted and
the cells were resuspended in the residual volume. Secondary conjugate antibodies were
added to the appropriate tubes and incubated on ice in the dark for 20 minutes. An
additional 500μl PBS + 2% FBS was added to wash the cells, gently mixed, and cells
were spun down at 1500 rpm for 7 minutes. Compensation beads and antibody-bound
cells were resuspended in 250μl PBS + 2% FBS and kept on ice in the dark until
analyzed using the FACs CantoII or LSRFortessa instruments (BD Biosciences). Cell
surface marker expression was analyzed using FlowJo (TreeStar Inc., Oregon).
Table 9. FACs Antibodies for Erythroid and Myeloid Surface Markers
Erythroid Lineage Cocktail
Myeloid Lineage Cocktail
APC-CD117
APC-CD117
PE-CD71
PE-CD41
Biotin-Ter119
Biotin-CD11b
SA-PECy7
SA-APCCy7
PE-Cy7-Gr1

CHAPTER FOUR
RESULTS
AIM 1: To determine which AF9 complex interactions are necessary for
normal hematopoietic development
Cloning and Stable Expression of full length AF9 point mutants
The C-terminus of AF9 has been shown to interact with four proteins, each of
which is associated with gene activation or repression. We sought to elucidate the
function of these protein interactions in normal hematopoiesis and leukemogenesis by
engineering point mutations in AF9 predicted to either destabilize the protein, block its
interaction with one or more known AF9 binding partners, or modify a potential
phosphorylation site.
Initial structural studies of AF9 from the Bushweller lab at the University of
Virginia identified four potential residues as mutation targets. The C-terminal region of
AF9 that has been shown to interact with multiple proteins is composed of three alpha
helices and one beta strand (Figure 10A). Alpha helices generally follow the ἰ + 4 rule, in
which the amine group of each amino acid donates a hydrogen bond to the carboxyl
group of the amino acid four residues upstream238. There are approximately 3.6 residues
per turn, and most commonly three helix turns correspond to ten amino acids total239.
Three amino acid residues, E506, K557, and L562, were selected as they are
located within α-helices in the AF9 C-terminus. Glutamate 506 is present in helix one,
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and lysine 557 and leucine 562 are located in helix three (Figure 10A). Helix one
and three are in close proximity to each other, and can form a potential protein-protein
interaction interface.
Polar amino acids often participate in salt bridges with amino acids of
complementary charge, creating stable electrostatic bonds that are important for protein
stability. Both E506 and K557 are charged residues that were mutated to an amino acid of
the opposite charge. Negatively charged glutamate 506 was mutated to positively charged
arginine, and positively charged lysine 557 was mutated to negatively charged glutamate.
We hypothesized that reversing the charge would disrupt the structure of the helix and
potential charge-charge interactions with other proteins at the helix interface.
Leucine 562 is a hydrophobic amino acid buried within helix three (Figure 10A).
Hydrophobic amino acids are often found in the core of protein structures, isolated from
the aqueous environment239. Mutation to small, slightly polar alanine is expected to
disrupt the proper folding of the helix, altering protein interactions mediated by the AF9
structure in this region.
A fourth residue chosen for mutation was isoleucine at amino acid 538 (Figure
8A). Isoleucine is a hydrophobic amino acid that prefers to be buried within hydrophobic
cores. Isoleucine has two branches at the β-carbon position, making it a bulkier structure
than amino acids with a single branch. Because of this, it is not often incorporated into αhelices, but is commonly found in β sheets239. Indeed, I538 is located at the C-terminal
end of β strand one in the AF9 structure. β strand one and β strand two form an
antiparallel β–sheet connected by a loop in the C-terminus of AF9. Mutation of I538 to
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alanine was predicted to disrupt the folding of the β sheet, and therefore potentially
altering any protein-protein interactions mediated by this secondary structure.
Serine 565 was identified as a potential phosphorylation site. It is located at the Cterminus of the AF9 protein, three amino acids from the end of the protein (Figure 8A).
Two mutations were introduced to study the potential functional relevance of this residue:
an alanine substitution mimicking an unphosphorylatable residue, or an aspartate
substitution mimicking a constitutively phosphorylated serine.
After the structure of AF9 was further resolved in complex with an AF4 peptide
in 2013156, additional structurally-informed amino acid mutational targets in AF9 were
identified. The D544R mutation was first identified through previous work in Dr.
Hemenway’s laboratory. They mapped the interacting region of AF9 to AF4 amino acids
760-770157. This region is highly conserved in all AFF family members, including a
conserved lysine residue (Figure 6B). AF4(K764) resulted in a loss of binding to AF9 in
a yeast two-hybrid assay240. Screening a mutagenized AF9 cDNA library for clones that
could restore binding to the AF4(K764) mutant identified an aspartic acid at residue 544
of AF9. Supporting structural studies in collaboration with the Bushweller laboratory
characterized the AF9(D544)-AF4(K764) interaction as forming a stable salt bridge.
Binding studies determined a dissociation constant 0.17mM for the interaction of AF9
with AF4. Mutation of the aspartic acid at position 544 in AF9 to aspartic acid reduced
the binding to wild type AF4 to Kd=7.39nM, indicating that the AF9-AF4 interaction
mediated by residues D544-K764 is necessary for high affinity binding of the two
proteins156, 240.
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Figure 10. Engineering and Stable Expression of Full Length AF9 Point Mutants
A

B

(A) Structure of AF9 solved in complex with AF4156 (PDB ID 2LM0) with point
mutations examined in these studies indicated. N- and C-terminal ends as well as the
three alpha helices are noted. (B) Detection of FLAG-tagged full length AF9 mutants in
Phoenix Ecotropic cells by western blot with Actin loading control.
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AF9 aspartate 546, two residues C-terminal to the aspartate critical for interaction
with AF4, was identified as mediating interaction with DOT1L (Figure 10A). Similar to
the AF9-AF4 salt bridge interaction, AF9 is thought to interact with DOT1L via a chargecharge interaction. There are three binding regions for AF9 on DOT1L: amino acids 628653, 863-878 and 878-900. These interaction sites have a conserved sequence of
LxL/I/VxIxI/LxxL/V, clustering together five hydrophobic residues within a 10 amino
acid region (unpublished data from the Bushweller lab). Structural studies identified AF9
residue D546 as a potential candidate to mutate to inhibit binding of AF9 at all three
DOT1L interfaces.
To express the full length AF9 point mutants in bone marrow cells, the plasmids
were packaged for retroviral transduction. For virus production, ecotropic Phoenix cells,
engineered from the human embryonic kidney (HEK 293) cell line to stably express the
retroviral packaging genes, were transfected with the AF9 plasmids. The supernatant
containing retroviral particles was collected and concentrated. Virus titers were
determined by serially diluting the virus and transducing Rat1a cells. Acceptable titers
were in the 1x106 to 1x107 virus particle/mL range.
To determine whether the mutant AF9 proteins were stably expressed, the
transfected ecotropic Phoenix cells were harvested and protein lysates were prepared to
assess expression of the AF9 point mutants. As some of the mutants were predicted to
disrupt local protein folding, it was important to show that introduction of amino acid
substitutions in AF9 did not affect the stability of the protein. An anti-FLAG antibody
was used to detect the AF9 point mutants, and Actin was used as a control for the amount
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of protein loaded in the western blot. Mutants D544R, I538A, S565A and S565D all
expressed comparably to the wild type AF9 protein (Figure 10B). A slight reduction in
expression of D546R, E506R, K557E and L562A mutants was evident, however proteins
are readily detected. All AF9 mutants are stably expressed and are of the expected size of
65 kilodaltons, indicating that introducing point mutants into AF9 did not result in
instability and degradation, and that these mutants can be used to assess the function of
interactions mediated at these residues in the following experiments.
Interaction of AF9(D546R) with DOT1L and AF4
The binding between AF9 mutants D544R, E506R, I538A, K557E, L562A and
S565D in the context of the C-terminal 376-568 amino acids of AF9 to DOT1L and AF4
was assessed by coimmunoprecipitation studies by a former graduate student in the
Hemenway lab, Dr. Bhavna Malik. The interaction between AF9 expressing the D546R
mutation and AF4 or DOT1L had not yet been studied, and so I sought to examine the
functional importance of this residue.
The D546R point mutation was predicted to specifically disrupt binding to
DOT1L while maintaining interaction with AF4; however, it was important to examine
functionally how this mutation would affect binding between AF9 and these interacting
partners. Coimmunoprecipitation studies were conducted to examine the binding of Cterminal AF9 residues 470-568 and 376-568 to fragments of DOT1L and AF4.
Approximately 75% of the MLL-AF9 fusions expressed in patients with MLL leukemia
include AF9 residues 376-568. However, 12% of patients express a MLL-AF9 fusion
including only amino acids 475-568 of AF9154, 241. Introduction of this MLL-AF9(475-
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568) fusion protein by homologous recombination into the endogenous Mll locus resulted
in AML development in mice, indicating that this smaller 94 amino acid AF9 fragment is
sufficient for transformation147. AF9 fragments 376-568 and 470-568 were tested for
binding to AF4 and DOT1L in order to elucidate any potential differences in binding
mediated by the 192 amino acid versus the 98 amino acid C-terminal tail of AF9.
FLAG-tagged AF9(470-568) or AF9(376-568), either wild type or containing the
D546R mutation, were coexpressed in HEK-293 cells with various fragments of GFPtagged AF4 or DOT1L to examine the interaction between these proteins. The AF9
protein was immunoprecipitated using anti-FLAG antibody-conjugated agarose beads,
and then FLAG-purified proteins were probed by western blots with an anti-GFP
antibody.
As mentioned above, unpublished binding studies from the Bushweller lab have
identified three sites in DOT1L that interact with AF9: amino acids 628-653, 863-878,
and 878-900. The D546R mutation in AF9 is predicted to disrupt binding to all three
DOT1L sites, but coimmunoprecipitation studies were necessary to examine the
interaction of this AF9 mutant with DOT1L. Constructs encompassing either the most Nterminal interacting site [mDot1(479-659)] or the two downstream sites [hDOT1L(8281095)], in addition to a construct expressing the full length Dot1l protein, were used to
assess binding to both C-terminal fragments of AF9, wild type or the D546R mutant.
These sites are present and highly homologous between both human and mouse DOT1L
proteins.
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The AF9(470-568) D546R mutant exhibits more than a 70% reduction in binding
to full length Dot1l or the DOT1L (828-1095) construct encompassing the two most Cterminal interaction sites compared to wild type AF9 (Figure 11A). Coexpression with
the Dot1l fragment containing the upstream AF9 interacting sequence (479-659)
increased binding 5-fold with the D546R mutant as compared to wild type. Of note,
coexpression of any DOT1L construct with AF9(D546R) mutant resulted in decreased
FLAG-AF9 detected in the input. All three DOT1L constructs had similar input amounts
regardless of coexpression with wild type or D546R mutant AF9 (Figure 11A).
Similar results were obtained with the larger AF9(376-568) D546R mutant
fragment (Figure 11B). Binding to full length Dot1l and DOT1L(828-1095) was
decreased with the D546R mutant 30% and 80%, respectively, as compared to wild type.
Interaction with the more N-terminal mDot1l(479-659) fragment was not significantly
different between AF9(376-568) wild type or D546R mutant. Coexpression of
AF9(D546R) with full length Dot1l or DOT1L(828-1095) resulted in decreased AF9
levels in the input, whereas coexpression with Dot1l(479-659) did not alter AF9 levels.
The input levels for all three GFP-tagged Dot1l constructs remained consistent (Figure
9B).
From these results, we conclude that AF9 residue D546 is involved in mediating
interaction with DOT1L, specifically interaction with the full length protein or the
DOT1L fragment encompassing two of the three AF9 binding sites (863-878 and 878900), but not the first site (628-653).
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Figure 11. Interaction of AF9(D546R) fragments 470-568 and 376-568 with DOT1L
A
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B

Coimmunoprecipitation studies of AF9 fragments 470-568 (A) or 376-568 (B) and
DOT1L constructs full-length mDotl, mDot1l (479-659) and hDOT1L(828-1095).
Figures are representative of two independent experiments. Pixel analysis was performed
using ImageJ software. Immunoprecipitated GFP-tagged DOT1L proteins were
normalized to FLAG-AF9 input. * = p<0.05, ** = p<0.02.
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Because AF9 is known to interact with AF4 amino acids 768-777157, a construct
containing this minimal interaction domain (AF4 755-777) was used to assess the effect
of the D546R mutation on the AF9-AF4 interaction. A second AF4 fragment containing a
slightly larger region of AF4, including the AF9 interaction domain but lacking the
bipartite nuclear localization signal (amino acids 647-871), was also used to examine
AF9(D546R) binding.
No statistically significant difference in binding of AF9(470-568) WT or D546R
to the larger AF4 fragment (647-871) was evident, but the D546R mutant shows an
almost 8-fold increase in binding to the AF4 755-777 fragment encompassing the
minimal AF9 interaction domain, despite a loss of detectable AF9 in the input (Figure
12A).
No statistically significant differences in binding of AF9(376-568) WT or D546R
were present with either AF4 construct, despite trends towards a slight reduction in
binding with the D546R mutant compared to wild type (Figure 12B). Again, there is a
reduction in detectable AF9(D546R) in the input samples of HEK293 cells cotransfected
with AF4(755-777). In contrast to the AF9(470-568) fragment, there is also a reduction in
AF9(376-568) D546R mutant when coexpressed with the larger 647-871 AF4 fragment
(Figure 12B).
From these results, we conclude that mutation of AF9 D546 to arginine does not
significantly abrogate binding of AF9 to AF4. An exception to this is the interaction of
the smaller AF9 fragment (470-568) with the minimal AF4 fragment (755-777), in which
binding of AF9(D546R) is statistically increased compared to wild type.
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Figure 12. Interaction of AF9(D546R) fragments 470-568 and 376-568 with AF4

A

B

Coimmunoprecipitation studies of AF9 fragments 470-568 (A) or 376-568 (B) and
AF4(647-871) or AF4(755-777). Figures are representative of two independent
experiments. Pixel analysis was performed using ImageJ software. Immunoprecipitated
GFP-tagged AF4 proteins were normalized to FLAG-AF9 input., ** = p<0.02.
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In vivo Deletion of Af9 Does Not Alter Levels of Hematopoietic Lineage-Specific
Transcription Factors in Af9-Inducible Knockout Mouse Bone Marrow Cells
The role of AF9 has not been well studied beyond its function in MLL fusion
proteins. As reviewed in the previous chapter, the Af9 knockout mouse dies perinatally
and exhibits skeletal defects as well as altered expression of developmental genes such as
Hoxd4. The cause of death was not further examined in these mice158. An independent
group overexpressed or knocked down AF9 using lentiviral expression vectors in CD34+
human cord blood cells159. They showed that overexpression of AF9 resulted in an
expansion of erythroid and megakaryocytic colonies in a colony forming cell (CFC)
assay. Conversely, knockdown of AF9 resulted in a complete loss of this compartment.
These two studies together indicate a critical role for Af9 in embryonic development, as
well as in differentiation of hematopoietic cells.
Our laboratory, in conjunction with Dr. Hemenway’s group, sought to further
assess the role of Af9 in an inducible knockout mouse system. Crosses were designed by
Dr. Zeleznik-Le and Dr. Hemenway. The initial rounds of breeding produced mice that
were heterozygous or homozygous for the Af9 allele flanked by two loxP sites.
Additional crosses with B6.129-Gt(ROSA)Sortm1(cre/ERT2)Tyj/J mice, which express a
tamoxifen-inducible Cre recombinase, yielded Af9fl/fl

Cre/+

mice. When tamoxifen is

administered to these mice by intraperitonal injection, the tamoxifen is processed to the
bioactive 4-OHT molecule which then binds to the estrogen response (ER) element in the
ubiquitously expressed Rosa26 promoter. Cre recombinase expression is then turned on
in all tissues, and the enzyme binds to and catalyzes DNA recombination between the
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paired loxP sites, excising the Af9 gene. This system allows for conditional deletion of
floxed region of Af9 at specific time points in all tissues.
Homozygous floxed-Af9 and homozygous floxed-Af9 Cre mice were administered
tamoxifen by I.P. injection at specific time points. Only mice with the Cre allele will
excise the floxed Af9 gene upon tamoxifen treatment. Mice were sacrificed at set times
after injection, and peripheral blood and bone marrow were assessed for hematopoietic
development. Other members of the laboratory examined surface marker expression in
the peripheral blood and bone marrow of these mice, while I assessed transcript levels of
lineage-specific transcription factor genes in bone marrow cells. Based on previous
studies, we hypothesized that Af9 is a critical regulator of erythroid/megakaryocyte
(E/Meg) lineage commitment, and that loss of Af9 would result in a decrease or loss of
differentiation of bone marrow cells to this lineage.
As discussed in the previous chapter, expression of specific transcription factors is
necessary for hematopoietic stem and progenitor cells differentiation to mature blood
cells. Expression of Gata1 and Gata2 is required for progenitor cells to differentiate into
the E/Meg lineage, whereas expression of Pu.1 and Cebpa is associated with
granulocyte/macrophage (GM) lineage commitment (Figure 1). If Af9 is required for
E/Meg lineage commitment, we expect to see a decrease in levels of mRNA encoding
transcription factors associated with differentiation to this lineage (Gata1 and Gata2),
with a possible compensatory increase in transcription factors associated with GM
lineage commitment.
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We do not see any significant changes in the transcript levels of erythroid (Gata1, Gata2)
or myeloid (Pu.1, Cebpa) lineage transcription factor genes in mice expressing Af9 compared to
those null for Af9 expression (Figure 13).

Figure 13. Expression of Lineage-Specific Transcription Factors in Af9 Inducible
Knockout Bone Marrow Cells

Transcript levels of erythroid lineage-associated transcription factor genes Gata1 and
Gata2 and myeloid lineage-associated transcription factor genes Pu.1 and Cebpa in the
bone marrow of Af9 fl/fl or Af9fl/fl cre/+ mice after intraperitonal injection with tamoxifen.
RNA was isolated from nine mice of each genotype, and cDNA was analyzed in
triplicate. Expression was normalized to Gapdh, and error bars indicate standard
deviation.

Loss of Af9 Does Not Alter Hematopoietic Lineage Differentiation in vitro
In addition to the ongoing in vivo studies in our laboratory, I assessed the
differentiation ability of bone marrow cells lacking Af9 in vitro. Rather than
administering tamoxifen to mice in vivo to induce deletion of Af9, c-kit+ bone marrow
progenitor cells were isolated from Af9fl/fl

Cre/+

mice that had not been exposed to
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tamoxifen. Cells were then plated in semi-solid methylcellulose media with cytokines
which potentiate differentiation of the erythroid, myeloid or megakaryocytic lineages
with or without 4-OHT, the bioactive derivative of tamoxifen, to induce deletion of Af9.
To examine the ability of cells to differentiate along the erythroid lineage
following loss of Af9, bone marrow progenitor cells from Af9fl/fl Cre/+ mice were plated in
methylcellulose with IL-3, IL-6 and EPO in the presence or absence of 4-OHT to
examine the role of Af9 in erythroid cell development. Loss of Af9 did not alter the
ability of bone marrow progenitor cells to differentiate to the erythroid lineage in this
system. There was no difference in the number of colonies formed in cells expressing or
lacking Af9 (Figure 14).

Figure 14. Erythroid Colony Formation by Af9 Inducible Knockout Bone Marrow
Progenitor Cells

Erythroid colony formation in c-kit+ bone marrow progenitor cells isolated from Af9fl/fl
cre/+
mice. Cells were treated with 4-OHT or ethanol control in vitro and plated in
methylcellulose in the presence of cytokines to promote differentiation to the erythroid
lineage. Colonies were enumerated per 10,000 cells plated. Experiments were repeated in
duplicate three times.
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FACs analysis was used to examine changes in expression of cell surface markers
associated with erythroid development, including CD71 and TER119, upon Af9 deletion.
CD71 is a transmembrane glycoprotein present on the surface of proliferating cells,
reticulocytes and erythroid precursor cells. TER119 is a cell surface antigen specific to
erythroid cells, expressed on proerythroblasts through mature erythrocytes, but not
expressed on earlier CFU-E and BFU-E cells. There was a significant reduction in
expression of CD71 in cells lacking expression of Af9 compared to wild type, although
there were no significant changes in expression of TER119. Levels of CD117, or the cKit receptor present on all hematopoietic progenitor cells, also remained unchanged in
wild-type cells or those lacking Af9 (Figure 15A).
In addition, I assessed the surface marker expression of myeloid lineageassociated cell surface markers, hypothesizing that any alterations in erythroid lineage
differentiation and surface marker expression may results in a compensatory response in
the myeloid lineage differentiation and surface marker expression. CD41 is the alpha
subunit of the gpIIb/gpIIIa complex expressed on the surface of platelets and
megakaryocytes. Gr-1 is a myeloid differentiation antigen expressed on granulocytes and
monocytes. CD11b, also known as Mac-1, is a transmembrane protein expressed on most
myeloid cells including granulocytes, monocytes, and dendritic cells. There were no
significant changes in expression of the myeloid surface markers CD41, Gr-1 or CD11b
in cells with or without Af9 (Figure 15B). We conclude based on these results that Af9 is
not required for the formation of erythroid colonies in vitro despite a reduction in CD71
surface marker staining in cells lacking Af9 expression.
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Figure 15. Surface Marker Staining of Af9 Inducible Knockout Bone Marrow
Progenitor Cells Plated for Erythroid Lineage Differentiation
A
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B
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Surface marker staining of Af9fl/fl cre/+ mouse bone marrow progenitor cells plated for
erythroid lineage differentiation. Unstained cells were used as a control, and the average
Mean Fluorescence Intensity (MFI) was calculated using the geometric mean of
fluorescence intensity of three experiments, * = p<0.05. (A) Expression of erythroid
lineage specific markers Ter119 and CD71, along with the hematopoietic progenitor
marker CD117 (B) Expression of CD117 and myeloid lineage-specific markers CD41,
Gr-1 and CD11b.

Next we examined the differentiation of inducible Af9 knockout cells to the
myeloid lineage by plating c-kit+ bone marrow cells from Af9fl/fl Cre/+ mice in cytokines
to promote myeloid lineage differentiation: IL-3, IL-6, SCF and GM-CSF. Cells were
plated in the presence of either 4-OHT or ethanol, and colony forming unit-granulocyte
macrophage (CFU-GM) colony formation was assessed after 12 days.
There was no significant change in colony formation of bone marrow cells with
or without Af9 expression (Figure 16). Similarly, there was no significant change in
myeloid-associated surface marker expression in these cells (Figure 17A). We also
examined the expression of erythroid lineage surface markers in these cells,

97

hypothesizing that any alterations in the myeloid lineage could be compensated by
increases or decreases in differentiation to the erythroid lineage and vice versa. We did
not see any changes in expression of erythroid-associated surface markers (Figure 17B).
From these results, we conclude that Af9 does not play a role in myeloid lineage
differentiation in vitro.

Figure 16. Myeloid Colony Formation by Af9 Inducible Knockout Bone Marrow
Progenitor Cells

Myeloid colony formation in c-kit+ bone marrow progenitor cells isolated from Af9fl/fl
cre/+
mice. Cells were treated with 4-OHT or ethanol control in vitro and plated in
methylcellulose in the presence of cytokines to promote differentiation to the myeloid
lineage. Colonies were enumerated per 10,000 cells plated. Experiments were repeated in
duplicate three times.
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Figure 17. Surface Marker Staining of Af9 Inducible Knockout Bone Marrow
Progenitor Cells plated for Myeloid Lineage Differentiation
A
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B
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Surface marker staining of Af9fl/fl cre/+ mouse bone marrow progenitor cells plated for
myeloid lineage differentiation. Unstained cells were used as a control, and the average
Mean Fluorescence Intensity (MFI) was calculated using the geometric mean of
fluorescence intensity of three experiments. Expression of hematopoietic progenitor
marker CD117 and (A) myeloid lineage-specific markers CD41, Gr-1 and CD11b or (B)
erythroid lineage specific markers CD71 and TER119.

We assessed the ability of bone marrow progenitor cells with or without Af9 to
differentiate to the megakaryocytic lineage in vitro. We hypothesized that loss of Af9
would result in a loss of differentiation to both erythroid and megakaryocytic lineages. To
test this, cells were plated in chamber slides in a semi-solid media supplemented with
TPO, IL-6 and IL-3, and either 4-OHT to induce recombination and deletion of Af9 or
ethanol control. After seven days, the slides were fixed and stained for
acetylcholinesterase

activity

(Figure

18A).

Mouse

megakaryocyte

and

early

megakaryocyte progenitors express the acetycholinesterase enzyme. When incubated
with acetylcholine substrate, the enzyme releases Cu2+ ions which precipitate as colorless
copper thiocoline. Subsequent incubation with ammonium sulfide converts the colorless
copper thiocoline molecules to brown-colored copper sulfate242. The slides also contain
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myeloid cells which do not stain brown. Acetycholinesterase-positive megakaryocytes
were counted, and no significant difference was seen between cells expressing or lacking
Af9 (Figure 18B). As these cells are fixed on the slides, surface marker staining was not
assessed. We conclude based on these assays that Af9 is not required for megakaryocyte
lineage commitment in vitro.

Figure 18. Acetylcholinesterase-Positive Megakaryocyte Staining of Af9 Inducible
Knockout Bone Marrow Progenitor Cells

A

B
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(A) Representative image of acetylcholinesterase-positive megakaryocytes among
acetylcholinesterase-negative myeloid cells (left, 4X magnification). Higher
magnification (10X) of positively-staining megakaryocytes (right). (B) Quantification of
Acetylcholinesterase-positive in vitro differentiated megakaryocytes from Af9fl/fl Cre/+
mouse bone marrow progenitor cells treated with 4-OHT or ethanol control. After plating
in semi-solid medium in the presence of cytokines to promote megakaryocytic
differentiation, chamber slides were dehydrated and stained for acetylcholinesterase
activity. Acetylcholinesterase-positive colonies were counted and enumerated per 10,000
cells plated. Experiments were conducted in duplicate three times.

Together these results show that loss of Af9 in vitro does not alter lineage
commitment of c-kit+ bone marrow cells to the myeloid or megakaryocytic lineages
under these conditions. Erythroid colony formation was not affected by the loss of Af9,
although there was a reduction in the early erythroid marker CD71.
Re-expression of Wild-Type AF9 or AF9 Mutants S565A and S565D Does
Not Alter in vitro Lineage Differentiation of Af9-Inducible Knockout Bone Marrow
Progenitor Cells
The first in vitro differentiation studies I conducted were based on the early
hypothesis that loss of Af9 would result in a loss of cells differentiating to the erythroid
and megakaryocyte compartment. Prior to obtaining the above described results, we
tested whether re-expression of wild-type AF9 could rescue any defects in lineage
commitment. Further, we wanted to see if expression of two AF9 mutants, S565A and
S565D, would alter the ability of cells to differentiate to the erythroid lineage. These
mutants were selected based on preliminary results from an earlier experiment that
indicated the serine residue at 565 may be critical in mediating progenitor cell maturation
(data not shown).
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Bone marrow progenitor cells were isolated from Af9fl/fl

Cre/+

mice, and were

transduced with retrovirus encoding AF9(WT), AF9(S565A), AF9(S565D) or vector
alone. As described previously, serine 565 near the C-terminus of AF9 was identified as a
possible phosphorylation site. A mutation to alanine would prevent this residue from
being phosphorylated, whereas mutation to an aspartic acid mimics constitutive
phosphorylation. All constructs were YFP tagged, allowing for sorting of YFP+ cells 36
hours after transduction. YFP+ cells were plated in methylcellulose in the presence of
cytokines to promote erythroid lineage differentiation with or without 4-OHT, as
described previously.
Cells transduced with empty vector showed no difference in erythroid colony
formation when treated with or without 4-OHT (Figure 19). This is consistent with the
results shown in figure 12. Re-expression of AF9(WT) or either mutant (S565A or
S565D) also did not significantly alter colony formation (Figure 19). The cells were also
subjected to surface marker analysis, examining both erythroid and myeloid-associated
surface markers as described previously. Consistent with colony formation data, there
were no significant differences in expression of surface markers associated with erythroid
(Figure 20A) or myeloid (Figure 20B) lineage upon loss of Af9, or re-expression of AF9
WT or mutants compared to the ethanol-treated vector control.
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Figure 19. Erythroid Colony Formation in Af9 Inducible Knockout Bone Marrow
Progenitor Cells Re-Expressing AF9 Wild-type, S565A or S565D Mutants

Erythroid colony formation by c-kit+ progenitor cells isolated from the bone
marrow of Af9fl/fl Cre/+ mice. Cells were transduced with retroviruses encoding YFPtagged empty MSCV vector, full length wild-type AF9, or full length AF9 mutants
S565A or S565D. YFP+ cells were plated in methylcellulose in the presence of cytokines
to promote erythroid lineage differentiation, and 4-OHT to induce deletion of Af9 unless
otherwise noted. Colonies were counted after four days and enumerated per 10,000 cells.
The experiment was conducted in duplicate.

From these results, we confirm that loss of Af9 does not alter the ability of c-kit+
murine bone marrow cells to form erythroid colonies in vitro under the conditions tested.
Additionally, re-expression of wild-type AF9, or AF9 mutants S565A or S565D does not
alter erythroid lineage commitment compared to the control cells.
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Figure 20. Surface Marker Staining Profiles of Af9 Inducible Knockout Bone
Marrow Progenitor Cells Re-Expressing Wild-type or Mutant AF9 plated for
Erythroid Lineage Differentiation

A

B

Surface marker staining of retrovirally transduced Af9fl/fl cre/+ mouse bone marrow
progenitor cells plated for erythroid lineage differentiation. Unstained cells were used as
a control, and the average Mean Fluorescence Intensity (MFI) was calculated using the
geometric mean of fluorescence intensity. Expression of hematopoietic progenitor marker
CD117 and erythroid lineage specific markers CD71 and TER119 (A) or myeloid
lineage-specific markers CD41, Gr-1 and CD11b (B) was calculated.
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AIM 2: To determine whether AF9 interactions with Af4 and Dot1l
are necessary for leukemogenesis
AF9 Interaction with AF4 Is Required for in vitro Leukemic Transformation
As discussed previously, AF9 has been shown to interact with AF4 in part
through AF9 residue D544 and AF4 residue K764. These charged amino acids form a salt
bridge that promotes stable bonding between the two proteins with a Kd of 0.17nM156.
Mutation of AF9 residue D544 to the positively charged arginine reduces this binding 43fold to 7.39nM240. Additionally, coimmunoprecipitation studies conducted in Dr.
Hemenway’s laboratory indicated a loss of binding to AF4 when AF9 residue D544 is
mutated to arginine240. Here, we sought to assess the functional relevance of the AF9AF4 interaction mediated by this salt bridge using an in vitro leukemic transformation
assay.
When normal bone marrow is plated in semi-solid methylcellulose media, the
bone marrow progenitor cells will form colonies within the first week, but then will
continue to differentiate and undergo cell cycle arrest. Hence, these untransformed cells
will not form colonies after replating. When oncogenic fusion proteins such as MLL-AF9
are introduced into bone marrow progenitor cells, the cells will be blocked from
differentiating and will continue to form colonies upon subsequent replating. We
hypothesized that the interaction of AF4 and AF9 in the context of the leukemia-causing
MLL-AF9 fusion is critical for the ability of the oncoprotein to transform bone marrow
cells. Loss of the AF9-AF4 interaction through mutation of the aspartic acid at residue
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544 in AF9 to an arginine would result in a reduction in colony forming ability in the in
vitro colony formation assay.
As previously discussed, AF9 interacts with AF4 which binds to and stabilizes the
pTEFb elongation complex. It is possible that AF9 in the context of the MLL-AF9 fusion
recruits the pTEFb elongation complex to MLL target genes through interaction with
AF4, resulting in aberrant transcription of genes that promote leukemogenesis. Loss of
this AF9-AF4 interaction would no longer bring the pTEFb elongation complex to target
genes, resulting in a loss of expression of genes required for the leukemic transformation
program, and loss of serial replating ability.
MLL-AF9 wild type, MLL-AF9(D544R) mutant or empty MSCVneo vector were
retrovirally expressed in c-kit+ bone marrow cells isolated from wild type mice.
Transduced cells were plated in methylcellulose media in the presence of cytokines to
promote growth. Colonies were counted after one week prior to replating up to four
times. Results indicate that while MLL-AF9(WT) transformed cells continue to form
colonies throughout the four weeks of the assay, there is a significant reduction in colony
formation in bone marrow cells expressing the MLL-AF9(D544R) fusion (Figure 21A).
Loss of colony formation was not a result of a lack of MLL-AF9(D544R) expression, as
this fusion protein was detected in cells harvested at the end of one week (Figure 21C).
In addition to forming fewer colonies compared to wild-type, the MLLAF9(D5444R)-expressing bone marrow cells form more diffuse colonies (Figure 21B).
The cells within those colonies appear more differentiated, with an increased cell size and
the presence of granules characteristic of differentiated cells in the myeloid lineage.
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MLL-AF9(WT)-expressing bone marrow cells appear blast-like; they are smaller in size,
lack granules, and have a high nucleus-to-cytoplasm ratio upon staining with WrightGiemsa (Figure 21B).

Figure 21. MLL-AF9(D544R) Colony Assay
A

B

C

(A) Colony formation by c-kit+ progenitor cells expressing MLL-AF9(WT), MLLAF9(D544R) or vector control throughout four weeks of replating. Colony assays were
conducted in duplicate a total of six times. (B) Representative colony photographs at 4X
and 10X magnification (top), and cell morphology by cytospin followed by WrightGiemsa staining (bottom). (C) Western blot of bone marrow cells expressing empty
vector, MLL-AF9(WT) or MLL-AF9(D544R) isolated after one week.
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As previously mentioned, leukemic transformation by MLL fusion proteins is
associated with an increase in expression of MLL target genes such as Meis1 and Hoxa9.
While MLL-AF9(WT) transduced bone marrow cells show a 92-fold increase in
expression of Hoxa9 and 43-fold increase in expression of Meis1 at week 1 compared to
the MSCVneo control at week one, cells transduced with MLL-AF9(D544R) show a
statistically significant reduction in expression, with only 13-fold increase in Hoxa9
expression and 15-fold increase in Meis1 expression compared to MSCVneo control
(Figure 22).

Figure 22. Hoxa9 and Meis1 Expression in MLL-AF9(D544R) Transduced Bone
Marrow Progenitor Cells
A

B

Relative expression of MLL target genes Hoxa9 (A) and Meis1 (B) in bone marrow
progenitor cells transduced with retroviruses encoding MLL-AF9(WT), MLLAF9(D544R) or empty vector following one week in methylcellulose. Expression was
normalized to Hprt and set relative to MSCVneo vector control. Three independent
experiments were each performed in triplicate. Error bars indicate standard deviation.
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These results indicate that the AF9-AF4 interaction mediated by the salt-bridge
formed between AF9 residue D544 and the lysine at 764 of AF4 is required for efficient
in vitro leukemic transformation.
Genetic Complementation of MLL-AF9(D544R) Restores
in vitro Transformation
From the previous findings, we concluded that the AF9-AF4 interaction mediated
by the AF9 D544 residues is required for transformation in vitro. We therefore
hypothesized that coexpression of the MLL-AF9(D544R) mutant with an AF4 mutant
substituting an aspartic acid for the positively charged lysine would restore the saline
interaction and would rescue transformation ability in vitro.
Since MLL-AF4 cannot transform bone marrow cells and we did not have access
to full-length AF4 cDNA, we utilized the highly conserved AF4 homolog AF5 to further
examine the requirement for the AF9-AF4/5 salt bridge interaction in leukemic
transformation. Functionally, AF4 or AF5 are necessary to stabilize the pTEFb
elongation complex, and can bind to AF9 or the AF9 homolog ENL. AF4 K764 is
conserved in all AFF family members, and functionally corresponds to amino acid K717
in AF5 (Figure 6B). Fluorescence anisotropy studies with fragments of AF9 and AF5
indicate comparable affinity of binding between AF9 and AF5, and AF9 and AF4 (kD of
0.2nM vs. 0.17nM, respectively)240.
We hypothesized that reversing the positive charge at AF5 K717 to an aspartic
acid with a negatively charged side chain would restore binding to the AF9(D544R)
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mutant with a positive charge, thus rescuing colony forming ability and target gene
expression.
We first wanted to assess the ability of MLL-AF5(WT or K717D) to transform
bone marrow progenitor cells. We hypothesized that MLL-AF5(WT) would transform
cells, and that MLL-AF5(K717D) would not transform cells as it would not form a salt
bridge with wild type AF9. As expected, MLL-AF5(WT) transduced bone marrow cells
continually replate, whereas MLL-AF5(K717D) expressing cells show a reduction in
colony formation (Figure 23A). This corresponds to a decrease in Meis1 expression in
MLL-AF5(K717D)-expressing cells as compared to wild-type (Figure 23B). MLLAF5(WT) expressing cells exhibit greater than forty-fold increase in Meis1 expression
over vector control at the end of week one whereas MLL-AF5(K717D) expressing cells
express only a 27-fold increase. Interestingly, Hoxa9 expression was not altered in cells
expressing the wild type or mutant fusion (Figure 23C). From these results, we conclude
expression of the MLL-AF5(K717D) mutant in c-kit+ progenitor cells severely impairs
the transformation ability of the MLL-AF5 fusion protein.
To test whether genetic complementation of the AF9(D544R) mutation could
rescue in vitro transformation ability, c-kit+ bone marrow progenitor cells were cotransduced with YFP-tagged AF9(WT or D544R) and G418-resistant MLL-AF5(K717D)
constructs. Cells were selected in G418 for one week before sorting for YFP+ cells to
select for cells expressing both constructs.
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Figure 23. MLL-AF5(K717D) Colony Assay and Hoxa9 and Meis1 Expression
A

B

C

(A) Colony formation by c-kit+ progenitor cells expressing MLL-AF5(WT), MLLAF5(K717D) or vector control throughout three weeks of replating. Quantitative RTPCR of (B) Meis1 and (C) Hoxa9 expression in bone marrow cells isolated after one
week in methylcellulose. Expression was normalized to Hprt and set relative to
MSCVneo vector control. Three independent experiments were each performed in
triplicate. Error bars indicate standard deviation.

113

Figure 24. Genetic Complementation of MLL-AF5(K717D) by AF9(D544R):
Colony Assay and Expression of Hoxa9 and Meis1
A

B

C

(A) Colony formation by c-kit+ progenitor cells co-expressing MLL-AF5(K717D) and
AF9(WT or D544R). Quantitative RT-PCR of (B) Meis1 and (C) Hoxa9 expression in
bone marrow cells isolated after one week in methylcellulose. Expression was normalized
to Hprt and set relative to MSCVneo vector control. Three independent experiments were
each performed in triplicate. Error bars indicate standard deviation.
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While cells coexpressing MLL-AF5(K717D) and AF9(WT) are unable to serially
replate in methylcellulose, coexpression of both MLL-AF5(K717D) and AF9(D544R)
mutants restored colony formation ability (Figure 24A). This increase in colony
formation corresponds to an increase in Meis1 expression compared to the MLLAF5(K717D)/AF9(WT) expressing cells (Figure 24B). Hoxa9 expression was
significantly reduced in the cells co-expressing both mutant constructs (Figure 24C). This
was a very surprising result and will be discussed further in the Discussion chapter.
These results indicate that the electrostatic interaction between AF9 and AF4/AF5
is necessary for in vitro leukemic transformation. Loss of the interaction through
introduction of charge-repulsion in AF9 can be rescued by expression of a
complementary charge in the AF5/AF4.
AF9 Interaction with DOT1L is Required for in vitro Leukemic
Transformation
As previously mentioned, AF9 interacts with DOT1L at three regions: DOT1L
628-653, 863-878 and 878-900. We hypothesized that mutation of aspartate D546 in AF9
to arginine would reverse the charge at this location, preventing AF9 from interacting
with DOT1L. Structural studies from the Bushweller lab indicate that this amino acid
substitution reduces binding of AF9 to DOT1L at all three binding interfaces
(unpublished data).
To assess the relevance of the AF9-DOT1L interaction in leukemic
transformation, c-kit+ bone marrow progenitor cells were retrovirally transduced with
MLL-AF9 fusions, either wild type or D546R mutant. We predicted that cells expressing
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the wild type fusion would serially replate for the duration of the experiment, whereas the
MLL-AF9(D546R)-expressing cells would not. In cells expressing the wild type fusion
gene, the AF9-DOT1L interaction would be maintained and Dot1l would be recruited via
AF9 interaction to MLL target genes, leading to the deposition of the H3K79 methyl
mark within the gene body of genes required for leukemic transformation. H3K79me2 is
associated with expression of MLL fusion target genes, and loss of H3K79me2 is
associated with a decrease in MLL target gene expression212. If the AF9-DOT1L
interaction is inhibited in cells expressing MLL-AF9(D546R), then DOT1L cannot be
recruited, and there would be a reduction in H3K79 methylation potentially coinciding
with a decrease in expression of target genes necessary for transformation.
Colony assays indicate that the MLL-AF9(WT) fusion-expressing cells
continually replate for the duration of the experiment, whereas cells expressing the
D546R mutant fusion have a statistically significant reduction in colony formation
(Figure 25A). Both the colony and cell morphology were drastically different, with the
MLL-AF9(WT) expressing bone marrow cells forming very tight, compact colonies
comprised of mainly blast cells, while the MLL-AF(D546R) mutant expressing cells
formed very few, very diffuse colonies composed of differentiated myeloid cells (Figure
25B). To assure that both fusion proteins were equally expressed, western blot analysis
was performed showing that MLL-AF9(WT) and (D546R) protein expression was
detectable in bone marrow cells after week one (Figure 25C).
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Figure 25. MLL-AF9(D546R) Colony Assay
A

B

C

(A) Colony formation by c-kit+ progenitor cells expressing MLL-AF9(WT), MLLAF9(D546R) or vector control throughout four weeks of replating. The experiment was
repeated eight times in duplicate. (B) Representative colony photographs at 4X and 10X
magnification (top), and cell morphology by cytospin followed by Wright-Giemsa
staining (bottom). (C) Western blot of bone marrow cells expressing empty vector, MLLAF9(WT) or MLL-AF9(D546R) isolated after one week.
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If recruitment of DOT1L to MLL-AF9 target genes is required for successful
elongation of transcripts, we would expect to see a decrease in Hoxa9 and Meis1
transcript levels in cells expressing the D546R mutant. Quantitative reverse transcription
PCR of bone marrow cells isolated after week one showed a significant reduction in
Hoxa9 (Figure 26A) and Meis1 (Figure 26B) expression in MLL-AF9(D546R)expressing cells compared to MLL-AF9(WT).

Figure 26. Hoxa9 and Meis1 Expression in MLL-AF9(D546R) Transduced Bone
Marrow Progenitor Cells
A

B

Relative expression of MLL target genes Hoxa9 (A) and Meis1 (B) in bone marrow
progenitor cells transduced with retroviruses encoding MLL-AF9(WT), MLLAF9(D546R) or empty vector following one week in methylcellulose. Expression was
normalized to Hprt and set relative to MSCVneo vector control. Three independent
experiments were each performed in triplicate. Error bars indicate standard deviation.
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From these studies, we can conclude that disruption of the AF9-DOT1L
interaction by charge reversal of AF9 aspartate residue 546 prevents in vitro leukemic
transformation.
MLL-AF9 Mutants E506R, I538A and K557E Do Not Alter the
in vitro Leukemic Transformation Ability of the MLL-AF9 Oncogenic Fusion
To test the functional effects of AF9 mutants E506R, I538A and K557E, all
predicted to disrupt the structure of AF9 itself, c-kit+ bone marrow progenitors were
retrovirally transduced with the empty MSCVneo vector which is not expected to
transform cells, MLL-AF9(WT) which is known to transform progenitor cells, and the
experimental mutants MLL-AF9(E506R), MLL-AF9(I538A) or MLL-AF9(K557E). If
protein interactions mediated by secondary structure imposed by E506, I538, or K557 of
AF9 are required for transformation, then mutation of these residues will result in a
decrease in colony formation.
There was no significant difference in the ability of MLL-AF9(WT) or mutant
fusions to transform bone marrow progenitor cells over the course of the experiment
(Figure 27A). Colony morphology was similar between all constructs, with the exception
of cells expressing MLL-AF9(I538A) which exhibited a slightly more diffuse
morphology and ragged edges compared to the tight, compact colonies formed by cells
expressing the other constructs (Figure 26B). The individual cells within these colonies
also appear slightly more differentiated than the MLL-AF9(WT) control cells (Figure
26B).
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Figure 27. MLL-AF9 Mutants E506R, I538A and K557E Colony Assay
A

B

(A) Colony formation by c-kit+ progenitor cells expressing MLL-AF9(WT), MLLAF9(E506R), MLL-AF9(I538A), MLL-AF9(K557E) or vector control throughout four
weeks of replating. Experiments were conducted in duplicate five to six times. (B)
Representative colony photographs at 4X and 10X magnification (top), and cell
morphology by cytospin followed by Wright-Giemsa staining (bottom).
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Target gene expression was also unaffected by expression of the mutants
compared to wild type. Neither Hoxa9 nor Meis1 levels were statistically reduced in
mutant-expressing cells compared to wild-type MLL-AF9-expressing cells (Figure 28).

Figure 28. Hoxa9 and Meis1 Expression in MLL-AF9 Point Mutant-Transduced
Bone Marrow Progenitor Cells
A

B

Relative expression of MLL target genes Hoxa9 (A) and Meis1 (B) in bone marrow
progenitor cells transduced with retroviruses encoding MLL-AF9(WT), MLLAF9(E506R), MLL-AF9(I538A), MLL-AF9(K557E) or empty vector following one
week in methylcellulose. Expression was normalized to Hprt and set relative to
MSCVneo vector control. Three independent experiments were each performed in
triplicate. Error bars indicate standard deviation.

Based on these results, we conclude that residues E506, I538 and K557 are not
critical for AF9 structure or mediating protein interactions required for in vitro leukemic
transformation.
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MLL-AF9 Fusion Proteins Resulting from Two Different Breakpoints in AF9
Are Equal in Transforming Potential
In MLL leukemia, the N-terminus of MLL breaks at the breakpoint cluster region
and fuses with one of over 79 fusion partners. To date, five distinct breakpoint regions
have been identified in AF9154, 241, 243, one of the most common MLL fusion partners.
The most frequent breakpoint in AF9, occurring in approximately 75% of patients
with t(9;11), results in a MLL fusion protein expressing amino acids 376-568 of AF9.
The second most common breakpoint, occurring in 12% of patients, results in a shorter
fragment of AF9 including amino acids 475-568154,

241, 243

. Knock-in studies of MLL-

AF9(475-568) under the control of endogenous Mll regulatory elements results in AML
development in mice, indicating that the 93 amino acids of AF9 present in this fusion are
sufficient for transformation147.
Because there is a one hundred amino acid difference between the fragment of
AF9 most commonly found in patients and the construct that is used to study the function
of the fusion in the laboratory, we sought to compare the constructs side-by-side in a
colony formation assay. The presence or absence of additional residues could
differentially modulate protein-protein interactions, and thus in vitro studies may not be
an accurate representation of what is happening in vivo.
To assess this, we transduced cells with retrovirus encoding MLL-AF9 fusions,
either with the 192 C-terminal amino acids found in MLL patients (376-568) or the
shorter 475-568 fragment, as well as a MSCVneo empty vector control. There were no
statistically significant changes in colony formation during the first three rounds of
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plating. By week four, the shorter fusion gained a statistically significant advantage
(Figure 30A). There were no detectable changes in colony or cell morphology (Figure
30B), and was there no significant change in Hoxa9 or Meis1 expression in cells
expressing the MLL-AF9(376-568) or MLL-AF9(475-568) fusion (Figure 29A).

Figure 29. MLL-AF9(376-568) and (475-568) Colony Assay
A

B

(A) Colony formation by c-kit+ progenitor
cells expressing wild-type MLL-AF9(376568), MLL-AF9(475-568) or vector control
throughout four weeks of replating. (B)
Representative colony photographs at 4X
and 10X magnification (top), and cell
morphology by cytospin followed by
Wright-Giemsa staining (bottom).
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Figure 30. Hoxa9 and Meis1 Expression in Bone Marrow Cells Transduced with
MLL-AF9(376-568) or (475-568)
A

B

Relative expression of MLL target genes Hoxa9 (A) and Meis1 (B) in bone marrow
progenitor cells transduced with retroviruses encoding wild-type MLL-AF9(376-568),
MLL-AF9(475-568) or empty vector following one week in methylcellulose. Expression
was normalized to Hprt and set relative to MSCVneo vector control. Three independent
experiments were each performed in triplicate. Error bars indicate standard deviation.
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From these results, we conclude that there is no significant difference in the
transformation ability of the MLL-AF9 fusion resulting from two different breakpoint
regions of AF9 at weeks one, two and three. There is a significant increase in colony
formation in cells expressing MLL-AF9(475-568) which will be further discussed.
Productive Transcription Elongation is Altered in
MLL-AF9(D544R and D546R)-expressing Bone Marrow Cells,
but not MLL-AF9 Mutants E506R, I538A or K557E-expressing Cells
We hypothesized that specific point mutations in the C-terminus of AF9 would
disrupt binding to one or more of the proteins known to interact with AF9. AF4, DOT1L
and CBX8 have all been identified as members of P-TEFb-associated complexes. To
examine whether these point mutations affect productive elongation, we used primers
designed to amplify four regions of the Meis1 gene. The Meis1 genomic region is
approximately 138 kilobases (kb), encoding a 3.3kb mRNA transcript containing 12
exons. We hypothesized that the proper and stable assembly of the P-TEFb elongation
complex is required for productive elongation of this long gene. Mutations in AF9 that
disrupt binding to AF4, DOT1L or CBX8 would disrupt the formation or function of the
Super Elongation Complex, and would prevent productive elongation as measured by
quantitiative real-time PCR using primer sets that span the length of the transcript.
Primer sets were used to assess transcription of four regions of Meis1 in MLLAF9 wild type or mutant-transduced bone marrow cells after one week in methycellulose.
One primer set was located in exon 1, 21 nucleotides after the transcription start site
(Figure 31A). The second primer set spanned exons 6 and 7, the third primer set spanned
exons 8 and 9, and the final primer set was located in the last exon of Meis1.
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Figure 31. Transcriptional Elongation of Meis1 in MLL-AF9 Wild-Type or Mutant
Transformed Bone Marrow Progenitor Cells

A

B

A) Meis1 locus encoding 12 exons in a 138 kb region (UCSC Genome Browser). Primer
sets were designed to amplify regions within exon 1, exons 6/7, exons 8/9 or exon 12. B)
Quantitative RT-PCR for expression of Meis1 with primers amplifying exon 1, exon 6/7,
exon 8/9 or exon 12. Expression was normalized to Gapdh and set relative to MLLAF9(WT). Three independent experiments were each performed in triplicate. Error bars
indicate standard error.
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If AF9 interaction with AF4, DOT1L, or CBX8 is required for RNA polymerase
II to successfully track along the length of the Meis1 gene, then expression of mutants
disrupting these interactions would result in reduced expression of Meis1 at the 3’ end of
the gene compared to the 5’ end.
Bone marrow cells transduced with MLL-AF9(D544R) or (D546R) exhibit
decreased expression of Meis1 when amplified using primers for exon 1 compared to
MLL-AF9(WT)-transduced cells. MLL-AF9 mutants E506R, I538A, and K557E show a
modest reduction in Meis1 expression using this primer set. Levels of Meis1 remain low
in MLL-AF9(D544R or D546R) expressing cells when using primers for exon 6/7, exon
8/9 and exon 12 compared to wild type. Expression levels of Meis1 as measured by the
exon 6/7 primers indicate comparable levels of expression in the E506R, I538A and
K557E mutants compared to MLL-AF9(WT) expressing cells. Analyzing transcript
levels further down the Meis1 gene with the exon 8/9 primer set indicates a modest
reduction in cells expressing MLL-AF9(E506R) whereas the I538A and K557E mutants
are similar to wild type. Expression at the 3’ end of Meis1 using the exon 12 primer set
indicates no change in expression in the E506R, I538A or K557E mutants compared to
wild type.

CHAPTER FIVE
DISCUSSION
Aim One: The Role of Af9 in Hematopoiesis
In the first aim of my project, I sought to examine the role of Af9 in
hematopoietic development, and to determine which protein interactions mediated by Af9
were required for normal hematopoiesis. As mentioned previously, the C-terminal AHD
of AF9 interacts with at least four proteins: AF4, DOT1L, CBX8 and BCoR. In
collaboration with the laboratory of Dr. Bushweller at the University of Virginia, specific
point mutations were identified that were predicted to disrupt binding to one partner
protein while maintaining binding with the others. Using these AF9 mutants, we sought
to elucidate which AF9-mediated protein interactions are required for proper
hematopoietic development.
All point mutations were readily expressed, with mutants D544R, I538A, S565A
and S565D expressing similarly to wild type AF9. The mutants D546R, E506R, K557E
and L562A were expressed at levels slightly less than wild-type. While this reduction is
minimal, it is not unexpected considering the location of these mutations within the
structured AF9 protein.
Residues E506, K557 and L562 are all present in alpha helices one or three of
AF9 (Figure 8). The formation of alpha helical structure is highly sequence-dependent,
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and disruption of the structure could result in misfolding and potential degradation. The
D546 residue was identified as mediating a potential salt bridge interaction with DOT1L.
It is possible that AF9 must bind to another protein to adopt structure and prevent
degradation, and that mutation of this residue may inhibit the stabilizing interaction. The
physiological role of intrinsically disordered proteins (IDPs) is not well understood, and
we do not know if other proteins, such as heat shock proteins, are required for the
stabilization of proteins like AF9 in vivo.
AF9(D546R) Interaction with AF4 and DOT1L
As part of her dissertation studies, Dr. Bhavna Malik examined the interaction of
AF9 point mutants with AF4, DOT1L and CBX8. She co-expressed the C-terminal 194
amino acids of AF9 (376-568), wild type or mutants D544R, E506R, K557E, L562A,
S565A or S565D with AF4, DOT1L or CBX8. The D546R mutation was later identified
as a potential disruptor of binding between AF9 and DOT1L, and so I examined the
interaction of AF9 wild type or D546R mutant with AF4 and DOT1L by
coimmunoprecipitation.
The C-terminal fragment of AF9 most often found in patients with MLL-AF9
rearrangement (376-568) or a smaller fragment (470-568) that is sufficient to transform
bone marrow cells and induce leukemia in a MLL-AF9 knock-in mouse model was
coexpressed147 with full length Dot1l, Dot1l 479-659, or DOT1L 828-1095. As
mentioned previously, the hydrophobic motif present in all AF9 binding partners (Figure
32) is repeated three times in the DOT1L protein. The 479-659 construct encompasses
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one site, whereas the 828-1095 fragment includes the two C-terminal hydrophobic motifs
(referred to as sites two and three, Figure 33).

Figure 32. Conservation of a Hydrophobic Motif in the AF9 Interacting Regions of
AF4/AF5q31, DOT1L, BCoR and CBX8

Conserved LxVxIxL/VxxL/V/I hydrophobic motif in AF9 interacting partners as
identified by Leach et al.

Coimmunoprecipitation studies show that expression of the AF9(D546R) mutant,
either in the context of the larger AF9 C-terminal fragment (376-568) or the shorter
fragment (470-568), results in reduced binding to full length Dot1l and to the fragment of
DOT1L encompassing the two C-terminal hydrophobic motifs (Figure 33). These results
indicate that the binding between AF9 and DOT1L is mediated in part by AF9 residue
D546.
Binding between AF9(376-568) and a Dot1l fragment including the site one
hydrophobic motif was not significantly affected by the D546R mutant, whereas
expression of AF9(D546R) in the context of the shorter AF9 fragment resulted in an
increase in binding to the Dot1l fragment encompassing site one (Figure 33). The
increase in binding between the shorter fragment of AF9(D546R) and Dot1l(479-659),
which is also a trend but statistically insignificant with the larger AF9(D546R) fragment,
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maybe be a result of different affinity binding between Dot1l site 1 versus sites 2 and 3.
Higher-affinity interactions may be more drastically affected by the introduction of a
mutation within the region, whereas lower affinity interactions may not be affected. Why
the D546R mutation in the context of the short AF9 fragment enhances binding over wild
type AF9 could be a result of enhanced affinity of the D546R mutant to a heat shock
protein or other protein necessary to stabilize AF9, which is reduced upon inclusion of
the additional amino acids in the larger fragment of AF9.

Figure 33. AF9(WT or D546R) Binding to DOT1L

Summary of immunoprecipitation studies with DOT1L full length, 479-659 or 828-1095
and AF9(WT or D546R) fragments 470-568 and 376-568. Repeated hydrophobic motifs
shown in Figure 32 are termed sites 1, 2 and 3.

Indeed, work by Lin et al showed that AF9 interacts with HSP90 and associated
co-chaperones HSP70 and p60/HOP244. The AF9-HSP90 interaction was identified using
amino acids 475-568 of AF9, the same region of AF9 that interacts with AF4, DOT1L,
CBX8 and BCoR. As discussed, structural studies suggest that AF9 binding to one of
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these four partner proteins is mutually exclusive. It would be informative to compare
binding of AF9 and HSP90 by HSQC spectral analysis to the HSQC spectra of AF9 in
complex with AF4/DOT1L/CBX8/BCoR. If all five AF9-interacting proteins bind to the
same residues of AF9 and induce the same structure, we would envision a sequential
binding model in which AF9 is translated in the cytoplasm, is transported into the nucleus
by through association with HSP90, and then is released by HSP90 to bind AF4, DOT1L,
CBX8 or BCoR.
Expression of the D546R mutant does not alter the binding to AF4. Coexpression
of the same AF9 fragments (376-568 or 470-568), wild type or mutant, with two
fragments of AF4 encompassing either the minimal AF9 interaction region (755-777) or a
slightly larger region including the AF9 binding domain (647-871), did not result in any
changes in binding between AF9 and AF4 (Figure 34). The exception to these results is
seen upon coexpression of the shorter 470-568 AF9(D546R) fragment with the minimal
AF4 fragment 755-777, which resulted in a statistically significant increase in binding.
As with binding to Dot1l, it appears that expression of the mutant in the 98 amino acid
fragment of AF9, but not the 192 amino acid fragment, enhances binding with the
minimal fragment of AF4 (or Dot1l, as discussed above). It may be more energetically
favorable for smaller proteins to interact245. Smaller proteins could have a lower degree
of entropy, and thus require lower activation energy for the conformational change to
occur upon binding to a partner protein. The electrostatic charges present also alter
entropy, and this could explain why the mutant D546R binds better to the minimal
fragment of AF9 compared to wild type AF9. Biochemical analyses would have to be
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conducted to determine the thermodynamics of binding between the longer and short
fragments of AF9 (wild type or D546R) with AF4 and DOT1L fragments.

Figure 34. AF9(WT or D546R) Binding to AF4

Summary of immunoprecipitation studies with AF4 fragments 755-777 and 647-871 and
AF9(WT or D546R) fragments 470-568 and 376-568.

In all of these coimmunoprecipitation studies, I overexpressed all proteins, either
full length or fragments of proteins. Coimmunoprecipitation of endogenous proteins may
show different results, as the additional domains in these proteins may also mediate
binding of AF9 to a partner protein. However, the fragments examined here are the amino
acids of AF9 present in MLL fusion proteins, and thus these studies are relevant in
examining the role of these protein interactions in MLL-AF9 leukemias.
Overall, these results highlight the importance of the AF9 D546 residue in
mediating interaction between AF9 and DOT1L. The structural studies from the
Bushweller lab identified a conserved hydrophobic motif present in all AF9 binding
partners, and suggested that AF9 binding to any of the four proteins AF4, DOT1L, CBX8
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or BCoR is mediated through this motif. However, the selective disruption of binding to
DOT1L but not AF4 with the AF9(D546R) residue indicates that interaction between
these two proteins is mediated, at least partially, through a region distinct from the
hydrophobic motif.
Of note, coexpression of AF9(D546R) with any of the four fragments used in
these immunoprecipitation experiments resulted in decreased detectable AF9(D546R)
protein in the input compared to wild-type, despite transfecting the same amount of
DNA. This result was reproducible and was evident even when the amount of plasmid
DNA transfected was adjusted in an attempt to normalize the input amounts, suggesting
that AF9(D546R), in the context of the larger 376-568 or the shorter 470-568 fragment, is
less stable than the same fragments of wild type AF9. This mutant was also expressed at
a slightly lower level than wild type in the context of the full length protein as seen in
Figure 8B. As discussed, this mutant may be less stable than wild type AF9 as a result of
decreased affinity binding to a protein required for stabilization such as a heat shock
protein. A recent study has also shown that the intrinsically disordered C-terminus of
DNA glycosylase NEIL1 is stabilized through intramolecular, primarily electrostatic,
interactions246. It is possible that the D546R mutation prevents potential intramolecular
interactions from occurring, and thus the protein is degraded.
As reviewed by Dyson and Wright, many transcriptional regulators are
intrinsically disordered proteins (IDPs)247. The process of coupled folding and binding, in
which an unstructured protein (or unstructured region of a protein) adopts a structure
upon interaction with a target, can allow for rapid and promiscuous protein-protein
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interaction. In the case of AF9, the ability to bind both activators and repressors could
allow for differential regulation of gene targets depending on other, yet unknown signals
in the cell. As disordered proteins are relatively unstable, they could be degraded without
chaperoning by another protein. Whether AF9 is complexed to other proteins in vivo that
promote its stability is unknown but would be an interesting question to pursue.
Of the studies published on the complex components of the SEC, only the Biswas
group identified proteins by biochemical purification of AF96. The authors overexpressed
FLAG-HA-tagged AF9 and examined associated proteins. We could interrogate
additional AF9-interacting proteins, and determine which of the proteins are required for
AF9 stability by knocking down candidates proteins and examining the levels of AF9.
The Role of Af9 in Hematopoietic Differentiation
To examine the role of Af9 in in vitro hematopoietic differentiation, I isolated ckit+ progenitor cells from the bone marrow of Af9fl/fl Cre/+ mice and plated these cells in
semi-solid media to promote the differentiation to erythroid, myeloid or megakaryocytic
lineages in the presence or absence of 4-OHT. We hypothesized that loss of Af9 upon 4OHT treatment would result in a loss of erythroid and megakaryocyte colony formation,
with a possible compensatory increase in myeloid lineage differentiation. However,
results show that Af9 is not required for in vitro differentiation to erythroid,
megakaryocyte, or myeloid lineages under the conditions tested here.
Erythroid Lineage Differentiation
While the number of erythroid colonies formed was not different in the presence
or absence of Af9, there is a significant decrease in the mean fluorescence intensity (MFI)
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of CD71 expression in cells null for Af9 compared to the ethanol control treated cells.
CD71 is marker of early erythroid precursor cells, so the decrease in MFI suggests that
while these cells are still expressing CD71, the level of expression is reduced upon loss of
Af9. Af9 may therefore play a role in the differentiation to erythroid precursor cells, but
this reduction is either not sufficient to alter overall colony formation ability, or it is
occurring in only a subset of cells that are not required for colony formation. There was
no change in Ter119 expression, and expression overall is low, which is consistent with
previous reports that Ter119 is expressed later in erythroid differentiation than the time
points examined here.
Examination of myeloid markers CD41, Gr-1 and CD11b in cells plated for
erythroid lineage differentiation did not indicate significant differences in cells
expressing or lacking Af9. CD41 levels are low in both control and 4-OHT-treated cells,
which is expected as CD41 is expressed on the surface of platelets and megakaryocytes,
both mature cell types that would not be present at this early four day time point. We
would expect to see CD41 expression, as well as expression of other myeloid surface
markers, appear by twelve days in culture. Levels of Gr-1 and CD11b are elevated in
these erythroid cytokine-cultured bone marrow cells, with an average MFI of
approximately 2500 relative units for Gr-1 and CD11b, but levels are not as high as in
Af9fl/fl cre/+ plated for myeloid differentiation in the presence or absence of 4-OHT with
average MFIs of 3500 and 4000 for Gr-1 and CD11b, respectively. This indicates that
despite being cultured in the presence of cytokines to promote erythroid lineage
commitment, there is at least a subset of cells that differentiate to the myeloid lineage.
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Interestingly, while the differences in MFI between ethanol and 4-OHT treated cells is
not significant, there is a trend toward increased myeloid marker expression in cells
lacking Af9. This would support our hypothesis that a loss of Af9 results in a loss of
erythroid lineage commitment (decreased MFI of CD71) with concurrent compensation
by myeloid lineage differentiation (increased MFI of Gr-1 and CD11b). Additional
replicates may elucidate whether this is a real effect, or if it is just variability between
experiments.
Myeloid Lineage Differentiation
There was no significant difference in myeloid colony formation in cells
expressing or lacking Af9. Examination of surface marker expression does not indicate
any statistically significant differences in the percent of positive cells or the mean
fluorescence intensity of either myeloid (CD41, Gr-1, CD11b) or erythroid (CD71,
Ter119) expression. Compared to cells plated for erythroid lineage differentiation, these
myeloid-directed cells express higher levels of CD41, Gr-1 and CD11b. In terms of
erythroid marker expression in these cells, we do see expression of CD71 in both control
and 4-OHT-treated cells, but the average MFI for these cells is less than half of that in
cells plated for erythroid lineage differentiation. Ter119 expression is elevated in the
myeloid-cultured cells as compared to cells cultured in erythroid cytokines. This is likely
a result of the later time point at which these cells were harvested, as Ter119 is expressed
later in erythroid development than the time point at which the erythroid cultured cells
were harvested.
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The presence of erythroid markers on these cells suggests that at least a subset of
cells are able to differentiate toward the erythroid lineage and acquire erythroid lineage
markers, despite being cultured in the presence of cytokines to promote myeloid lineage
differentiation. This may partially be due to the c-kit+ selection of murine bone marrow
cells for plating in these assays. C-kit is expressed on HSCs as well as committed
progenitor cells, including the MEP and the GMP. Using this protocol, the cells plated
were a heterogeneous population of stem and progenitor cells, which would express
different surface markers depending on the stage of differentiation at the time of
isolation. I could examine differences in surface marker expression and colony formation
using lineage (Lin)-depleted cells, or isolating Lin-Sca1+c-kit+ cells (LSK) which enrich
for HSCs.
Megakaryocytic Lineage Differentiation
As loss of Af9 does not alter erythroid or myeloid colony formation, it also does
not alter megakaryocyte differentiation as detected by acetylcholinesterase staining. The
method that I used to differentiate and quantify megakaryocyte differentiation does not
allow for surface marker analysis, but based on colony formation alone, Af9 is not
required for megakaryocytic development. Consistent with these in vitro studies on the
role of Af9 in hematopoietic lineage differentiation, I did not see alterations in the levels
of mRNA encoding erythroid or myeloid transcription factors in the bone marrow of
Af9fl/fl or Af9

fl/fl Cre/+

mice treated with tamoxifen. These results combined suggest that

Af9 is not a master regulator of murine erythroid/megakaryocytic lineage commitment.
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Re-expression of AF9 in Af9-null Bone Marrow Progenitor Cells
In addition to examining the role of Af9 in hematopoietic development, I
proposed to examine the role of specific Af9-partner protein interactions in hematopoietic
development by re-expressing full length AF9 point mutants in Af9fl/fl Cre/+ c-kit+ bone
marrow cells. We originally hypothesized that loss of Af9 would result in a loss of
erythroid and megakaryocytic colony formation that could be rescued by re-expression of
wild type AF9. These experiments were the first I conducted before obtaining the results
described above, but these experiments support the findings I reported.
Vector transduced cells formed the same number of colonies when plated for
erythroid lineage commitment in the presence or absence of 4-OHT, just as untransduced
cells formed the same number of colonies with or without 4-OHT treatment. Reexpression of wild-type AF9 or AF9 mutants S565A or S565D did not alter colony
forming ability. While there was no phenotype to rescue in this experiment, since loss of
Af9 did not alter colony formation, these results also suggest that overexpression of AF9
does not alter colony formation. Overexpression of AF9 in CD34+ CD38- human cord
blood resulted in an increase in the E/Meg compartment159, whereas here I saw no change
upon retroviral transduction of AF9 in c-kit+ cells. I did not compare the levels of
overexpressed AF9 with endogenous levels of Af9, but I would expect that high-titer
retroviral transduction of AF9 under the control of the Murine Stem Cell Virus promoter
would result in very high expression of AF9 in these cells, likely over that of endogenous
levels and therefore comparable to an overexpression system.
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In the study by Pina and colleagues, lentiviral knockdown of AF9 in human cord
blood resulted in a loss of erythroid progenitor colony formation. Here, complete genetic
loss of Af9 in murine c-kit+ bone marrow cells as detected by genotyping PCR does not
result in decreased colony formation. Overexpression of AF9 in human CD34+CD38cells caused an expansion of erythroid/megakaryocytic cells, but re-expression of AF9 in
Af9-/- c-kit+ cells does not alter colony formation. These results indicate that Af9 does not
play a role in hematopoietic differentiation in this system.
Af9 is Not a Critical Regulator of Adult Murine Hematopoiesis
The results described refute our hypothesis that Af9 is a critical regulator of
erythroid and megakaryocytic lineage commitment. This is contrary to the study by Pina
and colleagues159, but may align with the report of hematopoiesis in the constitutive Af9
knockout mouse. Collins et al reported that hematopoiesis was normal 158, but no data
were provided so it is impossible to compare our findings.
The discrepancy between our results and that of the Pina study could be a result of
differences in human versus murine hematopoiesis. Those authors used human cord
blood cells to examine the role of AF9 whereas we utilized a conditional Af9 knockout
mouse. There are many similarities in hematopoietic development between mice and
humans, but there are also many differences. A recent study compared the transcriptional
profile of early, intermediate and late erythroid progenitor cells in humans and mice.
These researchers found that at each stage of differentation, the top 500 most highly
expressed genes in human were orthologous to only 30% of the top 500 most highly
expressed genes in mice248. Phenotypically, erythropoiesis was not altered, but these
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results suggest that the transcriptional regulation of this process is highly divergent
between humans and mice. This is something to keep in mind when looking to translate
studies of mouse cells to the human system. The use of humanized mouse models, in
which human hematopoietic cells are grafted into mice, may provide a more translational
approach to studying hematopoiesis249.
Of note in regard to human hematopoiesis, global transcriptome analysis showed
that AF9 expression is highest in the HSC, and levels decrease by half by the CMP
stage159. If AF9 is a critical player in erythroid/megakaryocytic development, we would
expect high levels throughout differentiation to the CMP and MEP. However, this may
support the Adolfsson model of hematopoiesis in which the MEP arises directed from the
ST-HSC without transit through a CMP stage15. High levels of AF9 could support
differentiation directly to the erythroid/megakaryocytic lineage from the ST-HSC,
playing a role in earlier hematopoietic lineage commitment rather than terminal
differentiation from a later progenitor.
The source of the cells in which the role of Af9 was assessed may also play an
important role. The Pina et al study isolated human CD34+CD38- cord blood cells159. We
isolated murine c-kit+ bone marrow cells. In addition to isolating cells from different
species, there are several differences in cord blood versus bone marrow stem cells.
Patients transplanted with umbilical cord blood stem cells exhibit a low severity Graft vs.
Host Disease (GVHD) compared to patients transplanted with bone marrow stem cells,
although the patients receiving cord blood stem cells had a delayed engraftment250.
Umbilical cord blood also contains the largest percentage of CD34+CD38- stem cells
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compared to bone marrow or granulocyte colony-stimulating factor-mobilized peripheral
blood stem cells251,

252

. A study published by the Staal lab directly compared the

expression profile of CD34+ cells isolated from umbilical cord blood and bone marrow,
and identified 51 differentially expressed genes253. These genes were involved in
proliferation, apoptosis, differentiation and engraftment capacity, confirming that stem
cells isolated from different sources may have different characteristics.
Another reason we did not see an effect on hematopoietic differentiation in vitro
upon loss of Af9 may be a result of compensation by Af9 homolog Enl. As previously
discussed, Af9 and Enl are highly homologous in their N and C-terminal regions. While
these proteins are generally expressed in different tissues (discussed in Chapter One), it is
possible that loss of Af9 in hematopoietic cells could result in a compensatory increase in
Enl expression.
To test this hypothesis, we could transduce Af9fl/fl

Cre/+

mice with control

(scrambled) or Enl shRNAs and plate the cells with or without 4-OHT in cytokines for
erythroid, myeloid or megakaryocytic lineage commitment. If Enl is compensating for
loss of Af9 as a regulator of hematopoietic differentiation, then genetic loss of Af9
combined with shRNA-mediated knockdown of Enl may result in a loss of E/Meg
colonies, as we initially hypothesized. In addition to examining hematopoietic colony
formation, we could also examine surface marker expression and expression of
hematopoietic lineage transcription factors as previously described.
Whether AF9 and ENL play redundant or distinct roles within the cell is an
interesting question. The proteins are highly homologous, especially in the N and C
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terminal regions. AF9 and ENL are interchangeable members of the SEC, however they
show distinct tissue expression patterns. In leukemia, the MLL-AF9 fusion protein results
in a myeloid leukemia, whereas MLL-ENL fusion proteins often present as biphenotypic
or lymphoid leukemia. If the proteins are so similar, and the fusion partner dictates the
leukemic phenotype in MLL recombined leukemias, we would expect MLL-AF9 and
MLL-ENL to transform cells similarly. Further studies elucidating the role of these two
homologs is needed to identify their function in both hematopoiesis and leukemogenesis.
Aim Two: The Role of AF9 in Leukemogenesis
In my second aim, I sought to determine whether protein interactions mediated by
the C-terminus of AF9 in the context of the MLL-AF9 fusion protein were necessary for
in vitro leukemic transformation. The first mutant fusion gene examined was MLLAF9(D544R). As previously described, this mutation is predicted to disrupt an
electrostatic interaction mediated by AF9 aspartic acid D544 and AF4 lysine 764 by
reversing the charge at the AF9 544 residue. Coimmunoprecipitation studies using the
376-568 amino acid C-terminal fragment of AF9 shows that expression of the D544R
mutant reduces binding to AF4 compared to wild type, while maintaining interaction with
DOT1L and CBX8240.
MLL-AF9(D544R) Mutation Decreases Leukemic Transformation Potential
To assess the function of this mutation in vitro, I transduced c-kit+ bone marrow
cells with retrovirus encoding the MLL-AF9 fusion, either wild type or D544R. Colony
formation was significantly reduced in cells expressing the MLL-AF9(D544R) fusion
compared to wild-type, and the colonies that did form were smaller and more diffuse than
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the wild type control. The cells within these colonies were more differentiated than the
blast-like MLL-AF9(WT) expressing cells. Expression of MLL target genes Hoxa9 and
Meis1 were also reduced in these cells at the end of week one. Both Hoxa9 and Meis1 are
shown to be upregulated in MLL leukemias, and are required for transformation254.
The results indicate that the AF9 interaction with AF4 specifically is required for
in vitro leukemic transformation. Because the D544R mutant was shown by
coimmunoprecipitation studies to maintain interaction with DOT1L and CBX8240, this
suggests that the selective loss of interaction with AF4 is responsible for decreased
transformation ability.
These findings are further supported by binding data from the Bushweller lab,
indicating that the dissociation constant between fragments of wild type AF9 and AF4 is
0.17nM. Mutation of wild type AF9 to D544R results in a decrease in binding affinity to
a kD of 9.6nM. Charge reversal of AF4 lysine residue K717 to positively charged
asparagine restored binding to AF9(D544R) in colocalization studies conducted by Dr.
Ming-jin Chang, supporting the hypothesis that this salt bridge interaction is required for
binding between AF9 and AF4240.
Transformation is Rescued by Restoration of the AF4-AF9 Salt Bridge Interaction
We hypothesized that like the colocalization studies, complementary charge
reversal of AF4 K764 to glutamate could rescue the loss of colony formation by the
MLL-AF9(D544R) mutant-expressing cells. The original experimental design was to
coexpress MLL-AF9(D544R) with AF4(WT or K764), but overexpression of AF4 was
toxic to cells. MLL-AF4 does not transform progenitor cells7, so coexpression of MLL-
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AF4(WT or K764E) with AF9(WT or D544R) was not an option. We therefore utilized
the AF4 homolog AF5q31 which, as shown in Figure 6B, is highly homologous to AF4.
AF4 K764 is equivalent to AF5q31 K717, a conserved lysine in members of the AF4
family that mediates the salt bridge interaction with AF9. We do not have access to the
AF5 clone, and thus our experimental design was to coexpress MLL-AF5q31(WT or
K717D) with full length AF9 (WT or D544R).
We confirmed the findings by Yokoyama that MLL-AF5 efficiently transforms
bone marrow progenitor cells. Expression of MLL-AF5(K717D) results in reduced
colony forming ability, supporting our model that the charge reversal introduced by this
amino acid substitution prevents interaction with AF9 at amino acid D544. We also
examined MLL target gene expression in these cells and saw a significant reduction in
Meis1 expression in MLL-AF5(K717D)-expressing cells compared to wild type.
Interestingly, Hoxa9 was not altered between these mutants.
As far as I am aware, there have been no studies published showing differential
expression of Hoxa9 and Meis1 in colony assays with MLL fusion proteins. Hoxa9 and
Meis1 are specifically upregulated in ALL cases with MLL translocations compared to
non-MLL recombined ALLs255, 256. Additionally, transcriptional analysis of Hoxa9 and
Meis1 show upregulation of both genes in 13 of 14 examined ALL cases with MLL-AF4
translocations, and eight of eight AML patients with MLL recombination257. A previous
study showed that expression of Hoxa9 or Meis1 alone could not transform bone marrow
cells and cause leukemia, but coexpression of Hoxa9 and Meis1 resulted in leukemia
development and death in mice with a median latency of 67 days258. Based on these
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findings, we expected to see an increase in Hoxa9 and Meis1 in cells expressing MLLAF5(WT), with a decrease in expression of both genes in cells expressing MLLAF5(K717D), correlating with colony formation. However, that was not what we saw.
The N-terminus of MLL that is present in the fusion proteins directs the fusion to
gene targets, and it is thought that the C-terminal fusion partner provides a gain-offunction that results in aberrant expression of gene targets. I expect that both MLL-AF5
wild type and K717D are both being recruited to gene targets, and that could be
confirmed with chromatin immunoprecipitation studies. It is therefore likely that the
additional components being recruited to these loci are either different, or are
differentially required, between MLL-AF5 wild type and mutant expressing cells.
In terms of the general recruitment to target loci, AF5 and AF4 interchangeably
participate in the P-TEFb elongation complex. Both proteins bind directly to Cyclin T1 or
T2 of the P-TEFb dimer; residues 1-308 of AF4 and 1-300 of AF5 have been shown to
mediate this interaction183, 188. In the MLL fusion protein, the fusion point within AF4
occurs around amino acid 360, thus the MLL-AF4 fusion does not retain Cyclin T1
binding. AF4 and family members homo- and hetero-dimerize with other members of the
family via their C-terminal homology domain, with a preference for heterodimerization7.
Therefore, in the example of the experiment discussed here, MLL recruits the MLL-AF5
fusion to the target gene. AF5 then homodimerizes with full length AF5 or
heterodimerizes with AF4. The recruited AF4/5 can then bind to Cyclin T1 that interacts
with CDK9 to form P-TEFb, which binds to RNA Pol II. The recruited AF4/5, as well as
the portion of AF5 in the MLL fusion, can also bind to AF9/ENL through the minimal
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AF9/ENL interaction domain conserved in these proteins. AF9/ENL stabilize the P-TEFb
elongation complex and aid in its processivity during transcription.
The presence of the AF5(K717D) mutation disrupts the salt bridge interaction
between AF5 and AF9, and that would occur regardless of the loci to which it is targeted.
Therefore, the most likely explanation is that the proper formation of this SEC is required
at Meis1 to a greater degree than it is at Hoxa9. Meis1 is a much longer gene than Hoxa9,
encompassing a genomic region of 138 kilobases compared to only 5.6 kilobases for
Hoxa9. As RNA polymerase transcribes a gene, it often stalls and requires the
components of the SEC to overcome the stall and continue to process along the template
DNA. Without the proper formation of this complex, the Polymerase may be unable to
complete transcription of Meis1, whereas the association with SEC components may be
less necessary at Hoxa9.
In regard to the restoration of the salt bridge interaction by charge reversal on
both AF9 and AF5, coexpression of MLL-AF5(K717D) with AF9(WT) did not transform
bone marrow progenitor cells, whereas coexpression of both mutants MLL-AF5(K717D)
with AF9(D544R) resulted in increased colony formation through the third week of
replating. Corresponding to this serial replating ability was an increase in Meis1
expression compared to the MLL-AF5(K717D) + AF9(WT) expressing cells. Hoxa9
expression again seems to be differentially regulated from Meis1 expression in this
system. The hypothesis described above is applicable in this example as well, although I
would not necessarily expect to see a decrease in Hoxa9 expression in cells expressing
both mutants compared to expressing MLL-AF5(K717D) + AF9(WT); if proper
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formation of the SEC is not required for elongation of Hoxa9, I would expect to see no
changes in the levels.
A possible explanation for the decrease in Hoxa9 expression in cells expressing
both MLL-AF5(K717D) and AF9(D544R) compared to cells expressing MLLAF5(K717D) and AF9(WT) may be a result of simply overexpressing two mutants that
can bind to endogenous SEC proteins required for transcription at Hoxa9. Perhaps
overexpression of both an AF5 mutant and an AF9 mutant act in a dominant negative
manner, binding to endogenous proteins AF4/AF5, AF9/ENL, or DOT1L, and preventing
formation of the SEC that may be required for the high levels of transcription occurring
at the Hoxa9 locus.
These results are perplexing, but the presence of the mutations was verified in the
cDNA used in these samples. RNA was isolated from three independent experiments and
the results were consistent. ChIP analysis for SEC components such as AF4/AF5,
AF9/ENL and P-TEFb components CDK9 and Cyclin T1/2 at the Meis1 and Hoxa9 loci
may shed light on any differential regulation between these two genes previously thought
to play the similar roles in leukemogenesis.
These findings highlight the requirement for the AF9-AF4/AF5 salt bridge
interaction in leukemic transformation. As previously described, AF9 interacts with a
region of hydrophobic residues in AF4 (also conserved in AF5, Figure 32). This
hydrophobic region is present in other AF9 interacting proteins DOT1L, CBX8 and
BCoR. These results show that mutation of AF9 at aspartic acid D544 selectively disrupts
binding to AF4, while maintaining binding to DOT1L and CBX8 (BCoR binding was not
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assessed). These results show that the AHD of AF9 likely interacts with proteins through
both the hydrophobic motif shared by all proteins, but also through additional interactions
that may be specific to each partner protein.
AF4 K764 is located within the hydrophobic motif conserved in AF9 binding
partners (Figure 32). While the charge-reversal studies support the conclusion that the
electrostatic interaction between AF9 and AF4/AF5 is required for transformation, an
alternative hypothesis is that mutation of K764E, or K717D in the case of AF5q31,
disrupts the organization of the hydrophobic motif. Hydrophobic residues often associate
in the core of proteins to remain isolated from the aqueous environment. Disrupting the
charge on an amino acid within this motif may alter the packing altogether, losing the
binding interface with AF9, and that could result in the loss of transformation. However
the complementation experiment suggests that this is not the case, because coexpression
of AF5(K717D) with AF9(D544R) restores transformation ability. If the hydrophobic
motif was disrupted by the AF5(K717D) mutation, coexpression of AF9(D544R) would
not be able to rescue the folding of that motif.
Disruption of AF9 binding to AF4 specifically by this mutation provides an
attractive target to develop small molecule inhibitors. The Hemenway lab has designed
and tested AF4 mimetic peptides that disrupt the AF4-AF9 interaction. These peptides
show cytotoxicity specifically in MLL fusion-expressing cell lines, although the
mechanism is not well understood157, 189, 259.
It would be informative to examine whether the salt bridge interaction mediated
by AF9 homolog ENL with AF4 family members is also necessary for leukemic
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transformation. AF9 and ENL are highly homologous, and AF9 aspartate 544 is
conserved in ENL (Figure 4D). As either AF9 or ENL can participate in the P-TEFb
elongation complex, and both are fusion partners of MLL, it is likely that an electrostatic
interaction between ENL and AF4 family members would also be required for
leukemogenesis.
MLL-AF9(D546R) Reduces Leukemic Transformation Potential
The AF9 D546R mutant was predicted to specifically disrupt binding to DOT1L
while maintaining binding to AF4 and CBX8. Coimmunoprecipitation studies confirmed
that expression of AF9(376-568) D546R reduced binding to DOT1L compared to the
wild type AF9 fragment, while maintaining interaction with AF4 (CBX8 binding studies
are ongoing). Similar to the D544-K764 electrostatic interaction between AF9 and AF4
discussed above, AF9 D546 likely mediates an electrostatic interaction with a negatively
charged residue in DOT1L.
To test the effect of this mutation on in vitro transforming ability, c-kit+
progenitor cells were retrovirally transduced with MLL-AF9, wild type or D546R
mutant. Cells expressing MLL-AF9(D546R) showed decreased colony formation
compared to the wild-type fusion, and the colonies that did form were very small and
diffuse. The cells within these colonies were differentiated compared to the blast
morphology in the MLL-AF9(WT)-expressing cells. Both Hoxa9 and Meis1 expression
were significantly reduced in MLL-AF9(D546R) expressing cells compared to the wild
type control, indicating that the interaction mediated by AF9 residue D546 is required for
leukemic transformation in vitro.
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Identification of the residue on DOT1L mediating the interaction with AF9 D546
would allow for similar complementation studies conducted with the D544R mutant to
confirm that it is indeed a salt bridge interaction between these two proteins that, when
disrupted, results in a loss of transforming potential.
The D546 residue is two amino acids downstream of the D544 residue that
mediates AF4 interaction, yet these mutants seem to be selective for disrupting binding to
DOT1L and AF4, respectively. This is entirely plausible as structural studies indicate that
AF9 likely interacts with only one protein at a time. The AHD of AF9 is a small stretch
of 94 amino acids, and studies of the chemical shift of AF9 with AF4, DOT1L, CBX8 or
BCoR suggest that all four proteins bind to the same region of AF9 via a conserved
hydrophobic motif. Biochemical purification studies have also shown that AF9 and
DOT1L exist in a complex distinct from AF9 and AF4 and the other PTEF-b proteins,
further supporting the hypothesis that AF9 interacts singly with one of the four identified
proteins to mediate specific effects within the cell.
It would be very useful to examine the effects of a double AF9(D544R/D546R)
mutant in both binding studies and in in vitro colony formation assays. While MLLAF9(D544R)-expressing cells had reduced colony formation ability compared to wildtype, and expression of MLL-AF9(D546R) in bone marrow cells almost completely
abolished colony formation, there were colonies at the end of each of four weeks,
indicating that transformation was not completely inhibited in the cells. This may be
because the D544R-mutant cells can retain binding to Dot1l, and the D546R-mutant cells
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retain binding to Af4. The double mutant would presumably be unable to bind to both
proteins, and thus we may see a complete loss of colony formation.
MLL-AF9 Mutants E506R, I538A and K557E Do Not Alter Transformation Ability
Expression of additional MLL-AF9 mutants E506R, I538A and K557E did not
result in reduced colony formation compared to MLL-AF9(WT). There were no changes
in target gene expression, nor any gross alterations in colony or cell morphology. Of note,
however, is the MLL-AF9(I538A) mutation. This mutant was predicted to disrupt
binding to both AF4 and DOT1L. We expected to see a loss of colony formation ability
in bone marrow progenitors expressing this fusion, although results showed that
expression of MLL-AF9(I538A) transforms cells to the same degree as MLL-AF9(WT).
The colonies formed by MLL-AF9(I538A)-expressing cells, however, often had a dense
core surrounded by more diffuse cells that themselves appeared partially differentiated
compared to the wild type control.
Unpublished coimmunopreciptiation studies by Dr. Malik indicate that mutation
of AF9 residue I538 to alanine results in a loss of binding to AF4 and DOT1L, but this
mutant enhances binding to CBX8 compared to AF9(WT). If this is the case, it is
possible that the enhanced AF9-CBX8 interaction is leading the recruitment of CBX8 to
genes targeted by the MLL-AF9 fusion. CBX8 may then deposit repressive histone marks
to turn off gene expression, which could explain the partially differentiated phenotype. In
our studies, expression of MLL-AF9(I538A) does not result in a decrease in Hoxa9 or
Meis1 expression in bone marrow cells at week one, but perhaps we would see a decrease
if we examined later time points, or if we examined other MLL target genes. It would be
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interesting to examine the effect of this mutant in vivo, as we would expect leukemia to
develop based on the colony assay results, but the phenotype of the leukemia or the time
of onset may be different compared to MLL-AF9(WT) control.
Transformation Potential of MLL-AF9 Fusions Resulting from Two Different
Breakpoints in AF9
I also examined the transformation ability of MLL-AF9 fusions containing either
93 or 194 amino acids of AF9. To date, five breakpoint regions in AF9 have been
identified in patients with t(9;11)(p22;q23) rearrangements241. Of the reported cases in
the literature, approximately 75% of MLL-AF9 fusions expressed in patients include
amino acids 375-568 of AF9 in frame with 5’ MLL. These region was first identified by
Nakamura and colleagues as site A. Found less frequently, in approximately 12% of
patients with t(9;11), is a MLL fusion including amino acids 475-568 of AF9154. A
knock-in mouse model in which MLL-AF9(475-568) was introduced via homologous
recombination into the endogenous Mll locus resulted in development of AML in mice,
indicating that this shorter C-terminal region of AF9 is sufficient for transformation147.
The AHD of AF9 that mediates protein-protein interactions is fully present in
both the long and short form of the MLL-AF9 fusions. However, it was possible that the
100 amino acid difference between these two fusions could mediate additional
interactions that would alter transformation ability. I tested this in vitro by expressing the
long and short fusions in bone marrow cells, and assessing serial replating ability. I did
not see a statistically significant difference in colony formation ability between the cells
expressing either fusions until week four, at which point MLL-AF9(475-568)-expressing
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cells formed more colonies than cells expressing the longer form. It would be interesting
to examine whether the enhanced colony formation ability in cells expressing the short
form fusion would continue for subsequent replatings. In regard to human leukemia, it
would be interesting to examine the survival rates of patients harboring MLL-AF9
fusions resulting from the different AF9 breakpoint regions.
Neither Hoxa9 nor Meis1 expression levels were significantly different between
cells expressing MLL-AF9 fusions with the long or short AF9 C-terminal tail at the end
of week one. This result is consistent with the colony formation between cells expressing
these constructs at the end of week one. However, we may expect to see increased Hoxa9
and Meis1 levels at week four, the time point in which the MLL-AF9(475-568)expressing cells exhibited enhanced colony forming ability over MLL-AF9(376-568)
expressing cells.
It would be interesting to examine the affinity of binding between the long and
short form of the C-terminal AF9 tail with known AF9-interacting partners. If the shorter
form is indeed more transforming, perhaps this region binds to certain “activating”
proteins with higher affinity than does the longer form, or the longer form may bind to
proteins with repressive function with higher affinity. In terms of the coupled folding of
intrinsically disordered proteins, it may require less energy to induce structure of a 93
amino acid fragment as compared to 194 amino acids, making it easier for this smaller
fragment to bind to proteins that interact with AF9 and confer an “activating” function.
Elucidating any differences in protein interactions between the long and short Cterminus of AF9 would be useful in understanding the mechanisms of transformation
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mediated by these different MLL-AF9 fusion proteins, and could potentially inform
different treatment options for patients expressing the long or short MLL-AF9 fusion.
Transcription Elongation in Cells Expressing MLL-AF9 Mutants
All of the point mutants were engineered to disrupt binding of AF9 to AF4,
DOT1L, CBX8 or BCoR. We hypothesized that loss of AF9 interaction with one or more
of these proteins would result in decreased colony formation and target gene expression,
and indeed that was what we saw. The D544R mutation, which disrupts binding to AF4,
and the D546R mutation, which disrupt binding to DOT1L, both resulted in decreased
colony formation. To assess whether the interaction of AF9 with AF4 or DOT1L is
required for productive elongation of the RNA Polymerase II complex, we designed
primer sets spanning the length of the 138 kb Meis1 genomic region, hypothesizing that
the SEC would be unable to assemble or function properly to promote productive
elongation.
We saw reduced expression of Meis1 at all four genomic regions in cells
transduced with the D544R or D546R mutants compared to the wild type control,
supporting our model that decreased colony formation and target gene expression is a
result of disrupting required AF9-mediated protein interactions in the SEC. Interestingly,
we saw increased expression levels at the 3’ end of the gene compared to the 5’ end in
cells expressing either of these mutants. This could be a result of primer efficiency;
perhaps the exon 6/7, exon 8/9 and exon 12 primer sets amplify their target more
efficiently than the exon 1 primer set. The 5’ end of the transcript could also be degraded.
If the RNA Pol II complex is stalled for too long, the RNA Polymerase II complex can be
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ubiquitylated and targeted for degradation260. Capping enzymes, as well as splicing
factors and proteins responsible for 3’ polyadenylation often exert their functions
cotranscriptionally with RNA Pol II261, 262. A study in yeast showed that 5’ capping is an
early event in transcriptional elongation263. It could therefore be possible that RNA
Polymerase II cannot successfully elongate target gene transcripts in cells expressing the
MLL-AF9 D544R or D546R mutant. As a result, the nascent transcript is uncapped and is
degraded from the 5’ end.
The MLL-AF9 E506R, I538A and K557E mutants also show decreased
expression of Meis1 using the exon 1 primer set. These results suggest that all MLL-AF9
point mutants studied here exhibit defects in transcription initiation. It would be
interesting to examine RNA Pol II occupancy throughout the Meis1 locus in cells
transduced with these MLL-AF9 mutants. We could also assess the phosphorylation state
of the CTD of RNA Pol II to discern whether Pol II is stalled at initiation or is in the
productive elongation stage.
Model for AF9 Interaction with AF4 and DOT1L in Leukemogenesis
Overall, these studies have highlighted the requirement for AF9 interaction with
Af4 and Dot1l in in vitro models of leukemogenesis in the murine system. The use of
structurally-informed point mutations identified critical interactions that could potentially
be targeted by small molecule inhibitors to treat patients with MLL leukemia.
I used genetic mutation of AF9 in the context of the MLL-AF9 fusion protein to
disrupt binding with Af4 or Dot1l. We hypothesize that disrupting the AF9-AF4
interaction prevents P-TEFb from being recruited and/or stabilized at MLL target gene
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promoters, resulting in decreased expression of genes required for leukemogenesis
(Figure 35). We do see a decrease in target gene expression, but it would be interesting to
see if the SEC is being recruited to these loci upon loss of AF9-AF4 binding.

Figure 35. Model of AF9 Interaction with AF4 and DOT1L at MLL Target Genes

MLL fusions are recruited to MLL target genes via the N-terminal DNA binding activity
of MLL. The C-terminal AF9/ENL portion of the fusion protein recruits SEC proteins
AF4/AF5 which interact with P-TEFb to stabilize RNA polymerase. Downstream within
the gene body, AF9 interacts with DOT1L, which deposits methyl marks at H3K79. As
shown, mutations that disrupt AF9 interation with AF4/AF5 or DOT1L result in
decreased target gene expression. These protein-protein interactions are therefore
attractive targets for developing therapeutics for the treatment of MLL leukemias.

Similarly, we see that loss of AF9-DOT1L interaction results in reduced colony
formation, decreased target gene expression and differentiation of the leukemic blast
cells. However, the mechanism is not understood. DOT1L is the H3K79 histone
methyltransferase, so we hypothesize that loss of AF9-DOT1L interaction results in a
loss of H3K79 methylation at genes targeted by MLL-AF9. ChIP-seq studies addressing
this question are ongoing by our collaborators at the University of Virginia.
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Furthermore, the function of H3K79 methylation is not well understood. This
mark is often enriched in gene bodies264 and DOT1L has been identified in several
studies as a member of the Super Elongation Complex5, 187, thus it is hypothesized the
DOT1L and H3K79 methylation play a role in transcriptional elongation. This mark is
associated with actively transcribed genes in genome-wide studies in Drosophila265 and
mammalian cells266. At least one study in yeast, and an additional ChIP-seq study using
human CD4+ T cells, failed to find this correlation267,
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. In fact, H3K79me3 was

associated with gene repression in these CD4+ T cells. It is clear from our studies and
others, especially those utilizing Dot1l-/- mice, that Dot1l is required for leukemic
transformation by MLL fusions, although more work needs to be done to determine the
mechanism.
MLL-rearranged leukemias are very complex, but the use of structurally-informed
mutational analyses to dissect the mechanisms of leukemogenesis has proved to be a very
helpful method in studying the function of these fusion proteins. It is our hope that this
knowledge can be used in developing small molecule inhibitors and targeted therapeutics
to disrupt interactions required for leukemic transformation.
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